CN113197895B - 一种酮酰胺类化合物的药物用途 - Google Patents
一种酮酰胺类化合物的药物用途 Download PDFInfo
- Publication number
- CN113197895B CN113197895B CN202110119020.0A CN202110119020A CN113197895B CN 113197895 B CN113197895 B CN 113197895B CN 202110119020 A CN202110119020 A CN 202110119020A CN 113197895 B CN113197895 B CN 113197895B
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- amino
- 500mhz
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 ketoamide compound Chemical class 0.000 title claims abstract description 168
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 claims abstract description 27
- 102000050937 human CTSL Human genes 0.000 claims abstract description 27
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 8
- 229940094918 Cathepsin L inhibitor Drugs 0.000 claims abstract description 7
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 32
- 102000035195 Peptidases Human genes 0.000 claims description 28
- 108091005804 Peptidases Proteins 0.000 claims description 28
- 239000004365 Protease Substances 0.000 claims description 27
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 13
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 229910052805 deuterium Inorganic materials 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052722 tritium Inorganic materials 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 2
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 538
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 310
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 300
- 238000005160 1H NMR spectroscopy Methods 0.000 description 195
- 238000005481 NMR spectroscopy Methods 0.000 description 117
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 108
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 78
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 125000004450 alkenylene group Chemical group 0.000 description 26
- 241000700605 Viruses Species 0.000 description 24
- 125000002947 alkylene group Chemical group 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 235000019419 proteases Nutrition 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 10
- 125000004419 alkynylene group Chemical group 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 8
- LXYUSXFFUYVKOV-UHFFFAOYSA-N 1,3-dioxole-4-carboxamide Chemical compound NC(=O)C1=COCO1 LXYUSXFFUYVKOV-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 102000004172 Cathepsin L Human genes 0.000 description 5
- 108090000624 Cathepsin L Proteins 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 4
- 102000005927 Cysteine Proteases Human genes 0.000 description 4
- 108010005843 Cysteine Proteases Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 101800004803 Papain-like protease Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 4
- MLXWMEFKFOSOCP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=C=N[CH]N21 MLXWMEFKFOSOCP-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000034217 membrane fusion Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 3
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000029578 entry into host Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000001302 tertiary amino group Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 101800000504 3C-like protease Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 2
- 101800000596 Probable picornain 3C-like protease Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000026425 severe pneumonia Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- TYMUCBKTMCCTIC-JTQLQIEISA-N (2s)-2-[cyclohexyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound CC(C)(C)OC(=O)N([C@@H](C)C(O)=O)C1CCCCC1 TYMUCBKTMCCTIC-JTQLQIEISA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 1
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- 230000005545 community transmission Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical group CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004797 ketoamides Chemical class 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一类酮酰胺类化合物的新用途，具体而言，本发明涉及如通式A所示的酮酰胺类化合物作为2019新型冠状病毒(2019‑nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。本发明还涉及该类化合物的药用组合物、它们的药用盐、对映体形式、非对映异构体及外消旋化合物在在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。
Description
技术领域
本发明涉及医药领域，具体地涉及一种酮酰胺类化合物的医药用途。
背景技术
在急性传染病中，绝大部分都是病毒性传染病，病毒性传染病的发病率高，死亡率也很高。由于检测和诊断手段有限，导致新病毒引发的新疫情爆发往往具有突发性、随机性和不可预测性等特点，一旦爆发，如无有效的防治手段，极易造成大规模流行，严重威胁人民健康生命安全。新型冠状病毒(2019-nCoV或SARS-CoV-2)感染，引起严重肺炎。2019-nCoV病毒能通过飞沫和接触传播，且存在人传人、医务人员感染，一定社区传播风险，且病毒存在变异的可能。目前对于新型冠状病毒所致疾病没有特异的预防和治疗方法。
2019-nCoV冠状病毒属于冠状病毒科冠状病毒属，为具有包膜的单链正义RNA病毒。和其他已知冠状病毒类似，2019-nCoV冠状病毒也经过吸附、穿入、脱壳、生物合成、子代病毒的组装与释放等几个过程完成子代病毒的增殖。2019-nCoV冠状病毒感染宿主细胞起始于病毒包膜表面的刺突糖蛋白与宿主细胞表面的受体结合，随后发生膜融合，病毒进入宿主细胞，在细胞溶酶体等细胞器作用下，释放出病毒的遗传物质单链正义RNA，在宿主细胞的线粒体、核糖体等蛋白质合成元件以及必须的原料等作用下，翻译产生多聚蛋白，之后，2019-nCoV冠状病毒的两大必需半胱氨酸蛋白酶：木瓜样蛋白酶(papain-likeprotease,PLpro)和3C样蛋白酶(3C-like protease,3CLpro)在特定位点切割加工多聚蛋白前体，产生多个对病毒生命周期非常重要的非结构蛋白。在这些非结够蛋白的作用下，病毒RNA复制出子代病毒核酸物质，并大量翻译出所需的结构蛋白，完成子代病毒的组装和释放。2019-nCoV冠状病毒感染细胞的生命周期的任何环节或关键酶均可以作为抗病毒药物的研究靶点，如水解切割多聚蛋白前体的半胱氨酸蛋白酶PLpro和3CLpro，负责完成子代病毒遗传物质复制的RNA聚合酶等。
3CL蛋白酶(3chymotrypsin-like protease,3CLpro)，又称主蛋白酶(Mpro)，是冠状病毒RNA翻译出多聚蛋白pp1a和pp1ab后水解产生多个非结构蛋白过程中的关键蛋白酶，对病毒的复制和感染至关重要，抑制3CL蛋白酶的催化功能可有效抑制病毒多聚蛋白前体的切割，阻断病毒复制，抑制子代病毒生成。3CLpro属于半胱氨酸蛋白酶，是催化单正链RNA病毒前体蛋白水解的关键蛋白酶，对2019-nCoV等冠状病毒的复制活性具有重要的作用。因此，3CLpro是目前公认的研发抗冠状病毒药物的理想靶点。
人组织蛋白酶L属于溶酶体木瓜样蛋白酶家族半胱氨酸蛋白酶，其具有多种生物学功能，其作为靶标已被广泛应用于抗寄生虫感染药物研发领域，如锥虫感染导致的Chagas病。组织蛋白酶L在胞内首先以无活性的酶原形式存在，需要在胞内体或者溶酶体的酸性环境下自行剪切，或者通过其他蛋白酶活化才能形成具有催化活性的成熟酶。大量研究报道，人组织蛋白酶L与多种肿瘤的发生有着密切关系，且在心脏疾病中也发挥重要作用，此外，研究还发现人组织蛋白酶还参与病原微生物侵染宿主细胞。越来越多证据表明人组织蛋白酶L可以作为药物靶标，用于抗肿瘤、心脏疾病以及抗感染类药物的研发。SARS-CoV-2的刺突蛋白(S蛋白)需要经宿主蛋白酶水解活化后才能介导病毒与宿主细胞发生膜融合进而促进病毒侵入宿主细胞，根据宿主蛋白酶作用阶段差异，病毒侵入途径可分为II型跨膜丝氨酸蛋白酶(TMPRSSII)介导的表面膜融合途径，人组织蛋白酶L(cathepsin L)介导的内吞膜融合途径，因此这些宿主蛋白酶均可作为冠状病毒侵入宿主细胞的进入抑制剂。抑制人组织蛋白酶L可以有效阻止病毒侵入宿主细胞，因此人组织蛋白酶L抑制剂是抗SARS-CoV-2研发的理想靶标，有望解决靶向病毒的抗病毒药物出现突变耐药的潜在风险和问题。
目前，针对2019-nCoV冠状病毒导致的严重肺炎疾病尚无特效的疫苗和抗病毒药物。这些感染性疾病严重影响了人们的生命健康，研发效果好的小分子抗病毒药物迫在眉睫。针对2019-nCoV冠状病毒3CLpro和/或人组织蛋白酶L开发出结构新颖、低毒高效且具有自主知识产权的抗病毒药物，以满足国内外2019-nCoV冠状病毒感染患者的临床需求，具有重大的社会意义。
综上所述，本领域迫切需要开发针对2019-nCoV冠状病毒3CL蛋白酶的抑制剂和/或人组织蛋白酶L用于治疗新型冠状病毒感染引起的肺炎。
发明内容
本发明的目的是提供一种酮酰胺类化合物的新用途。
具体地，本发明提供了通式A所示的酮酰胺类化合物作为2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。
在本发明第一方面，提供了一种通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体的用途，用于制备(a)2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂；和(b)治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物：
其中，
*表示碳原子的立体化学异构分别独立地为R和/或S；
R1和R2各自独立地选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10环烷基C1-C10亚烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C3-C10杂环烷基C1-C10亚烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C10亚烷基、取代或未取代的C3-C20杂芳基C1-C10亚烷基、取代或未取代的C6-C20芳基C2-C10亚烯基、取代或未取代的C3-C20杂芳基C2-C10亚烯基、酰基、磺酰基；
R3选自下组：取代或未取代的C1-C10烷基、取代或未取代的C2-C10烯基、取代或未取代的C2-C10炔基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C10亚烷基、取代或未取代的C3-C8杂环烷基、取代或未取代的C3-C8杂环烷基C1-C10亚烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C10亚烷基、取代或未取代的C3-C20杂芳基C1-C10亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C2-C6亚烯基、取代或未取代的C6-C20芳基C2-C6亚炔基、取代或未取代的C3-C20杂芳基C2-C6亚炔基；
R4选自下组：取代或未取代的C1-C10烷基、取代或未取代的C2-C10烯基、取代或未取代的C2-C10炔基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C6-C20芳基C2-C6亚炔基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、取代或未取代的C3-C20杂芳基C2-C9亚炔基；
R6选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、酰基、磺酰基；
当-NR5与其相邻的-(C＝O)-CH2-成环时，R5为-(CH2)n-，n为2或3；
当-NR5不与其相邻的-(C＝O)-CH2-成环时，R5选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、酰基、磺酰基；
其中，在R1、R2、R3、R4、R5和R6中，所述取代各自独立地指被选自下组的1、2、3或4个取代基取代：卤素、羟基、巯基、硝基、氰基、胺基、亚胺基、叔胺基、叠氮基、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、C1-C6烷基羰基、C1-C6烷硫基、C1-C8烷氧基羰基、三氟甲基；所述杂环烷基和所述杂芳基各自独立地包含1、2、3或4个选自N、O、S的杂原子。
在另一优选例中，当R6为H时，-NR5(或-NR5R6)可与其相邻的-(C＝O)-CH2-成环(如5-6元杂环)或不成环。所述的5-6元杂环在环上含有1个N杂原子，其余的环原子为C。在另一优选例中，当-NR5与其相邻的-(C＝O)-CH2-成环时，R5为取代或未取代的-(CH2)n-，n为2或3，其中，所述取代各自独立地指被选自下组的1、2、3或4个取代基取代：卤素、羟基、C1-C8烷基、C3-C8环烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、三氟甲基。
在另一优选例中，
部分为取代或未取代的5-6元杂环基，其中，所述取代各自独立地指被选自下组的1、2、3或4个取代基取代：卤素、羟基、巯基、硝基、氰基、氧代基、胺基、亚胺基、叔胺基、叠氮基、C1-C8烷基、C3-C8环烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、C1-C6烷基羰基、C1-C6烷硫基、C1-C8烷氧基羰基、三氟甲基；优选地/>
部分为/>
其中，n1为1或2。
在另一优选例中，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
在另一优选例中，R1和R2各自独立地选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C3-C10杂环烷基C1-C5亚烷基、取代或未取代的C6-C14芳基、取代或未取代的C3-C10杂芳基、取代或未取代的C6-C14芳基C1-C5亚烷基、取代或未取代的C3-C10杂芳基C1-C5亚烷基、取代或未取代的C6-C10芳基C2-C5亚烯基、取代或未取代的C3-C10杂芳基C2-C5亚烯基、酰基、磺酰基；
R3选自下组：取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C3-C8杂环烷基、取代或未取代的C3-C8杂环烷基C1-C5亚烷基、取代或未取代的C6-C10芳基、取代或未取代的C3-C10杂芳基、取代或未取代的C6-C10芳基C1-C5亚烷基、取代或未取代的C3-C10杂芳基C1-C5亚烷基、取代或未取代的C6-C10芳基C2-C4亚烯基、取代或未取代的C3-C10杂芳基C2-C4亚烯基、取代或未取代的C6-C10芳基C2-C4亚炔基、取代或未取代的C3-C10杂芳基C2-C4亚炔基；
其中，在R1、R2和R3中，所述取代各自独立地指被选自下组的1、2或3个取代基取代：卤素、羟基、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C4烷基羰基、C1-C4烷硫基、C1-C6烷氧基羰基、三氟甲基；所述杂环烷基和所述杂芳基各自独立地包含1或2个选自N、O、S的杂原子。
在另一优选例中，所述化合物为式AA所示的化合物，
其中，R1、R2、R3、R4、R5和n如上文中所限定；
*表示碳原子的立体化学异构分别独立地为R和/或S。
在另一优选例中，R4选自下组：含1、2或3个选自N、O、S的杂原子的9-10元杂芳环、含1、2或3个选自N、O、S的杂原子的5-6元杂芳环；上述基团为取代或未取代的；其中，所述取代指基团上的氢原子被1、2、3或4个选自下组的取代基取代：卤素、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6烷硫基、卤代C1-C6烷硫基。
在另一优选例中，R6选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C10杂环烷基。
在另一优选例中，所述杂芳基是5、6、7、8、9或10元的饱和或部分饱和的杂芳环。
在另一优选例中，所述杂环烷基是5、6、7、8、9或10元的不饱和杂环。
在另一优选例中，R4选自下组：
取代或未取代的喹喔啉基、取代或未取代的喹唑啉基、取代或未取代的噌啉基、
取代或未取代的吲哚基、取代或未取代的异吲哚基、
取代或未取代的1,3-苯并二噁茂基、
取代或未取代的苯并咪唑基、取代或未取代的吲唑基、
取代或未取代的咪唑[1,2-A]吡啶基、取代或未取代的咪唑[1,5-A]吡啶基、
取代或未取代的吡唑基、取代或未取代的咪唑基、取代或未取代的噻唑基、取代或未取代的噁唑基、取代或未取代的异噁唑基、取代或未取代的1，2，3-三唑基、取代或未取代的1，2-噻二唑基、取代或未取代的1，2，4-三嗪基、
取代或未取代的吡啶基、取代或未取代的吡咯基、取代或未取代的吡嗪基、取代或未取代的嘧啶基、
取代或未取代的3,8a二氢-2H-苯并吡喃基、取代或未取代的苯并吡喃基、
取代或未取代的喹啉基、取代或未取代的异喹啉基、
取代或未取代的苯并噁唑基、取代或未取代的苯并噻唑基、
取代或未取代的苯并噻吩基、
取代或未取代的苯并呋喃基；
其中，所述取代指基团上的氢原子被1、2或3个选自下组的取代基取代：F、Cl、Br、I、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6烷硫基、卤代C1-C6烷硫基。
在本文中，R4为咪唑[1,2-A]吡啶对应本发明编号为A156至A161的化合物。
在本文中，“咪唑[1,2-A]吡啶”、“咪唑[1,2-a]吡啶”、“咪唑并[1,2-A]吡啶”和“咪唑并[1,2-a]吡啶”可互换使用。
在本文中，“咪唑[1,5-A]吡啶”、“咪唑[1,5-a]吡啶”、“咪唑并[1,5-A]吡啶”和“咪唑并[1,5-a]吡啶”可互换使用。
在本文中，R4为3,8a二氢-2H-苯并吡喃对应本发明编号为A132至A137的化合物。
在另一优选例中，当R6为H时，-NR5可与其相邻的-(C＝O)-CH2-成环(如5-6元杂环)或不成环。
在另一优选例中，当-NR5(或-NR5R6)与其相邻的-(C＝O)-CH2-成环时，R5为-(CH2)n-，n为3；
当-NR5(或-NR5R6)不与其相邻的-(C＝O)-CH2-成环时，R5选自下组：氢、氘、氚、羟基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8杂环烷基、取代或未取代的C6-C10芳基、取代或未取代的C3-C10杂芳基、取代或未取代的C6-C10芳基C1-C4亚烷基、取代或未取代的C6-C10芳基C2-C4亚烯基、取代或未取代的C3-C10杂芳基C1-C4亚烷基、取代或未取代的C3-C10杂芳基C2-C4亚烯基；
其中，所述取代各自独立地指被选自下组的1、2或3个取代基取代：F、Cl、Br、I、羟基、C1-C6烷基、C1-C6烷氧基、C1-C6烷硫基；所述杂环烷基和所述杂芳基各自独立地包含1、2或3个选自N、O、S的杂原子。
在另一优选例中，所述R1、R2、R3、R4、R5和R6各自独立地为实施例中具体化合物(A1-A310)中对应的基团。
在另一优选例中，所述通式(A)化合物选自下组：
在本发明第二方面，提供了一种药物组合物，其包括(a)治疗有效量的通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体或前药，和(b)药学上可接受的载体，其中，通式(A)所示的酮酰胺类化合物如本发明第一方面中所述。
在本发明第三方面，提供了本发明第二方面所述的药物组合物的用途，它用于制备治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物。
在另一优选例中，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
在本发明的第四方面，提供了一种治疗、预防、和/或缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的方法，包括步骤：给需要的对象施用安全有效量的通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体，其中所述的通式(A)所示的酮酰胺类化合物如上所述。
在另一优选例中，所述的对象为灵长目哺乳动物，如人。
在本发明的第五方面，提供了一种抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶的活性的方法，包括步骤：将通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体与2019-nCov的3CL蛋白酶和/或人组织蛋白酶L接触，从而抑制2019-nCov的3CL蛋白酶和/或人组织蛋白酶L的活性。
在另一优选例中，所述的方法是非治疗性和非诊断性的。
在另一优选例中，所述的方法是体外的。
在另一优选例中，所述的2019-nCov的3CL蛋白酶是重组的或2019-nCov表达的3CL蛋白酶。
本发明第六方面，提供了一种第一方面所述的式(A)化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体，
其中，
*表示碳原子的立体化学异构分别独立地为R和/或S；
R1和R2各自独立地选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10环烷基C1-C10亚烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C3-C10杂环烷基C1-C10亚烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C10亚烷基、取代或未取代的C3-C20杂芳基C1-C10亚烷基、取代或未取代的C6-C20芳基C2-C10亚烯基、取代或未取代的C3-C20杂芳基C2-C10亚烯基、酰基、磺酰基；
R3选自下组：取代或未取代的C1-C10烷基、取代或未取代的C2-C10烯基、取代或未取代的C2-C10炔基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C10亚烷基、取代或未取代的C3-C8杂环烷基、取代或未取代的C3-C8杂环烷基C1-C10亚烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C10亚烷基、取代或未取代的C3-C20杂芳基C1-C10亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C2-C6亚烯基、取代或未取代的C6-C20芳基C2-C6亚炔基、取代或未取代的C3-C20杂芳基C2-C6亚炔基；
R4选自下组：取代或未取代的C1-C10烷基、取代或未取代的C2-C10烯基、取代或未取代的C2-C10炔基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C6-C20芳基C2-C6亚炔基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、取代或未取代的C3-C20杂芳基C2-C9亚炔基；
R6选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、酰基、磺酰基；
当-NR5与其相邻的-(C＝O)-CH2-成环时，R5为-(CH2)n-，n为2或3；
当-NR5不与其相邻的-(C＝O)-CH2-成环时，R5选自下组：氢、氘、氚、氨基、羟基、取代或未取代的C1-C10烷基、取代或未取代的C3-C10环烷基、取代或未取代的C3-C10杂环烷基、取代或未取代的C6-C20芳基、取代或未取代的C3-C20杂芳基、取代或未取代的C6-C20芳基C1-C6亚烷基、取代或未取代的C6-C20芳基C2-C6亚烯基、取代或未取代的C3-C20杂芳基C1-C9亚烷基、取代或未取代的C3-C20杂芳基C2-C9亚烯基、酰基、磺酰基；
其中，在R1、R2、R3、R4、R5和R6中，所述取代各自独立地指被选自下组的1、2、3或4个取代基取代：卤素、羟基、巯基、硝基、氰基、胺基、亚胺基、叔胺基、叠氮基、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、C1-C6烷基羰基、C1-C6烷硫基、C1-C8烷氧基羰基、三氟甲基；所述杂环烷基和所述杂芳基各自独立地包含1、2、3或4个选自N、O、S的杂原子。
在另一优选例中，所述化合物为式AA所示的化合物，
其中，R1、R2、R3、R4、R5和n如上文中所限定；
*表示碳原子的立体化学异构分别独立地为R和/或S。
在另一优选例中，所述化合物为化合物A254-A310(即实施例254-310)。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1显示了本发明化合物可抑制2019nCoV病毒的复制。
图2显示了本发明部分化合物抑制2019新型冠状病毒(2019-nCov)的抑制曲线和EC50值。
具体实施方式
本发明人经过广泛而深入的研究，通过大量筛选，首次意外地开发了一类可有效抑制2019新型冠状病毒(2019-nCov)的活性成分，即通式A所示的化合物或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体。试验表明，本发明的活性成分可高效地抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶和/或人组织蛋白酶L的活性，从而抑制2019-nCov的复制和活力。在此基础上完成了本发明。
术语
如本文所用，术语“新型冠状病毒”、“2019-nCov”或“SARS-CoV-2”可互换使用，该新型冠状病毒是已知感染人的第7种冠状病毒，并且造成新冠肺炎(COVID-19)，是威胁全球人类健康的严重传染性疾病之一。此外，该术语还包括野生型和突变型病毒株。
在本文中，除特别说明之处，术语“取代”指基团上的一个或多个氢原子被选自下组的取代基取代：C1～C10烷基、C3～C10环烷基、C1～C10烷氧基、卤素、羟基、羧基(-COOH)、C1～C10醛基、C2～C10酰基、C2～C10酯基、氨基、苯基；所述的苯基包括未取代的苯基或具有1-3个取代基的取代苯基，所述取代基选自：卤素、C1-C10烷基、氰基、OH、硝基、C3～C10环烷基、C1～C10烷氧基、氨基。
除特别说明之处，本发明的所有化合物之中，各手性碳原子可以任选地为R构型或S构型，或R构型和S构型的混合物。
术语“C1～C6烷基”指具有1～6个碳原子的直链或支链烷基，例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、或类似基团。
术语“3-8元杂环基”指具有选自下组的1-3个杂原子的3～8元饱和环失去一个氢原子形成的基团：N、S、O；例如吡咯烷基、哌啶基、哌嗪基、吗啉基、或类似基团。
术语“6-10元芳基”指6～10元芳基失去一个氢原子形成的基团；例如苯基、萘基，或类似基团。
术语“5-10元杂芳基”指具有选自下组的1-3个杂原子的5～8元芳基失去一个氢原子形成的基团：N、S、O，其中每个杂芳基的环状体系可以是单环或多环的；例如吡咯基、吡啶基、噻吩基、呋喃基、咪唑基、嘧啶基、苯并噻吩基、吲哚基、咪唑并吡啶基、喹啉基或类似基团。
术语“C1～C6烷氧基”指具有1-6个碳原子的直链或支链烷氧基，例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基、叔丁氧基、或类似基团。
术语“C2-C6酯基”指具有2-6个碳原子的R-O-C(＝O)-基团，如-COOCH3、-COOC2H5、-COOC3H7、-COOC4H9，或类似基团。
术语“C2-C6烯基”指具有2-6个碳原子的烯烃失去一个或两个氢原子所形成的基团，所述的烯烃可以是单烯烃、二烯烃或三烯烃，例如-CH＝CH2、-C2H4＝CH2、-CH＝C2H4，或类似基团。
术语“卤素”指F、Cl、Br和I。
除非特别说明，本发明所描述的结构式意在包括所有的同分异构形式(如对映异构，非对映异构和几何异构体(或构象异构体)：例如含有不对称中心的R、S构型，双键的(Z)、(E)异构体和(Z)、(E)的构象异构体。因此本发明的化合物的单个立体化学异构体或其对映异构体、非对映异构体或几何异构体(或构象异构体)的混合物都属于本发明的范围。
术语“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒，从而互相转化。比如，质子互变异构体(即质子移变)包括通过质子迁移进行互变，如1H-吲唑与2H-吲唑、1H-苯并[d]咪唑与3H-苯并[d]咪唑，化合价互变异构体包括通过一些成键电子重组而进行互变。
在本文中，形如“C1～C6”，表示该基团可以具有1个至6个碳原子，例如1个、2个、3个、4个或5个。
活性成分
在本发明中，提供了一种可有效抑制2019新型冠状病毒(2019-nCov)复制的活性成分。该活性成分为通式A所示的化合物，该活性成分可有效预防、治疗和/或缓解2019-nCov相关疾病。
试验表明，本发明的活性成分可有效地抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶和/或人组织蛋白酶L，从而抑制2019新型冠状病毒(2019-nCov)的复制，进而预防、治疗和/或缓解2019-nCov相关疾病。
应理解，本发明的活性成分包括通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体、或其前药。应理解，本发明的活性成分还包括通式(A)化合物的晶型、无定形化合物、以及氘代化合物等形式。
所述“药学上可接受的盐”为通式(A)化合物与无机酸或有机酸反应形成常规的无毒盐。例如，常规的无毒盐可通过通式(A)化合物与无机酸或有机酸反应制得，所述无机酸包括盐酸、氢溴酸、硫酸、硝酸、胺基磺酸和磷酸等，所述有机酸包括柠檬酸、酒石酸、乳酸、丙酮酸、乙酸、苯磺酸、对甲苯磺酸、甲磺酸、萘磺酸、乙磺酸、萘二磺酸、马来酸、苹果酸、丙二酸、富马酸、琥珀酸、丙酸、草酸、三氟乙酸、硬酯酸、扑酸、羟基马来酸、苯乙酸、苯甲酸、水杨酸、谷氨酸、抗坏血酸、对胺基苯磺酸、2-乙酰氧基苯甲酸和羟乙磺酸等；或者通式(A)化合物与丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、天冬氨酸或谷氨酸形成酯后再与无机碱形成的钠盐、钾盐、钙盐、铝盐或铵盐；或者通式(A)化合物与有机碱形成的甲胺盐、乙胺盐或乙醇胺盐；或者通式(A)化合物与赖氨酸、精氨酸、鸟氨酸形成酯后再与盐酸、氢溴酸、氢氟酸、硫酸、硝酸或磷酸形成的对应的无机酸盐或与甲酸、乙酸、苦味酸、甲磺酸或乙磺酸形成的对应的有机酸盐。
药物组合物和应用
本发明还提供了以通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体及前药中的一种或多种的混合物为有效成分在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。
本发明所提供的药物组合物优选含有重量比为0.001-99wt％的活性成份，优选的比例是通式A化合物作为活性成分占总重量的0.1wt％～90wt％，其余部分为药学可接受的载体、稀释液或溶液或盐溶液。
需要的时候，在本发明药物中还可以加入一种或多种药学上可接受的载体。所述载体包括药学领域常规的稀释剂、赋形剂、填充剂、粘合剂、润湿剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。
本发明所提供的化合物和药物组合物可以是多种形式，如片剂、胶囊、粉剂、糖浆、溶液状、悬浮液和气雾剂等，并可以存在于适宜的固体或液体的载体或稀释液中和适宜的用于注射或滴注的消毒器具中。
本发明的药物组合物的各种剂型可按照药学领域的常规制备方法制备。其制剂配方的单位计量中通常包含0.05-400mg通式A化合物，优选地，制剂配方的单位计量中包含1mg-500mg通式A化合物。
本发明的化合物和药物组合物可对哺乳动物临床使用，包括人和动物，可以通过口、鼻、皮肤、肺或者胃肠道等的给药途径。最优选为口服。最优选日剂量为0.01-400mg/kg体重，一次性服用，或0.01-200mg/kg体重分次服用。不管用何种服用方法，个人的最佳剂量应依据具体的治疗而定。通常情况下是从小剂量开始，逐渐增加剂量一直到找到最适合的剂量。
本发明的药物或抑制剂可通过各种不同方式施用，例如可通过注射、喷射、滴鼻、滴眼、渗透、吸收、物理或化学介导的方法导入机体如肌肉、皮内、皮下、静脉、粘膜组织；或是被其他物质混合或包裹导入机体。
本发明的主要优点包括：
(a)本发明化合物可高效地抑制2019-nCoV 3CL蛋白酶，部分化合物的IC50值达到约2.4μM。
(b)本发明化合物可高效地抑制人组织蛋白酶L，部分化合物的IC50值达到约0.45nM。
(c)本发明化合物在病毒水平上对2019-nCoV的抑制率优于阳性对照CQ，展现出较好的抗2019-nCoV潜力，部分化合物的EC50值达到约0.3μM。
(d)本发明化合物的毒副作用低，成药性好。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
样品的分析数据由以下仪器测定：核磁共振由GEMINI-300型、Bruker AMX-400型和INVOA-600型核磁共振仪测定，TMS(四甲基硅烷)为内标，化学位移单位为ppm，耦合常数单位为Hz；质谱由Finnigan MAT-711型，MAT-95和LCQ-DECA型质谱仪以及IonSpec4.7Tesla质谱仪测定。
柱层析用硅胶200-300目(青岛海洋化工厂生产)；TLC硅胶板为烟台化工厂生产的HSGF-254型薄层层析预制板；石油醚沸程为60-90℃；采用紫外灯，碘缸显色。除另有说明外，以下实施例中所用常规试剂、药品均购自国药集团。实验中所用试剂及溶剂均按反应具体情况处理。
实施例1化合物A1
化合物1-2的合成：
氩气保护下，将N-叔丁氧羰基-L-谷氨酸二甲酯(1-1)(6g，21.8mmol)溶于60mL无水四氢呋喃中，于-78℃条件下缓慢滴LiHMDS(1M in THF)的四氢呋喃溶液(47mL,47mmol)，滴加过程保持温度稳定在-78℃，约持续1小时。滴毕后在-78℃条件搅拌1小时。将溴乙腈(2.79g，23.3mmol)溶于20ml四氢呋喃中，随后将该溶液缓慢滴入到反应体系中，滴加过程持续1～2小时。控温-78℃，继续反应3小时。TLC监测(碱性高锰酸钾显色)反应完毕后，向反应液中加入NH4Cl溶液淬灭反应，搅拌10min后升至室温。倾入40mL饱和氯化钠溶液充分搅拌，可见反应体系分层。分离有机层，并用乙酸乙酯(EA)萃取水相，合并有机层后用无水硫酸钠干燥，浓缩，柱层析(Flash,PE:EA＝1:5)得到淡黄色油状物1-2 3.9g，收率为58％。
化合物1-3的合成：
将1-2(1g，3.15mmol)溶于无水甲醇25mL，冰浴下搅拌至0℃后加入六水合二氯化钴(450mg，1.89mmol)。10min后分次少量加入硼氢化钠(715mg，18.9mmol)，反应液继续在冰浴下反应1h后转为室温反应。15h后用饱和NH4Cl溶液5mL淬灭后继续搅拌10min，利用滤除固体后将滤液蒸干，用水20mL和乙酸乙酯30×3mL萃取，合并有机相，以无水Na2SO4干燥1h后减压浓缩，柱层析分离[PE:EA＝1:2]得到白色粉末状固体460mg，产率51％。
化合物1-4的合成：
将化合物1-3(2.6g)溶于三氟乙酸的二氯甲烷溶液(1/1,v/v)中，室温搅拌1小时，浓缩后加入二氯甲烷100ml，饱和碳酸钠溶液洗，有机层用无水硫酸钠干燥，浓缩得油状物1-4(2.7g)，收率99％。
化合物1-5的合成：
将Boc-环己基丙氨酸(1.26g,5mmol)和EDCI(1.36g,6mmol)、HOBt(0.822g,6mmol)加入到80ml二氯甲烷溶液中，室温搅拌30min。随后加入化合物1-4(0.896g,5mmol)，滴入1.2当量的三乙胺，室温下搅拌。TLC监测(紫外)反应完全后采用二氯甲烷萃取，经稀盐酸、饱和碳酸氢钠溶液和饱和氯化钠洗涤后，合并有机层无水硫酸钠干燥，浓缩后得白色粘稠状固体1.2g，产率60％。
化合物1-6的合成：
将化合物1-5(2.5g)溶于三氟乙酸的二氯甲烷溶液(1/1,v/v)中，室温搅拌1小时，浓缩后加入二氯甲烷100ml，饱和碳酸钠溶液洗，有机层用无水硫酸钠干燥，浓缩得油状物1-6(2.61g)，收率99％。
化合物1-7的合成：
将吲哚2-甲酸(0.795g,5mmol)和EDCI(1.36g,6mmol)、HOBt(0.822g,6mmol)加入到80ml二氯甲烷溶液中，室温搅拌30min。随后加入化合物1-6(2.2g,5mmol)，滴入1.2当量的三乙胺，室温下搅拌。TLC监测(紫外)反应完全后采用二氯甲烷萃取，经稀盐酸、饱和碳酸氢钠溶液和饱和氯化钠洗涤后，合并有机层无水硫酸钠干燥，浓缩后得白色粘稠状固体1.3g，产率60％。
化合物1-8的合成：
将1-7(243mg,0.51mmol)溶于20ml甲醇中，分批缓慢加入硼氢化钠(107mg,2.9mmol)，室温下搅拌约2小时反应完全。待反应完毕后，加入约20ml饱和食盐水淬灭反应，浓缩反应体系甲醇后，加入二氯甲烷萃取。有机相经饱和食盐水洗涤、无水硫酸钠干燥后，浓缩得到白色固体物质1-8，可直接用于下步反应。
化合物1-9的合成：
将中间体1-8(129mg,0.29mmol)溶于20ml二氯甲烷溶于中，加入戴斯-马汀氧化剂(147mg,0.35mmol)和碳酸氢钠固体(29mg,0.35mmol)，在室温下搅拌。TLC监测(紫外)反应完全后，抽滤反应体系，所得滤液用饱和碳酸氢钠溶于萃取，有机层经饱和食盐
水洗涤，无水硫酸钠干燥后浓缩。经快速柱色谱(CH2Cl2:MeOH＝20:1)分离纯化，得到白色固体粉末化合物1共77mg，产率60％。
化合物1-10的合成：
将化合物1-9(129mg,0.29mmol)溶解在二氯甲烷溶剂中，加入醋酸(19.2mg，0.32mmol)和苄基异氰(37.6mg，0.32mmol)反应，得到化合物1-10，经快速柱色谱(CH2Cl2:MeOH＝20:1)分离纯化，得到白色固体粉末化合物1-10共126mg，产率70％。
化合物1-11的合成：
将化合物1-10(187mg,0.3mmol)溶解在甲醇溶剂中，加入LiOH(0.6mmol)搅拌，得到化合物1-11，经快速柱色谱(CH2Cl2:MeOH＝20:1)分离纯化，得到白色固体粉末化合物1-11共148mg，产率85％。
化合物1-12的合成：
将化合物1-11(174mg,0.3mmol)溶解在二氯甲烷溶剂中，加入Dess-Martin氧化剂(152mg,0.36mmol)，加入碳酸氢钠(30mg,0.36mmol)，搅拌，得化合物白色固体粉末化合物1-12共140mg，产率80％.
1H NMR(500MHz,Chloroform)δ9.76(s,1H),7.73(s,1H),7.39(s,1H),7.32–7.26(m,2H),7.22(s,1H),7.20–7.10(m,3H),7.01(s,1H),6.82(s,1H),6.68(s,1H),6.14(s,1H),5.57(s,1H),5.43(s,1H),4.38(s,1H),4.32(d,J＝19.2Hz,2H),3.45(s,1H),3.35(s,1H),3.06(s,1H),2.20(dd,J＝15.4,2.3Hz,4H),2.12–2.03(m,2H),1.92(s,1H),1.77(s,1H),1.73–1.67(m,3H),1.66–1.53(m,6H),1.37(s,1H).；
使用与实施例1相似的方法合成实施例2-310。
实施例2 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A2)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),7.51(d,J＝18.0Hz,2H),7.38(s,1H),7.12(s,1H),7.06(s,1H),6.26(s,1H),6.04(s,1H),5.80(s,1H),5.25(s,1H),4.81(s,1H),4.67(s,1H),3.45(s,1H),3.35(s,1H),2.55(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.96–1.91(m,3H),1.73–1.52(m,5H),1.40–1.36(m,2H),1.35–1.29(m,10H),1.20–1.09(m,3H).
实施例3 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A3)
1H NMR(500MHz,Chloroform)δ8.28(s,1H),7.48(d,J＝1.2Hz,2H),7.34(s,1H),7.10(d,J＝1.0Hz,2H),7.03(s,1H),6.05(s,1H),5.59(s,1H),5.30(s,1H),4.63(s,1H),4.45(s,1H),3.58(s,1H),3.45(s,1H),3.35(s,1H),2.95(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.98–1.90(m,3H),1.73–1.67(m,3H),1.65–1.61(m,2H),1.51(dtd,J＝12.9,8.9,1.3Hz,13H),1.45–1.39(m,3H),1.38–1.34(m,2H).
实施例4 N-((S)-3-环己基-1-(((S)-4-(新戊基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A4)
1H NMR(500MHz,Chloroform)δ8.46(s,1H),7.53(d,J＝3.4Hz,2H),7.40(d,J＝17.1Hz,2H),7.12(s,1H),7.06(s,1H),6.16(d,J＝14.3Hz,2H),5.65(s,1H),5.23(s,1H),4.44(s,1H),3.44(d,J＝11.4Hz,2H),3.35(s,1H),3.09(s,1H),2.97(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.75–1.68(m,4H),1.62(s,1H),1.48(dt,J＝16.0,8.0Hz,5H),1.37–1.31(m,2H),1.28(s,1H),1.09–1.05(m,9H).
实施例5 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A5)
1H NMR(500MHz,Chloroform)δ8.22(s,1H),7.96(s,1H),7.53(s,1H),7.42(s,1H),7.38(s,1H),7.29–7.24(m,4H),7.17(d,J＝29.6Hz,2H),7.07(s,1H),6.54(s,1H),5.74(s,1H),5.27(s,1H),5.06(s,1H),4.49(s,1H),4.41(s,1H),4.31(s,1H),3.24(d,J＝17.4Hz,2H),2.56(s,1H),2.08–2.04(m,2H),1.95–1.88(m,2H),1.78(d,J＝6.9Hz,2H),1.69(dt,J＝6.3,3.5Hz,7H),1.51(s,1H),1.40–1.36(m,2H),1.32(s,1H),1.15–1.11(m,2H),1.08(s,1H).
实施例6 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A6)
1H NMR(500MHz,Chloroform)δ8.30(s,2H),7.48(s,2H),7.43(s,2H),7.35(s,2H),7.10(s,2H),7.03(s,2H),6.45(s,2H),5.99(s,2H),5.76(s,2H),5.25(s,2H),4.81(s,2H),4.29(s,2H),3.24(d,J＝17.1Hz,4H),2.75(s,2H),2.05(t,J＝8.9Hz,6H),1.79(s,2H),1.71(t,J＝2.5Hz,7H),1.58–1.54(m,3H),1.51–1.33(m,10H),1.33–1.29(m,20H),1.23(s,2H),1.15–1.11(m,3H),0.94–0.90(m,3H)..
实施例7 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A7)
1H NMR(500MHz,Chloroform)δ9.29(s,1H),8.69(s,1H),7.52(s,1H),7.43(d,J＝15.1Hz,2H),7.13(s,1H),7.06(s,1H),5.93(s,1H),5.59(d,J＝3.5Hz,2H),5.11(s,1H),4.51(s,1H),3.41(s,1H),3.24(d,J＝16.6Hz,2H),2.66(s,1H),2.54(s,1H),2.08–2.04(m,2H),2.01–1.89(m,2H),1.89–1.77(m,4H),1.73–1.61(m,7H),1.55–1.50(m,3H),1.48(s,1H),1.44–1.39(m,2H),1.39–1.35(m,2H),1.31(s,1H),1.09–0.99(m,3H).
实施例8 N-((S)-3-环己基-1-(((S)-4-(新戊基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A8)
1H NMR(500MHz,Chloroform)δ8.45(s,4H),7.50(d,J＝31.7Hz,8H),7.46–7.46(m,1H),7.39(s,5H),7.13(s,4H),7.06(s,4H),6.01(s,4H),5.44(s,4H),5.40(s,4H),5.23(s,4H),4.89(s,4H),4.47(s,4H),3.30–3.20(m,12H),3.13(s,4H),2.30(s,4H),2.10–2.02(m,8H),1.97(s,3H),1.81–1.76(m,11H),1.71(t,J＝1.6Hz,11H),1.69–1.63(m,13H),1.50(s,3H),1.39–1.35(m,7H),1.31(s,4H),1.14–1.05(m,44H),1.02(s,3H).
实施例9 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A9)
1H NMR(500MHz,Chloroform)δ7.66(s,1H),7.34–7.28(m,5H),7.22(d,J＝7.1Hz,2H),7.10(s,1H),6.72(s,1H),6.17(s,1H),5.97(s,1H),5.84(s,1H),5.47(s,1H),4.42(s,1H),4.34(d,J＝9.3Hz,2H),3.45(s,1H),3.35(s,1H),3.22(s,1H),2.64(s,1H),2.18(s,1H),2.09–2.05(m,2H),2.05–1.98(m,2H),1.92(s,1H),1.75–1.66(m,4H),1.66–1.55(m,6H),1.36(s,1H).
实施例10 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A10)
1H NMR(500MHz,Chloroform)δ9.59(s,1H),8.31(s,1H),7.63(s,1H),7.50(s,1H),7.41(s,1H),7.22(s,1H),7.16(s,1H),6.40(s,1H),5.82(s,1H),4.81(s,1H),4.64(s,1H),3.97(s,1H),3.35(s,1H),2.69(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.94–1.88(m,3H),1.76–1.66(m,2H),1.66–1.48(m,3H),1.36–1.32(m,11H),1.28(s,1H),1.20(s,1H),0.99–0.95(m,2H).
实施例11 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A11)
1H NMR(500MHz,Chloroform)δ7.63(s,4H),7.47(s,4H),7.36(s,4H),7.26(s,4H),7.21(s,4H),7.14(s,4H),5.98(s,4H),5.77(s,4H),5.16(s,4H),4.60(s,4H),4.32(s,4H),3.53(s,3H),3.45(s,4H),3.35(s,3H),2.58(s,3H),2.19(s,3H),2.09–2.05(m,8H),1.95–1.88(m,11H),1.74–1.68(m,27H),1.65–1.61(m,6H),1.61–1.47(m,31H),1.44–1.39(m,8H),1.35–1.31(m,6H),1.24(s,3H).
实施例12 N-((S)-3-环己基-1-(((S)-4-(新戊基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A12)
1H NMR(500MHz,Chloroform)δ8.31(s,4H),7.60(s,4H),7.49(s,4H),7.40(s,4H),7.21(s,4H),7.15(s,4H),6.18(s,4H),5.46(s,4H),5.25(s,4H),5.12(s,4H),4.63(s,4H),3.43(d,J＝18.9Hz,8H),3.35(s,3H),3.11(s,4H),2.76(s,4H),2.17(s,3H),2.13–2.01(m,8H),1.93(s,4H),1.85–1.81(m,6H),1.73–1.69(m,7H),1.69–1.62(m,7H),1.61–1.42(m,16H),1.33–1.29(m,6H),1.26(s,3H),1.14–1.10(m,3H).
实施例13 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A13)
1H NMR(500MHz,Chloroform)δ7.59(s,4H),7.51(d,J＝1.4Hz,1H),7.46(d,J＝36.6Hz,7H),7.32–7.14(m,29H),6.56(s,4H),5.75(s,4H),5.66(s,4H),5.09(s,4H),4.56(s,4H),4.41(s,4H),4.32(s,4H),3.24(d,J＝17.0Hz,8H),2.32(s,4H),2.10–2.02(m,9H),1.99(s,4H),1.97–1.89(m,8H),1.79(s,4H),1.75–1.52(m,28H),1.40–1.36(m,7H),1.32(s,4H),1.23–1.19(m,8H),1.16(s,3H).
实施例14 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A14)
1H NMR(500MHz,Chloroform)δ7.63(s,1H),7.50(s,1H),7.37(s,1H),7.22(s,1H),7.16(s,1H),6.25(s,1H),6.08(s,1H),5.76(s,1H),4.70(d,J＝19.7Hz,2H),3.24(d,J＝14.7Hz,2H),2.83(s,1H),2.08–2.04(m,2H),2.01(s,1H),1.90(s,1H),1.85–1.78(m,3H),1.75–1.64(m,5H),1.56–1.41(m,6H),1.32(s,1H),1.25–1.21(m,9H).
实施例15 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A15)
1H NMR(500MHz,Chloroform)δ9.45(s,1H),8.16(s,1H),7.51(s,1H),7.42(s,1H),7.22(s,1H),7.16(s,1H),6.16(s,1H),6.07(s,1H),5.85(s,1H),5.08(s,1H),4.48(s,1H),3.32(s,1H),3.24(d,J＝16.1Hz,2H),2.92(s,1H),2.16–2.08(m,2H),2.08–2.04(m,2H),2.02(s,1H),1.80(s,1H),1.76–1.66(m,8H),1.65(s,1H),1.57(s,1H),1.55–1.40(m,8H),1.40–1.37(m,1H),1.31(s,1H),1.12(s,1H),0.90–0.82(m,2H).
实施例16 N-((S)-3-环己基-1-(((S)-4-(新戊基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A16)
1 1H NMR(500MHz,Chloroform)δ7.60(s,1H),7.49(s,1H),7.40(s,1H),7.21(s,1H),7.15(s,1H),6.20(s,1H),5.99(s,1H),5.91(s,1H),5.65(s,1H),4.86(s,1H),4.76(s,1H),3.30(s,1H),3.24(d,J＝17.4Hz,2H),2.92(s,1H),2.65(s,1H),2.08–2.04(m,2H),2.01(s,1H),1.90–1.84(m,2H),1.82(s,1H),1.77–1.65(m,5H),1.60–1.53(m,4H),1.52–1.48(m,2H),1.40(s,1H),1.34(s,1H),1.07–1.03(m,9H).
实施例17 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A17)
1H NMR(500MHz,Chloroform)δ8.13(s,5H),7.89(s,5H),7.65(s,5H),7.28(dd,J＝7.5,4.2Hz,20H),7.21(dd,J＝4.2,2.6Hz,2H),7.20–7.08(m,13H),6.14(s,5H),5.53(s,5H),5.37(s,5H),4.39–4.32(m,15H),4.24(s,5H),3.45(s,5H),3.35(s,4H),3.24(s,5H),2.94(s,4H),2.19(s,4H),2.09–2.05(m,10H),1.92(s,4H),1.80–1.67(m,25H),1.59–1.49(m,15H),1.46–1.38(m,19H),1.23(s,5H).
实施例18 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A18)
1H NMR(500MHz,Chloroform)δ8.37(s,1H),7.89(s,1H),7.73(s,1H),7.31(d,J＝1.5Hz,2H),6.28(s,1H),6.05(s,1H),5.80(s,1H),5.25(s,1H),4.82(s,1H),4.68(s,1H),3.45(s,1H),3.35(s,1H),2.56(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.95–1.88(m,3H),1.73–1.52(m,5H),1.41–1.37(m,2H),1.35–1.29(m,10H),1.18–1.09(m,3H).
实施例19 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A19)
1H NMR(500MHz,Chloroform)δ8.95(s,1H),8.43(s,1H),8.26(s,1H),7.90(s,1H),7.74(s,1H),7.61(s,1H),7.31(d,J＝2.0Hz,2H),5.94(s,1H),4.69(s,1H),4.53(s,1H),3.44(d,J＝9.6Hz,2H),3.35(s,1H),2.95(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.91(t,J＝7.7Hz,3H),1.75–1.68(m,5H),1.68–1.63(m,2H),1.62–1.58(m,2H),1.58–1.46(m,8H),1.45–1.40(m,2H),1.22–1.14(m,2H),1.07(s,1H).
实施例20 N-((S)-3-环己基-1-(((S)-4-(新戊基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A20)
1H NMR(500MHz,Chloroform)δ8.36(s,1H),7.88(s,1H),7.73(s,1H),7.30(d,J＝2.5Hz,2H),6.53(s,1H),6.04(s,1H),5.82(s,1H),5.52(s,1H),4.68(d,J＝6.4Hz,2H),3.45(s,1H),3.35(d,J＝3.1Hz,2H),2.90(s,1H),2.43(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.91(t,J＝5.9Hz,3H),1.74–1.65(m,4H),1.60–1.51(m,6H),1.34(s,1H),1.08–1.04(m,9H).
实施例21 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A21)
1H NMR(500MHz,Chloroform)δ8.31(s,1H),7.92(s,1H),7.74(s,1H),7.34–7.23(m,6H),7.20(s,1H),6.76(s,1H),5.59(s,1H),5.49(s,1H),5.08(s,1H),4.52(s,1H),4.42(s,1H),4.34(s,1H),3.24(d,J＝17.6Hz,2H),2.68(s,1H),2.08–2.04(m,2H),1.74–1.67(m,5H),1.64(dd,J＝2.9,1.7Hz,4H),1.36–1.32(m,2H),1.30(s,1H),1.26(s,1H),1.17(s,1H),1.13–1.05(m,2H),0.98(s,1H).
实施例22 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A22)
1H NMR(500MHz,Chloroform)δ8.34(s,1H),8.22(s,1H),7.88(s,1H),7.72(s,1H),7.30(d,J＝1.5Hz,2H),6.15(s,1H),6.10(s,1H),5.41(s,1H),4.64(d,J＝11.7Hz,2H),3.24(d,J＝14.8Hz,2H),2.90(s,1H),2.11–2.01(m,2H),1.89–1.81(m,4H),1.77(s,1H),1.73–1.68(m,4H),1.66–1.59(m,5H),1.55–1.49(m,2H),1.35(s,1H),1.32–1.28(m,9H).
实施例23 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并噻吩-2-羧酰胺(A23)
1H NMR(500MHz,Chloroform)δ8.93(s,1H),8.55(s,1H),7.91(s,1H),7.72(s,1H),7.30(d,J＝2.6Hz,2H),6.05(s,1H),5.83(s,1H),5.68(s,1H),5.13(s,1H),4.34(s,1H),3.33(s,1H),3.24(d,J＝15.0Hz,2H),2.73(s,1H),2.43(s,1H),2.08–2.04(m,5H),1.85(s,1H),1.78(s,1H),1.73–1.67(m,5H),1.66–1.52(m,7H),1.51(s,2H),1.44–1.39(m,3H),1.34–1.30(m,2H),1.27(s,1H),0.83–0.72(m,2H).
实施例24 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A24)
1H NMR(500MHz,Chloroform)δ7.61(s,2H),7.40–7.26(m,10H),7.18(dd,J＝24.7,8.9Hz,9H),6.51(s,2H),6.14(s,2H),5.17(s,2H),4.61(s,2H),4.40(s,2H),4.27(s,2H),4.19(s,2H),3.60–3.56(m,6H),3.52(s,2H),3.45(s,2H),3.35(s,2H),2.87(s,2H),2.18(s,2H),2.09–2.05(m,4H),1.92(s,2H),1.73–1.69(m,4H),1.60–1.50(m,11H),1.36–1.32(m,3H),1.18(s,2H),1.07–1.03(m,3H).
实施例25 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A25)
1H NMR(500MHz,Chloroform)δ7.40(s,1H),7.27(d,J＝5.4Hz,2H),7.18(d,J＝11.2Hz,2H),6.05(d,J＝0.5Hz,2H),5.79(s,1H),5.25(s,1H),4.80(s,1H),4.65(s,1H),3.88–3.84(m,3H),3.45(s,1H),3.35(s,1H),2.58(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.95–1.91(m,3H),1.73–1.52(m,5H),1.41–1.37(m,2H),1.35–1.29(m,10H),1.19–1.09(m,3H).
实施例26 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A26)
1H NMR(500MHz,Chloroform)δ7.24(s,1H),7.17(s,1H),7.12(d,J＝0.8Hz,2H),7.05(s,1H),6.01(s,1H),5.68(d,J＝17.0Hz,2H),4.92(s,1H),4.81(s,1H),3.98(s,1H),3.81(s,1H),3.74–3.70(m,3H),3.35(s,1H),2.62(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.95–1.91(m,3H),1.90–1.77(m,4H),1.73–1.69(m,2H),1.66–1.54(m,13H),1.39–1.35(m,2H),1.33(s,1H).
实施例27 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A27)
1H NMR(500MHz,Chloroform)δ7.43(s,1H),7.38–7.24(m,7H),7.20(d,J＝8.0Hz,2H),5.93(s,1H),5.87(s,1H),5.57(s,1H),5.47(s,1H),4.73(s,1H),4.55(s,1H),4.39(d,J＝18.9Hz,2H),3.61–3.57(m,3H),3.23(d,J＝15.5Hz,2H),2.08–2.04(m,2H),1.96–1.92(m,3H),1.85(s,1H),1.73–1.64(m,6H),1.61(s,1H),1.41(t,J＝7.7Hz,3H),1.32(s,1H),1.24(s,1H),1.14–1.07(m,2H).
实施例28 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A28)
1H NMR(500MHz,Chloroform)δ7.46(s,47H),7.26(d,J＝19.3Hz,98H),7.17(d,J＝7.3Hz,95H),6.39(s,47H),5.92(d,J＝11.5Hz,95H),5.44(s,47H),4.71(s,46H),4.53(s,46H),3.74–3.70(m,141H),3.24(d,J＝18.1Hz,90H),2.77(s,44H),2.11–2.01(m,97H),1.91(s,34H),1.81(s,43H),1.77–1.69(m,222H),1.66–1.62(m,70H),1.61–1.42(m,241H),1.49–1.42(m,10H),1.40–1.36(m,70H),1.32–1.22(m,478H).
实施例29 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A29)
1H NMR(500MHz,Chloroform)δ7.41(s,1H),7.35–7.22(m,2H),7.19(d,J＝7.5Hz,2H),5.92(s,1H),5.54(s,1H),5.38(s,1H),5.23(s,1H),5.04(s,1H),4.34(s,1H),3.99–3.95(m,3H),3.86(s,1H),3.24(d,J＝15.7Hz,2H),2.86(s,1H),2.08–2.02(m,4H),1.99(s,1H),1.81(s,1H),1.78–1.67(m,7H),1.66–1.51(m,10H),1.43(s,1H),1.41–1.37(m,2H),1.30(s,1H),0.77–0.70(m,2H).
实施例30 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A30)
1H NMR(500MHz,Chloroform)δ7.87(s,1H),7.29(t,J＝9.9Hz,3H),7.22–7.11(m,2H),6.98(s,1H),6.61(s,1H),6.43(s,1H),6.20(s,1H),5.62(s,1H),4.55(s,1H),4.43(d,J＝15.9Hz,2H),4.32(s,1H),3.45(s,1H),3.35(s,1H),3.12(s,1H),2.33(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.94–1.88(m,3H),1.74–1.66(m,4H),1.63–1.55(m,6H),1.35(s,1H).
实施例31 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A31)
1H NMR(500MHz,Chloroform)δ9.04(s,1H),8.68(s,1H),8.53(s,1H),7.42(s,1H),7.38(s,1H),7.06(s,1H),6.78(s,1H),5.77(s,1H),4.93(s,1H),4.55(s,1H),3.99(s,1H),3.35(s,1H),2.63(s,1H),2.19(s,1H),2.10–2.04(m,4H),1.93(s,1H),1.69(dt,J＝18.2,9.1Hz,5H),1.41–1.37(m,2H),1.35–1.27(m,11H),1.24(s,1H),1.05–1.01(m,2H).
实施例32 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A32)
1H NMR(500MHz,Chloroform)δ8.86(s,1H),8.48(s,1H),7.54(s,1H),7.41(s,1H),7.06(s,1H),6.01(s,1H),5.47(s,1H),5.20(s,1H),5.05(s,1H),4.55(s,1H),4.00(s,1H),3.58(s,1H),3.51(s,1H),3.35(s,1H),2.19(s,1H),2.12–2.02(m,2H),2.00–1.96(m,2H),1.94–1.87(m,3H),1.73–1.46(m,14H),1.40–1.36(m,2H),1.32(s,1H),1.12–1.06(m,3H).
实施例33 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A33)
1H NMR(500MHz,Chloroform)δ8.68(s,11H),7.45(s,11H),7.38(s,11H),7.31–7.23(m,34H),7.23–7.17(m,26H),7.16(s,8H),7.11(s,11H),5.89(s,11H),5.79(s,11H),4.76(s,11H),4.51(s,11H),4.35(s,11H),4.29(s,11H),3.24(d,J＝17.5Hz,21H),2.73(s,11H),2.10–2.04(m,23H),2.02(s,9H),1.83(s,10H),1.81–1.74(m,33H),1.73–1.65(m,23H),1.65–1.50(m,45H),1.52(d,J＝5.6Hz,2H),1.34–1.30(m,19H),1.28(s,11H),0.99–0.93(m,32H).
实施例34 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A34)
1H NMR(500MHz,Chloroform)δ8.35(s,1H),7.62(s,1H),7.39(s,1H),7.05(s,1H),6.43(s,1H),5.97(s,1H),5.59(s,1H),5.50(d,J＝15.7Hz,2H),4.67(s,1H),3.24(d,J＝17.3Hz,2H),2.48(s,1H),2.08–2.04(m,2H),1.87(t,J＝9.6Hz,3H),1.78(s,1H),1.72(dd,J＝8.3,4.2Hz,4H),1.67(s,1H),1.65–1.50(m,6H),1.45(s,1H),1.36–1.28(m,10H).
实施例35 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A35)
1H NMR(500MHz,Chloroform)δ8.51(s,1H),8.33(s,1H),8.28(s,1H),7.42(s,1H),7.07(s,1H),6.66(s,1H),6.41(s,1H),5.86(s,1H),5.04(s,1H),4.52(s,1H),3.32(s,1H),3.24(d,J＝16.6Hz,2H),2.97(s,1H),2.16–2.01(m,5H),2.01–1.92(m,2H),1.82(s,1H),1.78–1.69(m,8H),1.65(d,J＝15.4Hz,2H),1.56–1.46(m,3H),1.44–1.40(m,4H),1.32(s,1H),1.17(s,1H),1.07–1.00(m,2H).
实施例36 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A36)
1H NMR(500MHz,Chloroform)δ8.98(s,1H),8.03(d,J＝1.1Hz,2H),7.63(d,J＝5.1Hz,2H),7.37–7.27(m,4H),7.21(s,1H),6.95(s,1H),6.43(s,1H),6.01(s,1H),4.94(s,1H),4.85(s,1H),4.67(s,1H),4.41(s,1H),4.32(s,1H),3.45(s,1H),3.35(s,1H),2.77(s,1H),2.19(s,1H),2.13–2.01(m,2H),1.89(s,1H),1.83–1.74(m,2H),1.74–1.69(m,2H),1.66(d,J＝5.7Hz,2H),1.58–1.49(m,6H),1.31(s,1H).
实施例37 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A37)
1H NMR(500MHz,Chloroform)δ9.39(s,1H),8.47(s,1H),8.11(s,1H),7.62(d,J＝3.2Hz,2H),6.17(d,J＝6.0Hz,2H),5.59(s,1H),5.27(s,1H),4.98(s,1H),4.91(s,1H),3.45(s,1H),3.35(s,1H),2.51(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.98–1.95(m,2H),1.92(s,1H),1.73–1.61(m,5H),1.41–1.37(m,2H),1.34–1.28(m,10H),1.21–1.11(m,3H).
实施例38 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A38)
1H NMR(500MHz,Chloroform)δ9.09(s,1H),8.31(s,1H),8.03(d,J＝4.8Hz,2H),7.61(d,J＝2.2Hz,2H),6.41(s,1H),6.06(s,1H),5.27(s,1H),5.20(s,1H),4.45(s,1H),3.72(s,1H),3.45(s,1H),3.35(s,1H),2.73(s,1H),2.39–2.31(m,2H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.76–1.56(m,15H),1.55–1.45(m,6H),1.30(s,1H).
实施例39 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A39)
1H NMR(500MHz,Chloroform)δ9.55(s,1H),9.32(s,1H),8.12(s,1H),7.96(s,1H),7.64(d,J＝11.6Hz,2H),7.29–7.22(m,4H),7.19(s,1H),6.56(s,1H),6.06(s,1H),5.63(s,1H),5.02(s,1H),4.71(s,1H),4.41(s,1H),4.31(s,1H),3.24(d,J＝17.3Hz,2H),2.37(s,1H),2.10–2.02(m,2H),2.02–1.96(m,3H),1.82(s,1H),1.72(t,J＝9.8Hz,3H),1.69–1.57(m,3H),1.53(s,1H),1.38–1.34(m,2H),1.31(s,1H),1.13–1.04(m,3H).
实施例40 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A40)
1H NMR(500MHz,Chloroform)δ9.29(s,1H),8.16(s,1H),8.11(s,1H),7.65(d,J＝4.6Hz,2H),7.22(s,1H),5.87(d,J＝8.3Hz,2H),5.65(s,1H),4.94(s,1H),4.46(s,1H),3.24(d,J＝14.8Hz,2H),2.72(s,1H),2.11–2.01(m,2H),1.79(d,J＝1.0Hz,2H),1.76–1.62(m,5H),1.59(s,1H),1.49–1.42(m,4H),1.35–1.28(m,11H),1.25(s,1H),1.21–1.15(m,2H).
实施例41 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A41)
1H NMR(500MHz,Chloroform)δ9.64(s,4H),8.11(d,J＝10.4Hz,8H),7.65(d,J＝1.9Hz,8H),6.00(s,4H),5.76(s,4H),5.70(s,4H),5.64(s,4H),5.04(s,4H),4.45(s,4H),3.86(s,4H),3.24(d,J＝17.3Hz,8H),2.85(s,4H),2.11–2.01(m,9H),1.99–1.91(m,12H),1.91–1.80(m,9H),1.75(s,2H),1.75–1.53(m,62H),1.55–1.53(m,1H),1.51(s,3H),1.38–1.34(m,7H),1.30(s,4H),1.06(s,3H),1.03–0.99(m,8H).
实施例42 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A42)
1H NMR(500MHz,Chloroform)δ8.56(s,1H),8.19(s,1H),7.82(s,1H),7.58(s,1H),7.42(s,1H),7.42–7.28(m,5H),7.21(s,1H),6.00(d,J＝2.7Hz,2H),4.43(s,1H),4.33(s,1H),4.11(s,1H),3.83(d,J＝3.7Hz,2H),3.45(s,1H),3.35(s,1H),3.25(s,1H),2.15(s,1H),2.09–2.05(m,2H),1.91(s,1H),1.73–1.69(m,2H),1.62–1.55(m,3H),1.36–1.27(m,6H),1.23(s,1H),1.20–1.14(m,2H).
实施例43 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A43)
1H NMR(500MHz,Chloroform)δ9.34(s,1H),8.46(s,1H),8.17(s,1H),7.82(s,1H),7.72(s,1H),7.55(s,1H),7.50(s,1H),5.96(s,1H),5.84(s,1H),5.40(s,1H),5.22(s,1H),4.77(s,1H),3.45(s,1H),3.35(s,1H),2.83(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.94–1.81(m,3H),1.73–1.63(m,5H),1.40–1.36(m,2H),1.36–1.27(m,10H),1.18(s,1H),1.14–1.10(m,2H).
实施例44 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A44)
1H NMR(500MHz,Chloroform)δ8.47(s,1H),8.24(s,1H),8.06(s,1H),7.73(s,1H),7.65(s,1H),7.43(d,J＝13.7Hz,2H),6.58(s,1H),6.06(s,1H),5.40(s,1H),5.20(s,1H),4.45(s,1H),3.73(s,1H),3.45(s,1H),3.35(s,1H),2.72(s,1H),2.34–2.30(m,2H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.77–1.56(m,15H),1.55–1.46(m,6H),1.30(s,1H).
实施例45 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A45)
1H NMR(500MHz,Chloroform)δ8.42(s,1H),8.15(s,1H),7.79(s,1H),7.69(s,1H),7.47(s,1H),7.42(s,1H),7.34–7.25(m,4H),7.20(s,1H),6.77(s,1H),5.89(s,1H),5.82(s,1H),5.57(d,J＝7.5Hz,2H),4.42(d,J＝5.7Hz,2H),4.34(s,1H),3.24(d,J＝19.0Hz,2H),2.81(s,1H),2.43(s,1H),2.11–2.01(m,2H),1.95(s,1H),1.86(s,1H),1.81–1.74(m,3H),1.69(dt,J＝17.1,8.6Hz,5H),1.47(s,1H),1.41–1.37(m,2H),1.31(s,1H),0.84–0.77(m,2H).
实施例46 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A46)
1H NMR(500MHz,Chloroform)δ8.46(s,3H),8.13(s,3H),7.79(s,3H),7.69(d,J＝0.8Hz,6H),7.44(d,J＝32.8Hz,6H),6.55(s,3H),6.05(s,3H),5.75(s,3H),4.77(d,J＝2.1Hz,6H),3.25(s,3H),3.21(s,3H),2.70(s,3H),2.11–2.01(m,6H),1.96–1.87(m,6H),1.79(d,J＝13.1Hz,5H),1.70(dt,J＝19.3,3.5Hz,19H),1.60–1.51(m,18H),1.35–1.30(m,30H).
实施例47 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-喹啉-2-羧酰胺(A47)
1H NMR(500MHz,Chloroform)δ9.06(s,3H),8.44(s,3H),8.15(s,3H),7.79(s,3H),7.75(s,3H),7.70(s,3H),7.48(d,J＝8.2Hz,6H),7.38(s,3H),5.73(s,3H),4.96(s,3H),4.57(s,3H),3.90(s,3H),3.24(d,J＝14.7Hz,6H),2.92(s,3H),2.15–2.11(m,5H),2.11–2.01(m,9H),1.99(t,J＝7.9Hz,7H),1.80(s,2H),1.76–1.65(m,18H),1.65–1.58(m,24H),1.45(t,J＝13.5Hz,10H),1.36(dd,J＝21.5,15.7Hz,2H),1.33(s,3H),1.20(s,2H),1.11–1.04(m,6H).
实施例48 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A48)
1H NMR(500MHz,Chloroform)δ8.36(s,1H),7.55(d,J＝12.3Hz,2H),7.34(t,J＝21.8Hz,3H),7.30–7.17(m,9H),7.15(d,J＝2.2Hz,2H),7.09(s,1H),6.35(s,1H),6.01(s,1H),5.67(s,1H),5.03(s,1H),4.88(s,1H),4.37(s,1H),4.30(s,1H),3.45(s,1H),3.35(s,1H),3.15(d,J＝18.6Hz,2H),2.94(s,1H),2.19(s,1H),2.10–2.04(m,2H),1.92(s,1H).
实施例49 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A49)
1H NMR(500MHz,Chloroform)δ8.26(s,1H),7.46(s,1H),7.32(t,J＝17.0Hz,3H),7.20(dd,J＝7.8,5.2Hz,4H),7.12(s,1H),7.06(s,1H),6.01(s,1H),5.57(s,1H),4.84(s,1H),4.69(s,1H),4.53(s,1H),3.45(s,1H),3.41(s,1H),3.35(s,1H),3.30(s,1H),3.19(s,1H),2.96(s,1H),2.16(s,1H),2.13–2.01(m,2H),1.89(s,1H),1.30–1.26(m,9H).
实施例50 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A50)
1H NMR(500MHz,Chloroform)δ8.35(s,1H),7.90(s,1H),7.52(d,J＝25.5Hz,2H),7.39(s,1H),7.29–7.21(m,4H),7.14(d,J＝3.6Hz,2H),7.08(s,1H),6.52(s,1H),6.16(s,1H),5.70(s,1H),4.92(s,1H),4.78(s,1H),3.46(d,J＝5.2Hz,2H),3.35(s,1H),3.21(s,1H),2.85(d,J＝4.0Hz,2H),2.17(s,1H),2.13–2.02(m,2H),2.00–1.90(m,3H),1.68(s,1H),1.56–1.50(m,2H),1.49–1.45(m,3H),1.44–1.40(m,2H).
实施例51 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A51)
1H NMR(500MHz,Chloroform)δ8.70(s,1H),7.50(s,1H),7.39–7.20(m,5H),7.20–7.11(m,4H),7.09(d,J＝4.4Hz,2H),7.06–6.94(m,2H),6.90(s,1H),6.19(s,1H),5.93(s,1H),5.51(s,1H),4.70(s,1H),4.25(d,J＝17.1Hz,2H),3.79(d,J＝9.5Hz,2H),3.24(t,J＝8.3Hz,3H),3.04(s,1H),2.16(s,1H),2.12–2.04(m,3H),1.78(s,1H),1.72(s,1H),1.62(s,1H).
实施例52 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A52)
1H NMR(500MHz,Chloroform)δ8.64(d,J＝17.0Hz,2H),8.19(s,1H),7.56(s,1H),7.43(s,1H),7.36–7.27(m,2H),7.27–7.22(m,2H),7.14(d,J＝12.9Hz,2H),7.08(s,1H),5.63(s,1H),5.01(d,J＝14.2Hz,2H),4.78(d,J＝1.3Hz,2H),3.24(d,J＝18.2Hz,2H),3.18(s,1H),3.03(s,1H),2.97(s,1H),2.06(t,J＝3.5Hz,3H),1.94(s,1H),1.88(s,1H),1.81(s,1H),1.21–1.17(m,9H).
实施例53 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-2-羧酰胺(A53)
1H NMR(500MHz,Chloroform)δ8.76(s,1H),7.53(s,1H),7.41(d,J＝25.5Hz,2H),7.27–7.21(m,2H),7.21–7.18(m,2H),7.15(d,J＝7.6Hz,2H),7.08(s,1H),5.95(s,1H),5.61(s,1H),5.25(s,1H),5.14(s,1H),4.78(s,1H),3.42(s,1H),3.25(t,J＝12.6Hz,3H),2.87(s,1H),2.70(s,1H),2.56(s,1H),2.08–2.04(m,2H),2.02–1.90(m,2H),1.87(s,1H),1.80(s,1H),1.68(d,J＝3.3Hz,2H),1.55–1.51(m,4H),1.48(s,1H),1.45–1.39(m,2H).
实施例54 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A54)
1H NMR(500MHz,Chloroform)δ7.51(d,J＝8.2Hz,2H),7.41(s,1H),7.30–7.12(m,12H),6.67(s,1H),5.69–5.61(m,3H),5.09(s,1H),4.88(s,1H),4.41(s,1H),4.33(s,1H),3.45(s,1H),3.35(s,1H),3.26(s,1H),3.16(s,1H),3.07(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H).
实施例55 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A55)
1H NMR(500MHz,Chloroform)δ7.54(s,1H),7.47(d,J＝17.7Hz,2H),7.28–7.22(m,3H),7.18(dd,J＝20.8,5.2Hz,4H),6.42(s,1H),6.05(s,1H),5.83(s,1H),5.27(s,1H),4.98(s,1H),4.85(s,1H),3.45(s,1H),3.35(s,1H),3.19(s,1H),2.96(s,1H),2.61(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.34–1.30(m,9H).
实施例56 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A56)
1H NMR(500MHz,Chloroform)δ8.77(s,2H),8.67(s,2H),7.56(s,1H),7.50(s,3H),7.41(s,2H),7.28–7.19(m,6H),7.16(d,J＝4.9Hz,4H),7.13–7.04(m,4H),6.04(s,2H),5.93(s,2H),5.05(s,2H),4.66(s,2H),3.70(s,2H),3.45(s,2H),3.35(s,1H),3.25(s,2H),3.05(s,2H),2.88(s,2H),2.19(s,2H),2.09–2.05(m,4H),1.97–1.91(m,5H),1.68–1.64(m,3H),1.64–1.43(m,13H).
实施例57 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A57)
1H NMR(500MHz,Chloroform)δ7.48(s,1H),7.29(d,J＝38.0Hz,2H),7.25(s,1H),7.27–7.19(m,3H),7.19–7.05(m,10H),6.97(s,1H),6.43(s,1H),6.07(s,1H),5.18(d,J＝3.4Hz,2H),4.73(s,1H),4.63(s,1H),4.36(s,1H),4.29(s,1H),3.24(d,J＝16.8Hz,2H),3.10(s,1H),2.86(d,J＝21.8Hz,2H),2.43(s,1H),2.08–2.04(m,2H),1.85(s,1H),1.79(s,1H),1.64(s,1H).
实施例58 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A58)
1H NMR(500MHz,Chloroform)δ9.35(s,5H),7.60(s,5H),7.48(d,J＝29.1Hz,10H),7.28–7.18(m,27H),7.16(d,J＝17.5Hz,8H),5.86(s,5H),5.55(s,5H),4.94(s,5H),4.69(s,5H),3.24(t,J＝10.0Hz,14H),2.90(s,5H),2.66(s,5H),2.09–2.02(m,10H),1.92(s,4H),1.84–1.80(m,8H),1.76(s,4H),1.30–1.26(m,44H).
实施例59 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并呋喃-2-羧酰胺(A59)
1H NMR(500MHz,Chloroform)δ9.35(s,5H),7.60(s,5H),7.48(d,J＝29.1Hz,10H),7.28–7.18(m,27H),7.16(d,J＝17.5Hz,8H),5.86(s,5H),5.55(s,5H),4.94(s,5H),4.69(s,5H),3.24(t,J＝10.0Hz,14H),2.90(s,5H),2.66(s,5H),2.09–2.02(m,10H),1.92(s,4H),1.84–1.80(m,8H),1.76(s,4H),1.30–1.26(m,44H).
实施例60 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A60)
1H NMR(500MHz,Chloroform)δ8.40(s,1H),7.91(s,1H),7.76(s,1H),7.33(d,J＝3.7Hz,2H),7.32–7.16(m,10H),7.13(d,J＝16.7Hz,2H),6.27(s,1H),5.97(s,1H),5.64(s,1H),5.03(s,1H),4.89(s,1H),4.34(d,J＝4.2Hz,2H),3.45(s,1H),3.35(s,1H),3.15–3.11(m,2H),2.94(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H).
实施例61 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A61)
1H NMR(500MHz,Chloroform)δ8.93(s,1H),7.82(d,J＝4.4Hz,2H),7.28(dd,J＝20.7,7.2Hz,4H),7.22–7.11(m,3H),6.05(s,1H),4.70(s,1H),4.64(s,1H),4.59(s,1H),4.39(s,1H),3.99(s,1H),3.55(s,1H),3.45(s,1H),3.35(s,1H),3.15(s,1H),2.95(s,1H),2.17(s,1H),2.13–2.02(m,2H),1.89(s,1H),1.21–1.17(m,9H).
实施例62 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A62)
1H NMR(500MHz,Chloroform)δ8.73(s,1H),8.54(s,1H),8.35(s,1H),7.91(s,1H),7.74(s,1H),7.32(d,J＝1.5Hz,2H),7.28–7.23(m,2H),7.15(s,1H),7.12–7.05(m,2H),6.14(s,1H),5.94(s,1H),5.04(s,1H),4.66(s,1H),3.45(d,J＝3.2Hz,2H),3.35(s,1H),3.26(s,1H),3.05(s,1H),2.89(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.95–1.91(m,3H),1.73–1.64(m,3H),1.56–1.52(m,2H),1.50(s,1H),1.46–1.40(m,2H).
实施例63 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A63)
1H NMR(500MHz,Chloroform)δ8.49(s,1H),8.30(s,1H),8.00(s,1H),7.63(s,1H),7.29(dd,J＝19.0,2.9Hz,4H),7.18–7.07(m,5H),7.07–6.97(m,3H),6.33(s,1H),6.11(s,1H),4.93–4.89(m,2H),4.36(d,J＝9.1Hz,2H),4.29(s,1H),3.28–3.20(m,3H),2.92(s,1H),2.58(s,1H),2.16(s,1H),2.08–2.04(m,2H),1.83(s,1H),1.77(s,1H),1.73(s,1H).
实施例64 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A64)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),7.90(s,1H),7.75(s,1H),7.30(dd,J＝17.5,1.0Hz,4H),7.26–7.19(m,2H),7.17(s,1H),7.02(s,1H),6.45(s,1H),6.10(s,1H),5.93(s,1H),4.93(s,1H),4.86(s,1H),3.27–3.11(m,3H),2.95(s,1H),2.83(s,1H),2.11–2.01(m,2H),1.95(s,1H),1.83(s,1H),1.76(s,1H),1.56(s,1H),1.35–1.31(m,9H).
实施例65 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-苯并噻吩-2-羧酰胺(A65)
1H NMR(500MHz,Chloroform)δ8.28(s,6H),7.86(s,6H),7.60(s,6H),7.27(dd,J＝17.2,1.6Hz,20H),7.24–7.12(m,22H),5.78(s,6H),5.41(s,6H),5.09(s,6H),4.97(s,6H),4.85(s,6H),3.31–3.10(m,30H),2.97(s,6H),2.60(s,4H),2.51(s,5H),2.12–2.00(m,12H),1.97–1.86(m,12H),1.71(t,J＝16.5Hz,17H),1.58–1.45(m,30H),1.45–1.36(m,12H),1.12(s,4H).
实施例66 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A66)
1H NMR(500MHz,Chloroform)δ8.78(s,1H),7.69(s,1H),7.49(s,1H),7.34–7.13(m,12H),7.13–7.05(m,2H),6.10(s,1H),5.99(s,1H),5.07(s,1H),4.69(s,1H),4.36(d,J＝3.5Hz,2H),3.78–3.74(m,3H),3.45(s,1H),3.35(s,1H),3.24(s,1H),3.06(s,1H),2.88(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H).
实施例67 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A67)
1H NMR(500MHz,Chloroform)δ7.38(s,1H),7.29–7.13(m,9H),6.07(s,1H),5.82(d,J＝4.8Hz,2H),5.28(s,1H),4.94(s,1H),4.87(s,1H),3.67–3.63(m,3H),3.45(s,1H),3.35(s,1H),3.19(s,1H),2.93(s,1H),2.68(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.94(s,1H),1.34–1.30(m,9H).
实施例68 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A68)
1H NMR(500MHz,Chloroform)δ7.49(s,3H),7.34–7.20(m,23H),7.20(s,3H),7.15(s,2H),6.73(s,3H),6.27(s,3H),5.73(s,3H),5.11(s,3H),4.83(s,3H),3.98(s,2H),3.76(s,3H),3.58–3.54(m,9H),3.35(s,2H),3.22(s,3H),2.88(s,3H),2.63(s,3H),2.19(s,2H),2.09–2.05(m,6H),1.95–1.91(m,7H),1.76–1.66(m,7H),1.66–1.55(m,20H).
实施例69 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A69)
1H NMR(500MHz,Chloroform)δ7.35–7.29(m,2H),7.29–7.26(m,1H),7.26–7.06(m,11H),6.67(s,1H),6.05(d,J＝11.7Hz,2H),5.74(s,1H),4.95(s,1H),4.77(s,1H),4.39(s,1H),4.34(s,1H),3.86–3.82(m,3H),3.29–3.17(m,3H),2.95(s,1H),2.56(s,1H),2.44(s,1H),2.12–2.00(m,2H),1.85(s,1H),1.78(s,1H),1.41(s,1H),1.15(s,1H).
实施例70 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A70)
1H NMR(500MHz,Chloroform)δ7.51(s,1H),7.31(s,1H),7.22(ddd,J＝42.8,13.4,8.7Hz,8H),6.91(s,1H),6.06(s,1H),5.93(s,1H),5.54(s,1H),4.80(s,1H),4.71(s,1H),3.73–3.69(m,3H),3.26(t,J＝14.0Hz,3H),2.82(d,J＝27.3Hz,2H),2.11–2.01(m,2H),1.92(s,1H),1.82(s,1H),1.75(s,1H),1.54(s,1H),1.32–1.28(m,9H).
实施例71 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A71)
1H NMR(500MHz,Chloroform)δ8.25(s,1H),7.38(s,1H),7.28(dd,J＝15.9,3.4Hz,4H),7.24–7.12(m,5H),5.93(s,1H),5.32(s,1H),5.07(s,1H),4.75(s,1H),4.41(s,1H),3.85–3.77(m,4H),3.27–3.20(m,3H),3.04(s,1H),2.84(s,1H),2.49(s,1H),2.17–2.10(m,2H),2.10–2.02(m,2H),1.86–1.75(m,6H),1.65(s,1H),1.58–1.52(m,4H).
实施例72 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A72)
1H NMR(500MHz,Chloroform)δ8.55(s,1H),7.52(s,1H),7.44(s,1H),7.38(s,1H),7.32–7.27(m,4H),7.27–7.12(m,8H),7.10(s,1H),6.00(s,1H),5.04(s,1H),4.92(s,1H),4.77(s,1H),4.38(s,1H),4.30(s,1H),3.45(s,1H),3.35(s,1H),3.27(s,1H),3.12(s,1H),2.87(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H).
实施例73 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A73)
1H NMR(500MHz,Chloroform)δ8.55(s,1H),8.14(s,1H),7.52(s,1H),7.44(s,1H),7.28–7.22(m,2H),7.22–7.11(m,3H),7.09(s,1H),6.01(s,1H),5.55(s,1H),5.12(s,1H),4.74(s,1H),4.31(s,1H),3.45(s,1H),3.35(s,1H),3.30(s,1H),3.08(s,1H),2.92(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.39–1.35(m,9H).
实施例74 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A74)
1H NMR(500MHz,Chloroform)δ8.85(s,1H),8.44(s,1H),8.39(s,1H),7.58(s,1H),7.42(s,1H),7.28–7.23(m,2H),7.15(s,1H),7.12–7.06(m,3H),6.10(s,1H),5.94(s,1H),5.03(s,1H),4.66(s,1H),3.45(d,J＝5.0Hz,2H),3.35(s,1H),3.27(s,1H),3.06(s,1H),2.90(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.95–1.91(m,3H),1.72–1.68(m,3H),1.56–1.52(m,2H),1.50(s,1H),1.46–1.41(m,2H).
实施例75 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A75)
1H NMR(500MHz,Chloroform)δ8.67(s,13H),7.46(s,13H),7.30–7.24(m,28H),7.24–7.14(m,80H),7.12–7.00(m,30H),7.00(s,11H),6.93(d,J＝12.0Hz,26H),6.07(s,13H),4.91(s,13H),4.80(s,13H),4.36(s,13H),4.31(s,13H),4.27(s,13H),4.04(s,13H),3.31(d,J＝52.2Hz,35H),3.22(s,5H),3.01(s,14H),2.86(s,11H),2.31(s,9H),2.08–2.04(m,25H),1.83(s,12H),1.77(s,10H),1.54(s,9H).
实施例76 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A76)
1H NMR(500MHz,Chloroform)δ8.53(s,8H),7.62(s,8H),7.43(s,8H),7.38(s,8H),7.26–7.21(m,16H),7.21–7.14(m,21H),7.14–7.11(m,4H),7.09(s,8H),5.81(s,8H),5.66(s,8H),5.34(s,8H),4.92(s,8H),4.75(s,8H),3.33–3.20(m,24H),2.87(s,7H),2.59(s,7H),2.08–2.04(m,16H),1.86(s,6H),1.80(s,7H),1.73(s,6H),1.48(s,6H),1.34–1.30(m,72H).
实施例77 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A77)
1H NMR(500MHz,Chloroform)δ9.14(s,1H),9.09(s,1H),7.58(s,1H),7.47(s,1H),7.33–7.27(m,2H),7.27–7.14(m,3H),7.10(s,1H),6.82(s,1H),5.96(s,1H),5.80(s,1H),4.98(s,1H),4.82(s,1H),3.35(s,1H),3.24(d,J＝14.7Hz,2H),3.16(s,1H),2.96(s,1H),2.83(s,1H),2.16–2.04(m,5H),1.82(s,1H),1.75(dd,J＝19.9,8.6Hz,4H),1.59–1.49(m,4H),1.44–1.40(m,2H).
实施例78 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A78)
1H NMR(500MHz,Chloroform)δ9.21(s,1H),8.80(s,1H),8.10(d,J＝21.9Hz,2H),7.71(s,1H),7.63(d,J＝6.0Hz,2H),7.30–7.11(m,10H),6.38(s,1H),5.97(s,1H),4.90(s,1H),4.69(s,1H),4.36(d,J＝4.9Hz,2H),3.45(s,1H),3.35(s,1H),3.16(s,1H),2.95(s,1H),2.86(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H).
实施例79 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A79)
1H NMR(500MHz,Chloroform)δ9.43(s,1H),9.01(s,1H),8.10(d,J＝11.8Hz,2H),7.68–7.64(m,2H),7.25–7.19(m,1H),7.19–7.09(m,4H),6.12(s,1H),6.04(s,1H),5.51(s,1H),5.09(s,1H),4.74(s,1H),3.45(s,1H),3.35(d,J＝2.3Hz,2H),3.11(s,1H),2.89(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.39–1.35(m,9H).
实施例80 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A80)
1H NMR(500MHz,Chloroform)δ9.46(s,1H),8.10(d,J＝1.3Hz,2H),7.64(d,J＝1.4Hz,2H),7.29–7.21(m,4H),7.15(s,1H),6.17(s,1H),5.60(s,1H),5.41(s,1H),5.16(s,1H),4.42(s,1H),3.77(s,1H),3.45(s,1H),3.35(d,J＝2.0Hz,2H),2.94(s,1H),2.49(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.81–1.74(m,6H),1.74–1.70(m,2H),1.57–1.51(m,2H).
实施例81 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A81)
1H NMR(500MHz,Chloroform)δ9.04(s,1H),8.07(d,J＝5.3Hz,2H),7.62(d,J＝0.9Hz,2H),7.30–7.20(m,5H),7.20–7.12(m,5H),7.10(s,1H),6.69(s,1H),5.68(d,J＝19.5Hz,2H),5.14(s,1H),5.08(s,1H),4.42(s,1H),4.34(s,1H),3.37(s,1H),3.24(d,J＝17.2Hz,2H),2.95(s,1H),2.15(s,1H),2.09–2.03(m,2H),1.76(s,1H),1.70(s,1H),1.63(s,1H),1.43(s,1H).
实施例82 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A82)
1H NMR(500MHz,Chloroform)δ9.37(s,1H),8.11(d,J＝1.9Hz,2H),7.64(d,J＝1.0Hz,2H),7.32–7.26(m,2H),7.26–7.13(m,3H),6.08(s,1H),5.93(d,J＝13.8Hz,2H),5.60(s,1H),4.97(s,1H),4.83(s,1H),3.24(d,J＝16.7Hz,2H),3.18(s,1H),2.93(s,1H),2.70(s,1H),2.11–2.01(m,2H),1.98(s,1H),1.78(s,1H),1.71(s,1H),1.42(s,1H),1.35–1.31(m,9H).
实施例83 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹喔啉-2-羧酰胺(A83)
1H NMR(500MHz,Chloroform)δ9.67(s,6H),8.12(d,J＝8.3Hz,12H),7.66(d,J＝1.4Hz,12H),7.26–7.16(m,25H),7.14(s,6H),6.12(s,6H),5.79(s,6H),5.56(s,6H),5.33(s,6H),5.10(s,6H),4.95(s,6H),3.84(s,6H),3.27(t,J＝34.6Hz,16H),3.21(d,J＝6.1Hz,2H),3.02(s,6H),2.83(s,6H),2.11–2.01(m,13H),2.01–1.94(m,18H),1.75(s,4H),1.71–1.55(m,59H).
实施例84 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A84)
1H NMR(500MHz,Chloroform)δ8.46(s,1H),8.12(s,1H),7.78(s,1H),7.65(s,1H),7.54(s,1H),7.44(s,1H),7.31–7.24(m,4H),7.24–7.14(m,4H),7.12(s,2H),5.72(s,1H),5.54(s,1H),5.14(s,1H),4.70(s,1H),4.59(s,1H),4.29(d,J＝9.5Hz,2H),3.74(s,1H),3.35(s,1H),3.31(s,1H),3.08(s,1H),2.72(s,1H),2.17(s,1H),2.10–2.05(m,2H),1.89(s,1H).
实施例85 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A85)
1H NMR(500MHz,Chloroform)δ8.40(d,J＝39.3Hz,11H),8.36–8.34(m,1H),8.19(s,6H),7.80(s,6H),7.71(s,6H),7.49(d,J＝5.7Hz,12H),7.30–7.25(m,12H),7.25–7.15(m,14H),7.14(s,4H),6.20(s,6H),5.92(s,6H),5.07(s,6H),4.75(s,6H),3.45(s,6H),3.38(d,J＝25.1Hz,12H),3.32(s,1H),3.02(s,6H),2.35(s,5H),2.19(s,4H),2.09–2.05(m,12H),1.92(s,5H),1.36–1.32(m,53H).
实施例86 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A86)
1H NMR(500MHz,Chloroform)δ8.46(s,1H),8.12(s,1H),7.81(s,1H),7.69(s,1H),7.49(d,J＝7.1Hz,2H),7.26–7.20(m,2H),7.20–7.09(m,3H),5.94(d,J＝1.5Hz,2H),5.63(s,1H),5.44(s,1H),4.91(s,1H),4.76(s,1H),3.89(s,1H),3.45(s,1H),3.34(d,J＝11.1Hz,2H),3.01(s,1H),2.19(d,J＝10.9Hz,2H),2.14–2.04(m,4H),1.92(s,1H),1.65–1.49(m,8H).
实施例87 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A87)
1H NMR(500MHz,Chloroform)δ8.46(s,1H),8.10(s,1H),7.78(s,1H),7.66(s,1H),7.55(s,1H),7.45(s,1H),7.26–7.11(m,10H),6.86(s,1H),5.98(s,1H),5.89(s,1H),5.56(d,J＝16.8Hz,2H),4.75(s,1H),4.44(s,1H),4.32(s,1H),3.44(s,1H),3.23(d,J＝18.1Hz,2H),2.84(s,1H),2.72(s,1H),2.11–2.01(m,2H),1.98(s,1H),1.63(s,1H),1.56(s,1H),1.25(s,1H).
实施例88 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A88)
1H NMR(500MHz,Chloroform)δ8.50(d,J＝13.8Hz,2H),8.17(s,1H),7.81(s,1H),7.69(s,1H),7.65(s,1H),7.48(s,1H),7.28–7.24(m,1H),7.24–7.11(m,4H),6.95(s,1H),6.17(s,1H),5.50(s,1H),5.00(s,1H),4.79(s,1H),3.24(d,J＝15.4Hz,2H),3.08(s,1H),2.90(s,1H),2.69(s,1H),2.11–2.01(m,2H),1.90(s,1H),1.84(d,J＝3.8Hz,2H),1.78(s,1H),1.29–1.25(m,9H).
实施例89 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-喹啉-2-羧酰胺(A89)
1H NMR(500MHz,Chloroform)δ9.70(s,4H),8.44(s,4H),8.18(s,4H),7.80(s,4H),7.69(d,J＝18.4Hz,8H),7.48(d,J＝4.0Hz,8H),7.32–7.26(m,8H),7.23–7.13(m,12H),6.67(s,4H),5.84(s,4H),4.95(s,4H),4.88(s,4H),3.90(s,4H),3.31(d,J＝56.1Hz,10H),3.22(s,2H),2.99(s,4H),2.86(s,4H),2.11–2.04(m,8H),2.01(t,J＝7.0Hz,12H),1.81(s,3H),1.74(s,3H),1.67–1.60(m,35H),1.45(s,3H).
实施例90 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A90)
1H NMR(500MHz,Chloroform)δ8.36(s,1H),7.52(d,J＝19.2Hz,2H),7.39(s,1H),7.26–7.19(m,4H),7.18(s,1H),7.13(s,1H),7.07(s,1H),6.32(s,1H),6.24(s,1H),6.05(s,1H),5.47(s,1H),5.27(s,1H),4.61(s,1H),4.41(s,1H),4.32(s,1H),3.59(s,1H),3.45(s,1H),2.17(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.73(d,J＝11.4Hz,2H),1.63(s,1H),1.55(s,1H),1.12–0.99(m,6H).
实施例91 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A91)
1H NMR(500MHz,Chloroform)δ9.33(s,1H),8.28(s,1H),7.46(d,J＝15.1Hz,2H),7.35(s,1H),7.10(s,1H),7.03(s,1H),6.79(s,1H),6.12(s,1H),5.28(s,1H),4.95(s,1H),4.31(s,1H),3.45(s,1H),3.35(s,1H),2.75(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.70(d,J＝19.2Hz,2H),1.44(s,1H),1.36–1.32(m,9H),0.99–0.85(m,6H).
实施例92 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A92)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),7.51(d,J＝17.6Hz,2H),7.37(s,1H),7.12(s,1H),7.06(s,1H),6.50(s,1H),6.00(s,1H),5.60(s,1H),5.50(s,1H),5.00(s,1H),4.68(s,1H),3.45(s,1H),3.35(s,1H),3.29(s,1H),2.71(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.97–1.91(m,3H),1.70(t,J＝9.1Hz,3H),1.59–1.55(m,2H),1.50(dd,J＝10.4,1.1Hz,4H),1.43–1.38(m,2H),1.13–1.00(m,6H).
实施例93 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A93)
1H NMR(500MHz,Chloroform)δ8.63(s,1H),7.56(s,1H),7.46(d,J＝25.5Hz,2H),7.29–7.24(m,2H),7.24–7.17(m,3H),7.17–7.06(m,3H),6.14(s,1H),5.63(s,1H),5.02(d,J＝15.0Hz,2H),4.43(s,1H),4.37(s,1H),4.30(s,1H),3.24(d,J＝17.4Hz,2H),2.81(s,1H),2.21(s,1H),2.08–2.04(m,2H),1.85(s,1H),1.77(t,J＝13.2Hz,3H),1.51(s,1H),1.41(s,1H),1.04–0.90(m,6H).
实施例94 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A94)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),8.13(s,1H),7.49(s,1H),7.41(s,1H),7.37(s,1H),7.12(s,1H),7.04(s,1H),5.95(s,1H),5.30(d,J＝18.0Hz,2H),4.86(s,1H),4.51(s,1H),3.23(d,J＝15.7Hz,2H),2.45(s,1H),2.19(s,1H),2.08–2.04(m,2H),1.96(s,1H),1.75(s,1H),1.69(d,J＝8.0Hz,2H),1.51(s,1H),1.36–1.27(m,10H),1.12–0.99(m,6H).
实施例95 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1H-吲哚-2-羧酰胺(A95)
1H NMR(500MHz,Chloroform)δ9.04(s,1H),8.28(s,1H),7.50(d,J＝31.2Hz,2H),7.38(s,1H),7.13(s,1H),7.06(s,1H),6.19(s,1H),5.81(s,1H),5.63(s,1H),4.78(s,1H),4.59(s,1H),3.94(s,1H),3.24(d,J＝18.2Hz,2H),2.35(s,1H),2.13–2.04(m,4H),2.00(s,1H),1.83–1.60(m,8H),1.57(s,1H),1.52–1.46(m,2H),1.45–1.41(m,2H),1.33(s,1H),1.13–1.01(m,6H).
实施例96 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A96)
1H NMR(500MHz,Chloroform)δ7.74(s,1H),7.42(s,1H),7.36–7.26(m,4H),7.23(s,1H),7.17(s,1H),7.07(s,1H),6.96(s,1H),6.46(s,1H),6.22(s,1H),5.75(s,1H),5.06(s,1H),4.63(s,1H),4.46(d,J＝17.5Hz,2H),4.34(s,1H),3.45(s,1H),3.35(s,1H),3.28(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.67(s,1H),1.55(s,1H),1.19(s,1H),1.07–0.94(m,6H).
实施例97 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A97)
1H NMR(500MHz,Chloroform)δ8.17(s,1H),7.45(d,J＝28.3Hz,2H),7.22(s,1H),7.15(s,1H),6.41(s,1H),6.00(s,1H),5.96(s,1H),4.94(s,1H),4.55(s,1H),3.45(s,1H),3.35(s,1H),2.53(s,1H),2.18(s,1H),2.13–2.02(m,2H),1.93(s,1H),1.76(s,1H),1.65(s,1H),1.35–1.31(m,9H),1.25(s,1H),1.07–0.94(m,6H).
实施例98 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A98)
1H NMR(500MHz,Chloroform)δ7.59(s,4H),7.55–7.39(m,12H),7.22(s,4H),7.15(s,4H),6.04(s,4H),5.94(s,4H),5.89(s,4H),4.87(s,4H),4.48(s,4H),3.80(s,4H),3.45(s,4H),3.35(s,3H),2.58(s,4H),2.18(s,4H),2.11–2.04(m,8H),1.95–1.88(m,19H),1.87(t,J＝3.1Hz,4H),1.75(d,J＝29.9Hz,6H),1.71(d,J＝3.3Hz,2H),1.69–1.64(m,8H),1.62(s,3H),1.59–1.51(m,8H),1.06–0.93(m,24H).
实施例99 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A99)
1H NMR(500MHz,Chloroform)δ7.58(s,1H),7.52(d,J＝13.8Hz,2H),7.38–7.32(m,2H),7.30(s,1H),7.26(s,1H),7.23–7.16(m,3H),6.21(s,1H),5.77(s,1H),5.68(s,1H),4.86(s,1H),4.82(s,1H),4.56(s,1H),4.37(s,1H),4.33(s,1H),3.24(d,J＝17.0Hz,2H),2.63(s,1H),2.05(t,J＝5.4Hz,3H),1.82(s,1H),1.75(s,1H),1.60(d,J＝3.4Hz,2H),1.48(s,1H),1.39(s,1H),1.09–1.00(m,6H).
实施例100 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A100)
1H NMR(500MHz,Chloroform)δ7.58(s,1H),7.52(d,J＝13.8Hz,2H),7.38–7.32(m,2H),7.30(s,1H),7.26(s,1H),7.23–7.16(m,3H),6.21(s,1H),5.77(s,1H),5.68(s,1H),4.86(s,1H),4.82(s,1H),4.56(s,1H),4.37(s,1H),4.33(s,1H),3.24(d,J＝17.0Hz,2H),2.63(s,1H),2.05(t,J＝5.4Hz,3H),1.82(s,1H),1.75(s,1H),1.60(d,J＝3.4Hz,2H),1.48(s,1H),1.39(s,1H),1.09–1.00(m,6H).
实施例101 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并呋喃-2-羧酰胺(A101)
1H NMR(500MHz,Chloroform)δ7.59(s,1H),7.48(d,J＝9.6Hz,2H),7.20(s,1H),7.14(s,1H),5.80(s,1H),5.26(s,1H),5.11(d,J＝5.2Hz,2H),4.91(s,1H),3.81(s,1H),3.24(d,J＝17.3Hz,2H),2.61(s,1H),2.09–2.02(m,4H),1.95–1.87(m,2H),1.84(s,1H),1.77(s,1H),1.69(s,1H),1.58(d,J＝5.5Hz,2H),1.51–1.44(m,4H),1.26–1.22(m,4H),1.08–0.95(m,6H).
实施例102 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A102)
1H NMR(500MHz,Chloroform)δ8.47(s,1H),7.91(s,1H),7.78(s,1H),7.33(d,J＝6.1Hz,2H),7.28–7.17(m,5H),6.42(s,1H),6.05(s,1H),5.73(s,1H),5.38(s,1H),5.27(s,1H),4.46(s,1H),4.36(d,J＝16.9Hz,2H),3.45(s,1H),3.35(s,1H),2.67(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.82(s,1H),1.70(s,1H),1.52(s,1H),1.10–0.96(m,6H).
实施例103 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A103)
1H NMR(500MHz,Chloroform)δ8.37(s,1H),7.89(s,1H),7.73(s,1H),7.30(d,J＝2.2Hz,2H),6.58(s,1H),6.03(s,1H),5.61(s,1H),5.53(s,1H),5.02(s,1H),4.70(s,1H),3.45(s,1H),3.35(s,1H),2.69(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.69(d,J＝8.4Hz,2H),1.49(s,1H),1.32–1.28(m,9H),1.10–1.02(m,6H).
实施例104 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A104)
1H NMR(500MHz,Chloroform)δ8.63(s,1H),7.91(s,1H),7.74(s,1H),7.34–7.30(m,2H),6.18(d,J＝11.5Hz,2H),6.02(s,1H),4.62(s,1H),4.48(s,1H),3.45(s,1H),3.35(s,1H),3.27(s,1H),2.56(s,1H),2.19(s,1H),2.11–2.05(m,3H),1.92(s,1H),1.83–1.70(m,3H),1.69(s,1H),1.59–1.54(m,3H),1.50(t,J＝6.7Hz,3H),1.42–1.37(m,2H),1.12–0.98(m,6H).
实施例105 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A105)
1H NMR(500MHz,Chloroform)δ8.43(s,1H),7.93(d,J＝0.7Hz,2H),7.74(s,1H),7.33(d,J＝2.2Hz,2H),7.30–7.25(m,4H),7.20(s,1H),6.65(s,1H),6.05(s,1H),5.58(s,1H),4.71(s,1H),4.52(s,1H),4.40(s,1H),4.30(s,1H),3.23(d,J＝15.8Hz,2H),2.73(s,1H),2.16(s,1H),2.08–2.04(m,2H),1.80(s,1H),1.69(d,J＝6.6Hz,2H),1.63(s,1H),1.44(s,1H),1.35(s,1H),1.12–0.99(m,6H).
实施例106 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A106)
1H NMR(500MHz,Chloroform)δ8.39(s,1H),7.91(s,1H),7.71(s,1H),7.31(d,J＝2.6Hz,2H),6.50(s,1H),5.87(s,1H),5.71(s,1H),5.57(s,1H),4.80(s,1H),4.75(s,1H),3.23(d,J＝15.7Hz,2H),2.64(s,1H),2.08–2.04(m,2H),1.87(d,J＝17.5Hz,2H),1.68(d,J＝6.0Hz,2H),1.61(d,J＝2.0Hz,2H),1.37(s,1H),1.32–1.28(m,9H),1.10–0.97(m,6H).
实施例107 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-苯并噻吩-2-羧酰胺(A107)
1H NMR(500MHz,Chloroform)δ8.30(s,15H),8.25(s,15H),7.87(s,15H),7.71(s,15H),7.30(d,J＝1.3Hz,30H),6.03(s,15H),5.58(s,15H),5.39(s,15H),5.03(s,15H),4.37(s,15H),3.85(s,15H),3.24(d,J＝16.7Hz,29H),2.67(s,11H),2.57(s,13H),2.08–2.04(m,30H),1.96–1.90(m,46H),1.86(s,15H),1.79(s,12H),1.76–1.53(m,169H),1.58(d,J＝5.6Hz,3H),1.05–0.92(m,93H).
实施例108 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A108)
1H NMR(500MHz,Chloroform)δ7.39(d,J＝5.1Hz,10H),7.31–7.22(m,12H),7.22–7.06(m,35H),5.99(s,5H),5.29(s,5H),4.40(d,J＝4.6Hz,10H),4.30(d,J＝5.3Hz,1H),4.24(d,J＝52.5Hz,9H),3.68–3.64(m,15H),3.58(s,5H),3.45(s,5H),2.78(s,5H),2.17(s,3H),2.15–1.95(m,17H),1.89(s,4H),1.81(s,5H),1.62(s,5H),1.48(s,4H),1.07–0.94(m,31H).
实施例109 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A109)
1H NMR(500MHz,Chloroform)δ8.20(s,1H),7.48(s,1H),7.27(d,J＝17.1Hz,2H),7.18(d,J＝7.0Hz,2H),6.13(s,1H),5.90(s,1H),5.38(s,1H),5.08(s,1H),4.65(s,1H),3.79–3.75(m,3H),3.45(s,1H),3.35(s,1H),2.81(s,1H),2.17(s,1H),2.13–2.02(m,2H),1.93(s,1H),1.67(s,1H),1.60(s,1H),1.55(s,1H),1.34–1.30(m,9H),1.13–1.00(m,6H).
实施例110 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A110)
1H NMR(500MHz,Chloroform)δ7.37(s,3H),7.28(d,J＝4.7Hz,6H),7.19(d,J＝11.4Hz,6H),6.24(s,3H),5.90(s,3H),5.81(s,3H),5.30(s,3H),4.90(s,3H),4.68(s,3H),3.90–3.86(m,9H),3.45(s,3H),3.37–3.33(m,5H),2.70(s,3H),2.19(s,3H),2.12–2.04(m,6H),1.93(s,3H),1.86–1.76(m,9H),1.71–1.60(m,11H),1.60–1.54(m,1H),1.51(dd,J＝18.4,1.5Hz,11H),1.44–1.38(m,6H),1.08–0.95(m,18H).
实施例111 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A111)
1H NMR(500MHz,Chloroform)δ7.62(s,1H),7.34(s,1H),7.30–7.17(m,8H),6.58(s,1H),6.10(s,1H),5.61(s,1H),5.41(s,1H),4.83(s,1H),4.48(s,1H),4.37(s,1H),4.32(s,1H),3.76–3.72(m,3H),3.24(d,J＝17.6Hz,2H),2.57(s,1H),2.08–2.04(m,2H),1.80(s,1H),1.76(s,1H),1.71–1.65(m,2H),1.56(d,J＝15.2Hz,2H),1.21(s,1H),1.10–0.97(m,6H).
实施例112 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A112)
1H NMR(500MHz,Chloroform)δ7.57(s,1H),7.51(s,1H),7.31(s,1H),7.25(s,1H),7.18(d,J＝5.1Hz,2H),5.92(s,1H),5.59(s,1H),5.43(s,1H),4.99(s,1H),4.47(s,1H),3.74–3.70(m,3H),3.24(d,J＝16.8Hz,2H),2.71(s,1H),2.41(s,1H),2.08–2.04(m,2H),1.76(dd,J＝34.2,16.8Hz,4H),1.55(s,1H),1.45(s,1H),1.30–1.26(m,9H),1.09–0.96(m,6H).
实施例113 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-1-甲基-1H-吲哚-2-羧酰胺(A113)
1H NMR(500MHz,Chloroform)δ7.57(s,1H),7.51(s,1H),7.31(s,1H),7.25(s,1H),7.18(d,J＝5.1Hz,2H),5.92(s,1H),5.59(s,1H),5.43(s,1H),4.99(s,1H),4.47(s,1H),3.74–3.70(m,3H),3.24(d,J＝16.8Hz,2H),2.71(s,1H),2.41(s,1H),2.08–2.04(m,2H),1.76(dd,J＝34.2,16.8Hz,4H),1.55(s,1H),1.45(s,1H),1.30–1.26(m,9H),1.09–0.96(m,6H).
实施例114 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A114)
1H NMR(500MHz,Chloroform)δ9.48(s,5H),7.69(s,5H),7.37(s,5H),7.29(d,J＝6.5Hz,3H),7.28–7.15(m,23H),7.06(s,5H),6.19(s,5H),5.64(s,5H),5.49(s,5H),5.18(s,5H),4.42(s,5H),4.35(d,J＝14.2Hz,10H),3.45(s,5H),3.35(d,J＝1.5Hz,9H),3.05(s,5H),2.19(s,4H),2.09–2.05(m,10H),1.92(s,4H),1.68(s,5H),1.58(s,5H),1.52(s,5H),1.02–0.89(m,31H).
实施例115 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A115)
1H NMR(500MHz,Chloroform)δ8.36(s,1H),7.60(s,1H),7.40(s,1H),7.06(s,1H),6.45(s,1H),6.04(s,1H),5.52(d,J＝2.2Hz,2H),4.99(s,1H),4.68(s,1H),3.45(s,1H),3.35(s,1H),2.72(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.70(d,J＝9.3Hz,2H),1.49(s,1H),1.32–1.28(m,9H),1.11–1.02(m,6H).
实施例116 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A116)
1H NMR(500MHz,Chloroform)δ9.33(s,1H),8.27(s,1H),7.54(s,1H),7.37(s,1H),7.03(s,1H),6.84(s,1H),6.14(s,1H),5.29(s,1H),4.95(s,1H),4.31(s,1H),3.83(s,1H),3.45(s,1H),3.35(s,1H),2.73(s,1H),2.19(s,1H),2.09–2.05(m,2H),2.05–1.90(m,3H),1.72(s,1H),1.70–1.44(m,9H),1.44(d,J＝5.3Hz,1H),0.98–0.85(m,6H).
实施例117 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A117)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),7.67(s,1H),7.42(s,1H),7.29–7.22(m,4H),7.19(s,1H),7.10(d,J＝11.4Hz,2H),6.65(s,1H),5.62(s,1H),5.55(s,1H),4.99(s,1H),4.48(s,1H),4.37(s,1H),4.33(s,1H),3.24(d,J＝16.8Hz,2H),2.56(s,1H),2.45(s,1H),2.08–2.04(m,2H),1.80(d,J＝3.6Hz,2H),1.72(d,J＝14.6Hz,2H),1.55(s,1H),1.46(s,1H),1.10–0.97(m,6H).
实施例118 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A118)
1H NMR(500MHz,Chloroform)δ8.59(s,1H),7.55(s,1H),7.41(s,1H),7.05(s,1H),6.20(s,1H),5.74(s,1H),5.41(s,1H),4.71(s,1H),4.48(s,1H),3.24(d,J＝17.3Hz,2H),2.48(s,1H),2.06(t,J＝2.1Hz,3H),1.86–1.74(m,3H),1.68(s,1H),1.58(s,1H),1.53(s,1H),1.32–1.28(m,9H),1.15–1.01(m,6H).
实施例119 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A119)
1H NMR(500MHz,Chloroform)δ8.63(s,1H),8.33(s,1H),7.58(s,1H),7.40(s,1H),7.07(s,1H),6.32(s,1H),5.80(s,1H),5.52(s,1H),4.79(s,1H),4.59(s,1H),3.96(s,1H),3.24(d,J＝17.9Hz,2H),2.36(s,1H),2.15–2.08(m,2H),2.08–2.04(m,2H),2.00(s,1H),1.74–1.68(m,5H),1.68–1.60(m,3H),1.60–1.50(m,5H),1.33(s,1H),1.13–1.01(m,6H).
实施例120 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A120)
1H NMR(500MHz,Chloroform)δ8.79(s,1H),8.05(s,1H),8.01(s,1H),7.64(d,J＝1.5Hz,2H),7.36–7.25(m,4H),7.20(s,1H),5.82(s,1H),5.78(s,1H),5.24(s,1H),4.97(s,1H),4.68(s,1H),4.36(s,1H),4.23(s,1H),3.68(s,1H),3.45(s,1H),3.35(s,1H),2.21(s,1H),2.09–2.05(m,2H),1.90(d,J＝15.7Hz,2H),1.76(s,1H),1.65(s,1H),1.45(s,1H),1.10–0.97(m,6H).
实施例121 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A121)
1H NMR(500MHz,Chloroform)δ9.24(s,1H),8.11(d,J＝7.7Hz,2H),7.85(s,1H),7.65(d,J＝1.9Hz,2H),6.22(s,1H),6.11(s,1H),5.66(s,1H),4.77(s,1H),4.62(s,1H),3.45(s,1H),3.35(s,1H),2.79(s,1H),2.17(s,1H),2.13–2.02(m,2H),1.92(s,1H),1.67(d,J＝2.5Hz,2H),1.51(s,1H),1.34–1.30(m,9H),1.11–1.02(m,6H).
实施例122 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A122)
1H NMR(500MHz,Chloroform)δ9.29(s,1H),8.09(d,J＝18.4Hz,2H),7.60(d,J＝2.0Hz,2H),6.27(s,1H),6.23(s,1H),5.90(s,1H),5.24(s,1H),4.80(s,1H),4.70(s,1H),3.45(s,1H),3.35(d,J＝1.2Hz,2H),2.58(s,1H),2.18(s,1H),2.11–2.03(m,2H),1.93(s,1H),1.86–1.71(m,3H),1.71–1.60(m,4H),1.55–1.46(m,4H),1.44–1.39(m,2H),1.09–0.96(m,6H).
实施例123 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A123)
1H NMR(500MHz,Chloroform)δ9.35(s,1H),8.12(s,1H),7.95(s,1H),7.64(d,J＝15.8Hz,2H),7.33–7.26(m,3H),7.26–7.21(m,2H),6.55(s,1H),6.29(s,1H),5.62(d,J＝10.0Hz,2H),4.84(s,1H),4.54(s,1H),4.16(d,J＝16.2Hz,2H),3.24(d,J＝17.4Hz,2H),2.98(s,1H),2.32(s,1H),2.10–2.04(m,3H),1.85(s,1H),1.78(s,1H),1.71(s,1H),1.59(s,1H),1.45(s,1H),1.13–1.00(m,6H).
实施例124 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A124)
1H NMR(500MHz,Chloroform)δ9.23(s,1H),8.12(d,J＝11.8Hz,2H),7.65(d,J＝2.9Hz,2H),6.31(s,1H),6.08(s,1H),5.70(s,1H),5.63(s,1H),4.89(s,1H),4.62(s,1H),3.24(d,J＝17.3Hz,2H),2.62(s,1H),2.04(t,J＝12.6Hz,3H),1.80(s,1H),1.76–1.69(m,3H),1.51(s,1H),1.40(s,1H),1.33–1.29(m,9H),1.12–0.99(m,6H).
实施例125 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹喔啉-2-羧酰胺(A125)
1H NMR(500MHz,Chloroform)δ9.32(s,1H),8.97(s,1H),8.11(d,J＝3.7Hz,2H),7.65(d,J＝2.2Hz,2H),5.73(s,1H),5.60(s,1H),5.56(s,1H),4.72(s,1H),4.51(s,1H),3.31–3.20(m,3H),2.59(s,1H),2.08–2.00(m,5H),1.81(s,1H),1.69(d,J＝9.0Hz,2H),1.62(s,1H),1.60–1.54(m,3H),1.53–1.42(m,3H),1.39(dd,J＝11.3,3.2Hz,4H),1.09–0.96(m,6H).
实施例126 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A126)
1H NMR(500MHz,Chloroform)δ8.47(s,1H),8.14(s,1H),7.80(s,1H),7.68(s,1H),7.52(s,1H),7.47(s,1H),7.30–7.26(m,1H),7.26–7.17(m,5H),6.50(s,1H),6.42(s,1H),6.10(s,1H),5.27(s,1H),4.65(d,J＝5.3Hz,2H),4.40(s,1H),4.32(s,1H),3.45(s,1H),3.35(s,1H),2.65(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.69(s,1H),1.59(d,J＝10.7Hz,2H),1.13–1.00(m,7H).
实施例127 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A127)
1H NMR(500MHz,Chloroform)δ8.36(s,1H),8.14(s,1H),7.77(s,1H),7.69(s,1H),7.46(s,1H),7.40(s,1H),6.36(s,1H),6.13(s,1H),6.02(s,1H),5.67(s,1H),4.93(s,1H),4.61(s,1H),3.45(s,1H),3.35(s,1H),2.63(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.73(d,J＝1.3Hz,2H),1.52(s,1H),1.33–1.29(m,9H),1.09–1.03(m,6H).
实施例128 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A128)
1H NMR(500MHz,Chloroform)δ9.46(s,1H),8.44(s,1H),8.17(s,1H),7.80(s,1H),7.71(s,1H),7.47(d,J＝10.8Hz,2H),5.88(s,1H),5.82(s,1H),5.18(s,1H),4.96(s,1H),4.52(s,1H),3.74(s,1H),3.45(s,1H),3.35(s,1H),2.64(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.95(t,J＝7.9Hz,3H),1.71(s,1H),1.57(tt,J＝16.6,2.2Hz,9H),1.44(s,1H),1.11–0.98(m,6H).
实施例129 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-4-甲基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A129)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),8.18(s,1H),7.81(s,1H),7.72(s,1H),7.47(d,J＝14.9Hz,2H),7.29–7.21(m,4H),7.19(s,1H),6.66(s,1H),6.36(s,1H),5.90(s,1H),5.60(s,1H),5.00(s,1H),4.50(s,1H),4.34(d,J＝14.6Hz,2H),3.24(d,J＝16.9Hz,2H),2.47(d,J＝1.9Hz,2H),2.08–2.04(m,2H),1.80(s,1H),1.77–1.69(m,3H),1.55(s,1H),1.46(s,1H),1.09–0.96(m,6H).
实施例130 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A130)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),8.17(s,1H),7.81(s,1H),7.71(s,1H),7.48(d,J＝2.3Hz,2H),5.90(s,1H),5.74(s,1H),5.54(s,1H),5.27(s,1H),5.13(s,1H),4.51(s,1H),3.24(d,J＝17.6Hz,2H),2.61(s,1H),2.08–2.04(m,2H),1.89–1.64(m,5H),1.48(d,J＝18.1Hz,2H),1.33–1.29(m,9H),1.09–0.96(m,6H).
实施例131 N-((S)-3-环己基-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代戊-2-基)-喹啉-2-羧酰胺(A131)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),8.17(s,1H),7.81(s,1H),7.71(s,1H),7.49(d,J＝4.2Hz,2H),6.05(s,1H),5.83(s,1H),5.54(s,1H),5.39(s,1H),5.11(s,1H),4.52(s,1H),3.30–3.20(m,3H),2.61(s,1H),2.08–2.04(m,2H),2.02–1.90(m,2H),1.87–1.77(m,3H),1.75–1.68(m,5H),1.55–1.44(m,5H),1.44–1.39(m,2H),1.09–0.96(m,6H).
实施例132 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A132)
1H NMR(500MHz,Chloroform)δ7.39–7.29(m,2H),7.29–7.20(m,7H),7.18(s,1H),6.65(s,1H),6.45(d,J＝4.2Hz,2H),6.24(s,1H),6.13(d,J＝3.8Hz,2H),6.03(s,1H),5.47(s,1H),4.93(d,J＝16.9Hz,2H),4.66(s,1H),4.42(s,1H),4.33(s,1H),3.66(s,1H),3.45(s,1H),3.40–3.30(m,3H),3.18(s,1H),2.96(d,J＝11.1Hz,2H),2.18(s,1H),2.12–2.02(m,2H),1.93(s,1H).
实施例133 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A133)
1H NMR(500MHz,Chloroform)δ7.27–7.21(m,2H),7.21–7.11(m,3H),7.10(s,1H),6.49(s,1H),6.31(s,1H),6.20(s,1H),6.13(s,1H),5.96(d,J＝15.6Hz,2H),5.67(s,1H),4.90(s,1H),4.85(s,1H),4.66(s,1H),4.14(s,1H),3.69(s,1H),3.42(d,J＝26.2Hz,2H),3.33(d,J＝15.0Hz,2H),3.23(s,1H),2.83(s,1H),2.68(s,1H),2.17(s,1H),2.09–2.05(m,2H),1.91(s,1H),1.36–1.32(m,10H).
实施例134 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A134)
1H NMR(500MHz,Chloroform)δ8.76(s,5H),8.45(s,5H),7.29–7.23(m,10H),7.16(s,5H),7.14–7.05(m,10H),6.44(s,5H),6.29(s,5H),6.03(s,5H),5.93(d,J＝10.5Hz,10H),5.21(s,5H),5.05(s,5H),4.64(d,J＝18.2Hz,10H),3.67(s,4H),3.48–3.46(m,2H),3.43(t,J＝11.4Hz,14H),3.37(dt,J＝43.5,18.6Hz,29H),3.05(s,5H),2.86(s,5H),2.19(s,5H),2.09–2.05(m,10H),1.95–1.86(m,15H),1.72–1.64(m,15H),1.56–1.52(m,9H),1.50(s,6H),1.45–1.40(m,10H).
实施例135 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A135)
1H NMR(500MHz,Chloroform)δ7.82(s,1H),7.30–7.22(m,4H),7.21–7.07(m,6H),6.48(s,1H),6.29(s,1H),6.16(s,1H),6.09(s,1H),5.96(d,J＝19.6Hz,2H),5.31(s,1H),4.94(s,1H),4.66(s,1H),4.61(s,1H),4.41(s,1H),4.33(s,1H),3.72(s,1H),3.51–3.12(m,5H),3.24(d,J＝16.9Hz,2H),3.24(d,J＝16.9Hz,2H),2.96(s,1H),2.43(s,1H),2.19(s,1H),2.08–2.03(m,2H),1.80(s,1H),1.73(s,1H),1.55(s,1H).
实施例136 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A136)
1H NMR(500MHz,Chloroform)δ7.32–7.26(m,2H),7.18(s,1H),7.15–7.08(m,2H),6.45(s,1H),6.28(s,1H),6.02(s,1H),5.94(d,J＝3.0Hz,2H),5.80(s,1H),5.63(s,1H),5.14(s,1H),4.66(s,1H),4.55(s,1H),3.91(s,1H),3.65(s,1H),3.49–3.10(m,5H),3.25(t,J＝14.8Hz,3H),3.25(t,J＝14.8Hz,3H),3.01(s,1H),2.53(s,1H),2.08–2.04(m,2H),1.94(s,1H),1.80(d,J＝1.0Hz,2H),1.73(s,1H),1.34–1.30(m,9H).
实施例137 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氯-3,8a-二氢-2H-苯并吡喃-3-羧酰胺(A137)
1H NMR(500MHz,Chloroform)δ7.30–7.26(m,1H),7.26–7.14(m,4H),6.52(s,1H),6.47(s,1H),6.14(s,1H),6.04(s,1H),5.96(s,1H),5.87(d,J＝16.5Hz,2H),5.02(d,J＝1.5Hz,2H),4.66(s,1H),4.48(s,1H),3.68(s,1H),3.51(s,1H),3.40(s,1H),3.31(d,J＝10.7Hz,2H),3.24(d,J＝17.3Hz,2H),3.01(d,J＝17.6Hz,2H),2.12–2.04(m,5H),1.96(s,1H),1.82(s,1H),1.75(s,1H),1.71–1.64(m,3H),1.56–1.52(m,2H),1.48(s,1H),1.45–1.40(m,2H).
实施例138 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A138)
1H NMR(500MHz,Chloroform)δ7.52(s,1H),7.43–7.23(m,8H),7.23–7.19(m,3H),7.16(s,1H),6.92(s,1H),6.04(s,1H),5.92–5.88(m,2H),5.21(s,1H),4.83(s,1H),4.75(s,1H),4.44(s,1H),4.38(s,1H),3.45(s,1H),3.36(d,J＝13.2Hz,2H),2.95(s,1H),2.80(s,1H),2.18(s,1H),2.09–2.05(m,2H),1.92(s,1H).
实施例139 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A139)
1H NMR(500MHz,Chloroform)δ7.48(s,1H),7.32(s,1H),7.29–7.23(m,2H),7.23–7.14(m,3H),6.91(s,1H),5.95(s,1H),5.92–5.88(m,2H),4.76(d,J＝1.1Hz,2H),4.71(s,1H),3.46(d,J＝12.3Hz,2H),3.35(s,1H),3.08(s,1H),2.99(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.40–1.36(m,9H).
实施例140 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A140)
1H NMR(500MHz,Chloroform)δ7.30(dd,J＝21.6,15.7Hz,4H),7.28–7.23(m,1H),7.28–7.14(m,4H),6.89(s,1H),6.05(s,1H),5.92–5.88(m,2H),5.08(s,1H),4.75(d,J＝16.1Hz,2H),3.59(s,1H),3.45(d,J＝2.5Hz,2H),3.35(s,1H),3.12(s,1H),2.99(s,1H),2.19(s,1H),2.10–2.04(m,4H),1.93(s,1H),1.81–1.70(m,3H),1.58–1.54(m,2H),1.51(s,1H),1.47–1.42(m,2H).
实施例141 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A141)
1H NMR(500MHz,Chloroform)δ7.41(s,1H),7.36(s,1H),10.00–7.08(m,14H),6.54(s,1H),6.07(s,1H),5.92–5.88(m,2H),5.10(s,1H),4.42(s,1H),4.37(d,J＝6.5Hz,2H),4.30(s,1H),3.60(s,1H),3.25(t,J＝13.9Hz,3H),3.03(s,1H),2.73(s,1H),2.09–2.03(m,2H),1.79(d,J＝5.2Hz,2H),1.73(s,1H),1.57(s,1H).
实施例142 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A142)
1H NMR(500MHz,Chloroform)δ8.38(s,28H),7.44(s,29H),7.30–7.23(m,86H),7.23–7.15(m,82H),7.15(d,J＝1.8Hz,4H),6.98(s,29H),5.92–5.85(m,85H),5.21(s,28H),5.00(s,27H),4.81(s,28H),4.66(s,28H),3.26(t,J＝21.5Hz,87H),2.91(s,30H),2.78(s,26H),2.21(s,20H),2.11–2.02(m,61H),2.00(s,21H),1.83(s,25H),1.77(s,21H),1.32–1.28(m,251H).
实施例143 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A143)
1H NMR(500MHz,Chloroform)δ8.29(s,1H),7.48(s,1H),7.38(s,1H),7.28–7.23(m,2H),7.23–7.11(m,3H),6.94(s,1H),6.09(s,1H),5.92–5.88(m,2H),5.06(s,1H),4.91(s,1H),4.73(s,1H),4.38(s,1H),3.36(s,1H),3.31–3.20(m,3H),3.07(s,1H),2.85(s,1H),2.08–2.03(m,4H),1.88(s,1H),1.81(s,1H),1.78–1.69(m,3H),1.67(s,1H),1.58(s,1H),1.51(t,J＝7.6Hz,3H),1.43–1.39(m,2H).
实施例144 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)苯[d][1,3]间二氧杂环戊烯-5-羧酰胺(A144)
1H NMR(500MHz,Chloroform)δ8.29(s,1H),7.48(s,1H),7.38(s,1H),7.28–7.23(m,2H),7.23–7.11(m,3H),6.94(s,1H),6.09(s,1H),5.92–5.88(m,2H),5.06(s,1H),4.91(s,1H),4.73(s,1H),4.38(s,1H),3.36(s,1H),3.31–3.20(m,3H),3.07(s,1H),2.85(s,1H),2.08–2.03(m,4H),1.88(s,1H),1.81(s,1H),1.78–1.69(m,3H),1.67(s,1H),1.58(s,1H),1.51(t,J＝7.6Hz,3H),1.43–1.39(m,2H).
实施例145 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟烟酰胺(A145)
1H NMR(500MHz,Chloroform)δ8.60(d,J＝2.3Hz,2H),7.83(s,1H),7.23(d,J＝6.4Hz,1H),7.22–7.08(m,5H),5.97(s,1H),5.48(s,1H),4.88(s,1H),4.38(s,1H),4.01(s,1H),3.45(s,1H),3.35(s,1H),3.26(s,1H),2.96(s,1H),2.69(s,1H),2.40(s,1H),2.16(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.32–1.28(m,10H).
实施例146 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟烟酰胺(A146)
1H NMR(500MHz,Chloroform)δ8.82(s,1H),8.50(s,1H),7.89(s,1H),7.31–7.24(m,4H),7.17(s,1H),6.22(s,1H),5.95(s,1H),5.47(s,1H),5.14(s,1H),4.38(s,1H),3.45(s,1H),3.37(d,J＝16.6Hz,2H),3.29(s,1H),2.86(s,1H),2.47(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.93(s,1H),1.91–1.79(m,2H),1.70(s,1H),1.58–1.51(m,4H),1.50(s,1H),1.45–1.40(m,2H).
实施例147 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟烟酰胺(A147)
1H NMR(500MHz,Chloroform)δ8.80(s,1H),8.58(s,1H),7.99(s,1H),7.41–7.32(m,2H),7.32–7.18(m,6H),7.16(s,1H),7.09(s,1H),6.51(s,1H),6.23(s,1H),5.85(s,1H),4.87(s,1H),4.36(s,1H),4.30(d,J＝5.9Hz,2H),3.24(d,J＝15.2Hz,2H),3.09(s,1H),2.82(s,1H),2.57(s,1H),2.08–2.04(m,2H),1.98(s,1H),1.82(s,1H),1.76(s,1H),1.65(s,1H).
实施例148 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟烟酰胺(A148)
1H NMR(500MHz,Chloroform)δ8.82(s,1H),8.52(s,1H),8.05(s,1H),7.30–7.22(m,4H),7.15(s,1H),6.03(s,1H),5.79(s,1H),5.01(s,1H),4.84(s,1H),4.27(s,1H),3.36(s,1H),3.24(d,J＝14.9Hz,2H),2.95(s,1H),2.72(s,1H),2.07(t,J＝5.5Hz,3H),1.85(s,1H),1.78(s,1H),1.70(s,1H),1.32–1.28(m,9H).
实施例149 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟烟酰胺(A149)
1H NMR(500MHz,Chloroform)δ8.86(s,7H),8.52(s,7H),7.93(s,7H),7.42(s,7H),7.24–7.19(m,14H),7.14(s,7H),7.12–7.04(m,14H),6.15(d,J＝16.5Hz,14H),5.79(s,7H),4.89(s,7H),4.62(s,7H),3.87(s,7H),3.27(t,J＝22.0Hz,22H),3.17(t,J＝12.5Hz,1H),3.11(d,J＝17.0Hz,14H),2.12(s,5H),2.10–2.01(m,16H),2.01–1.94(m,14H),1.87(s,5H),1.80(s,5H),1.67–1.58(m,67H).
实施例150 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A150)
1H NMR(500MHz,Chloroform)δ7.52(s,5H),7.32–7.14(m,55H),7.13(t,J＝1.5Hz,1H),7.07(s,5H),6.09(s,5H),6.01(s,5H),5.64(s,5H),5.02(s,5H),4.84(s,5H),4.36(s,5H),4.29(s,5H),3.89–3.85(m,15H),3.45(s,5H),3.35(s,4H),3.17(s,4H),3.11(s,5H),2.93(s,5H),2.19(s,4H),2.10–2.04(m,10H),1.92(s,4H).
实施例151 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A151)
1H NMR(500MHz,Chloroform)δ7.86(s,1H),7.42(s,1H),10.00–7.19(m,6H),7.17(s,1H),7.05(s,1H),5.92(d,J＝15.2Hz,2H),5.77(s,1H),5.06(s,1H),4.87(s,1H),3.89–3.85(m,3H),3.45(s,1H),3.35(s,1H),3.18(s,1H),2.88(d,J＝18.2Hz,2H),2.17(s,1H),2.13–2.02(m,2H),1.92(s,1H),1.34–1.30(m,9H).
实施例152 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A152)
1H NMR(500MHz,Chloroform)δ7.28–7.17(m,5H),7.15(s,1H),7.08(s,1H),6.04(s,1H),5.89(s,1H),4.77(s,1H),4.30(s,1H),4.02–3.98(m,3H),3.83(s,1H),3.71(s,1H),3.45(s,1H),3.35(s,1H),3.30(s,1H),3.05(s,1H),2.97(s,1H),2.65(s,1H),2.20(s,1H),2.09–2.05(m,2H),2.04–2.00(m,1H),1.91(s,1H),1.67–1.55(m,7H).
实施例153 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A153)
1H NMR(500MHz,Chloroform)δ8.58(s,7H),8.29(s,7H),7.42(s,7H),7.32–7.24(m,28H),7.18(dt,J＝57.0,25.2Hz,40H),7.08–7.07(m,2H),6.51(s,7H),6.01(s,7H),5.10(s,7H),4.81(s,7H),4.38(s,7H),4.32(s,7H),3.93–3.89(m,21H),3.30(d,J＝53.3Hz,17H),3.21(s,3H),3.21(s,6H),2.99(s,7H),2.17(s,6H),2.11–2.01(m,14H),1.76(d,J＝12.9Hz,12H),1.68(s,5H),1.42(s,6H).
实施例154 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A154)
1H NMR(500MHz,Chloroform)δ9.02(s,1H),7.53(s,1H),7.31–7.25(m,2H),7.17(dd,J＝16.8,9.4Hz,4H),6.20(s,1H),6.11(s,1H),5.60(s,1H),5.16(s,1H),4.76(s,1H),3.90–3.86(m,3H),3.24(d,J＝15.4Hz,2H),3.12(s,1H),2.92(d,J＝17.7Hz,2H),2.05(t,J＝4.4Hz,3H),1.82(s,1H),1.76(s,1H),1.56(s,1H),1.31–1.27(m,9H).
实施例155 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1-甲基-1H-吡唑-4-羧酰胺(A155)
1H NMR(500MHz,Chloroform)δ8.38(s,1H),7.28–7.22(m,2H),7.22–7.11(m,3H),7.04(s,1H),6.62(s,1H),5.99(s,1H),4.76(s,1H),4.62(s,1H),4.30(s,1H),3.83–3.79(m,3H),3.26(dd,J＝17.5,12.1Hz,4H),3.05(s,1H),3.01(s,1H),2.72(s,1H),2.20–2.13(m,3H),2.09–2.03(m,2H),1.86(s,1H),1.80(s,1H),1.72–1.66(m,3H),1.56(t,J＝5.2Hz,3H),1.49(s,1H),1.46–1.41(m,2H).
实施例156 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A156)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),7.77(s,1H),7.68(s,1H),7.58(s,1H),7.40(s,1H),7.32–7.26(m,4H),7.26–7.11(m,7H),6.00(s,1H),5.04(s,1H),4.92(s,1H),4.77(s,1H),4.38(s,1H),4.30(s,1H),3.45(s,1H),3.35(s,1H),3.27(s,1H),3.11(s,1H),2.85(s,1H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H).
实施例157 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A157)
1H NMR(500MHz,Chloroform)δ8.80(s,1H),8.37(s,1H),7.69(d,J＝2.2Hz,2H),7.59(s,1H),7.28–7.21(m,2H),7.21–7.11(m,3H),6.78(s,1H),5.98(s,1H),5.45(s,1H),4.93(s,1H),4.66(s,1H),3.45(s,1H),3.35(s,1H),3.22(s,1H),2.96(d,J＝29.5Hz,2H),2.19(s,1H),2.09–2.05(m,2H),1.92(s,1H),1.34–1.30(m,9H).
实施例158 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A158)
1H NMR(500MHz,Chloroform)δ8.39(s,1H),7.69(d,J＝16.1Hz,2H),7.60(s,1H),7.36–7.20(m,9H),7.19(d,J＝13.6Hz,2H),6.50(s,1H),6.28(s,1H),6.16(s,1H),6.10(s,1H),4.75(d,J＝4.7Hz,2H),4.39(s,1H),4.30(s,1H),3.24(t,J＝8.9Hz,3H),3.01(s,1H),2.72(s,1H),2.11–2.01(m,2H),1.84(s,1H),1.80(s,1H),1.73(s,1H),1.36(s,1H).
实施例159 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A159)
1H NMR(500MHz,Chloroform)δ8.41(s,1H),8.18(s,1H),7.79–7.57(m,3H),7.27–7.21(m,2H),7.21–7.10(m,3H),6.09(s,1H),5.52(s,1H),5.08(s,1H),4.74(s,1H),4.45(s,1H),3.25(t,J＝9.9Hz,3H),3.01(s,1H),2.85(s,1H),2.10–2.02(m,2H),1.88(s,1H),1.81(s,1H),1.68(s,1H),1.60(s,1H),1.35–1.31(m,9H).
实施例160 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A160)
1H NMR(500MHz,Chloroform)δ9.87(s,1H),8.26(s,1H),7.68(s,1H),7.57(d,J＝11.2Hz,2H),7.27–7.21(m,2H),7.21–7.10(m,3H),6.07(s,1H),4.94(s,1H),4.78(s,1H),4.51(s,1H),3.54(s,1H),3.45(s,1H),3.24(d,J＝16.2Hz,2H),3.17(s,1H),2.97(s,1H),2.92(s,1H),2.28(s,1H),2.09–2.04(m,4H),1.81(s,1H),1.74(s,1H),1.70(s,1H),1.59–1.52(m,4H),1.49(d,J＝1.6Hz,2H),1.47–1.41(m,2H).
实施例161 N-((S)-1-(((S)-4-(苯基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A161)
1H NMR(500MHz,Chloroform)δ7.62(d,J＝18.9Hz,2H),7.34–7.23(m,9H),7.23–7.12(m,3H),6.92(s,1H),6.17(s,1H),5.35(s,1H),5.03(s,1H),4.70(d,J＝4.7Hz,2H),4.38(s,1H),4.33(s,1H),4.03(s,1H),3.35(s,1H),3.27(s,1H),3.04(s,1H),2.82(s,1H),2.17(s,1H),2.12–2.03(m,2H),1.93(s,1H).
实施例162 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A162)
1H NMR(500MHz,Chloroform)δ7.68(s,1H),7.59(s,1H),7.30–7.25(m,2H),7.22–7.16(m,2H),7.16–7.06(m,3H),6.17(s,1H),5.89(s,1H),5.84(s,1H),5.11(s,1H),4.98(s,1H),3.45(s,1H),3.35(s,1H),3.25(s,1H),3.04(s,1H),2.28(s,1H),2.19(s,1H),2.11–2.03(m,2H),1.92(s,1H),1.35–1.31(m,9H).
实施例163 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A163)
1H NMR(500MHz,Chloroform)δ7.70(s,1H),7.57(d,J＝4.5Hz,2H),7.22(dd,J＝17.6,7.1Hz,4H),7.18–7.07(m,3H),5.97(s,1H),5.74(s,1H),5.03(s,1H),4.50(d,J＝11.0Hz,2H),4.41(s,1H),3.61(s,1H),3.45(s,1H),3.35(s,1H),3.21(s,1H),3.03(s,1H),2.80(s,1H),2.17(s,1H),2.09–2.05(m,2H),1.93–1.78(m,3H),1.71(s,1H),1.64–1.60(m,2H),1.58–1.54(m,2H),1.50(s,1H),1.48–1.42(m,2H).
实施例164 N-((S)-1-(((S)-4-(苯基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A164)
1H NMR(500MHz,Chloroform)δ7.73(s,1H),7.67(s,1H),7.38(t,J＝17.9Hz,3H),7.27–7.13(m,9H),7.11(s,1H),6.99(s,1H),6.45(s,1H),5.48(s,1H),4.94(d,J＝7.2Hz,2H),4.89(s,1H),4.32(s,1H),4.26(s,1H),3.42(s,1H),3.24(d,J＝18.2Hz,2H),3.06(s,1H),2.92(s,1H),2.13(s,1H),2.11–2.00(m,2H),1.92(s,1H),1.86(s,1H),1.79(s,1H).
实施例165 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A165)
1H NMR(500MHz,Chloroform)δ9.34(s,4H),7.98(s,4H),7.79(s,4H),7.62(s,4H),7.54(s,4H),7.42–7.28(m,23H),7.28–7.26(m,2H),7.16(s,4H),5.87(s,4H),5.43(s,4H),5.16(s,4H),4.27(s,4H),3.33–3.20(m,12H),2.94(s,4H),2.82(s,4H),2.08–2.04(m,8H),1.96(s,3H),1.82(s,3H),1.76(s,3H),1.63(s,3H),1.33–1.29(m,36H).
实施例166 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A166)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),8.24(s,1H),7.65(s,1H),7.60(s,1H),7.53(s,1H),7.24(dd,J＝20.9,2.1Hz,4H),7.16–7.04(m,3H),5.61(s,1H),5.36(s,1H),5.09(s,1H),4.63(s,1H),3.50(s,1H),3.41(s,1H),3.24(d,J＝15.7Hz,2H),2.98(s,1H),2.66(s,1H),2.57(s,1H),2.27–2.16(m,2H),2.08–2.04(m,2H),1.98(s,1H),1.85(s,1H),1.78(s,1H),1.72(s,1H),1.63–1.55(m,4H),1.55–1.44(m,3H).
实施例167 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A167)
1H NMR(500MHz,Chloroform)δ9.78(s,1H),8.99(s,1H),8.23(s,1H),7.81(s,1H),7.49(d,J＝90.0Hz,2H),7.40–7.38(m,4H),7.30(d,J＝15.0Hz,5H),7.19(s,34H),7.14(s,4H),7.07(s,1H),6.56(s,1H),6.10(s,1H),5.29(s,1H),5.09(s,1H),4.85(s,1H),4.34(s,2H),3.63(s,21H),3.51(s,1H),3.33(s,1H),3.08(s,1H),2.65(s,1H),2.20(s,1H),2.02(s,1H),1.90(s,1H).
实施例168 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A168)
1H NMR(500MHz,Chloroform)δ8.95(s,1H),8.26(d,J＝60.3Hz,2H),7.78(s,1H),7.55(s,1H),7.31–7.18(m,4H),7.16(s,1H),7.31–6.84(m,7H),6.55(d,J＝16.4Hz,2H),5.97(s,1H),5.15(s,1H),4.79(s,1H),3.63(s,1H),3.51(s,1H),3.32(s,1H),3.07(s,1H),2.54(s,1H),2.21(s,1H),2.02(s,1H),1.91(s,1H),1.26(s,9H).
实施例169 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A169)
1H NMR(500MHz,Chloroform)δ8.98(s,13H),8.34(s,13H),8.22(s,14H),7.80(s,13H),7.57(s,14H),7.37–7.20(m,2H),7.18(s,14H),7.37–6.87(m,82H),6.56(s,13H),6.49(s,13H),5.99(s,13H),5.17(s,7H),4.95(s,5H),4.79(s,7H),3.64(s,6H),3.52(s,6H),3.33(s,15H),3.08(s,14H),2.55(s,5H),2.20(d,J＝14.4Hz,31H),2.02(s,14H),1.88(d,J＝38.0Hz,37H),1.80(s,5H),1.62(s,9H),1.37(s,27H),1.31(s,11H),1.20(s,23H).
实施例170 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A170)
1H NMR(500MHz,Chloroform)δ8.99(s,2H),8.23(s,2H),8.06(s,2H),7.81(s,2H),7.58(s,2H),7.29(d,J＝15.0Hz,9H),7.19(s,1H),7.14(s,9H),7.05(d,J＝24.0Hz,3H),6.56(s,2H),6.06(s,2H),5.05(s,2H),4.76(s,1H),4.34(s,4H),3.55–2.80(m,10H),3.48–2.77(m,10H),3.28–2.80(m,8H),2.87–2.77(m,1H),2.70(s,1H),2.34(s,1H),2.01(s,1H),1.91(d,J＝2.6Hz,2H),1.60(s,1H).
实施例171 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A171)
1H NMR(500MHz,Chloroform)δ8.99(s,1H),8.23(s,1H),7.91(s,1H),7.81(s,1H),7.58(s,1H),7.26–7.21(m,4H),7.19(s,1H),7.26–6.88(m,6H),6.57(d,J＝15.1Hz,2H),6.06(s,1H),5.06(s,1H),4.71(s,1H),3.33(s,1H),3.21(d,J＝15.0Hz,2H),3.08(s,1H),2.93(s,1H),2.43(s,1H),2.39(s,1H),2.01(s,1H),1.91(d,J＝1.1Hz,1H),1.58(s,13H),1.27(s,9H).
实施例172 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-1H-吲哚-5-羧酰胺(A172)
1H NMR(500MHz,Chloroform)δ8.99(s,1H),8.23(s,1H),7.81(s,1H),7.68(s,1H),7.58(s,1H),7.26–7.21(m,7H),7.19(s,1H),7.26–6.88(m,6H),6.53(d,J＝28.7Hz,2H),6.50–6.48(m,5H),6.08(s,1H),5.06(s,1H),4.95(s,1H),4.70(s,1H),3.33(s,1H),3.21(d,J＝15.0Hz,2H),3.08(s,1H),2.94(s,1H),2.44(d,J＝13.0Hz,2H),2.19(s,2H),2.03–1.73(m,5H),1.84(s,3H),1.84(s,2H),1.60(d,J＝15.4Hz,2H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例173 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A173)
1H NMR(500MHz,Chloroform)δ8.75(s,2H),8.14(s,2H),7.54(d,J＝24.9Hz,4H),7.37–7.24(m,13H),7.17(s,1H),7.11(d,J＝10.0Hz,11H),6.85(s,2H),6.14(s,2H),5.18(s,2H),4.86(s,1H),4.33(s,4H),3.65(s,1H),3.53(s,1H),3.28(s,4H),3.03(s,1H),2.54(s,2H),2.22(s,2H),2.02(s,2H),1.93(s,1H).
实施例174 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A174)
1H NMR(500MHz,Chloroform)δ8.73(s,1H),8.12(s,1H),7.55(d,J＝25.0Hz,2H),7.51(s,3H),7.16(dd,J＝31.6,6.6Hz,7H),6.56(s,1H),6.10(s,1H),5.19(s,1H),4.83(s,1H),3.65(s,1H),3.54(s,1H),3.29(s,1H),3.04(s,1H),2.58(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,5H),1.27(s,9H).
实施例175 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A175)
1H NMR(500MHz,Chloroform)δ8.74(s,1H),8.08(s,1H),7.55(d,J＝25.0Hz,2H),7.51(s,3H),7.19(d,J＝2.2Hz,2H),7.13(d,J＝10.0Hz,5H),6.44(s,1H),6.11(s,1H),5.19(s,1H),4.83(s,1H),3.67(d,J＝15.7Hz,1H),3.54(s,1H),3.29(s,1H),3.04(s,1H),2.58(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.74(s,1H),1.46(t,J＝12.5Hz,3H),1.21(s,1H),1.11(s,1H).
实施例176 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A176)
1H NMR(500MHz,Chloroform)δ8.71(s,2H),8.61(s,2H),7.69(s,2H),7.58(s,2H),7.53(s,1H),7.33–7.20(m,12H),7.19(s,1H),7.13(d,J＝10.0Hz,10H),5.84(s,2H),5.09(s,1H),4.57(s,1H),4.34(s,4H),3.29(s,1H),3.21(d,J＝15.0Hz,4H),3.04(s,2H),2.73(s,1H),2.41(s,1H),2.28(s,1H),2.01(s,1H),1.91(d,J＝4.5Hz,2H),1.53(s,1H).
实施例177 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A177)
1H NMR(500MHz,Chloroform)δ8.68(s,1H),8.29(s,1H),7.54(d,J＝25.0Hz,2H),7.49(s,3H),7.24(s,1H),7.17(s,1H),7.11(d,J＝10.0Hz,5H),6.61(s,1H),5.90(s,1H),5.05(s,1H),4.68(s,1H),3.28(s,1H),3.22(s,1H),3.11(d,J＝77.9Hz,2H),2.85(s,1H),2.33(s,1H),2.13(s,1H),2.01(s,1H),1.89(d,J＝13.2Hz,11H),1.53(s,5H),1.27(s,9H).
实施例178 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-氟-1H-吲哚-2-羧酰胺(A178)
1H NMR(500MHz,Chloroform)δ8.69(s,1H),8.21(s,1H),7.58(s,1H),7.53(s,1H),7.23(s,1H),7.19(s,1H),7.13(d,J＝10.0Hz,5H),6.53(s,1H),5.93(s,1H),5.07(s,1H),4.95(s,1H),4.67(s,1H),3.29(s,1H),3.25–2.88(m,3H),2.85(s,1H),2.36(s,1H),2.17(d,J＝18.2Hz,3H),2.01(s,1H),1.90(d,J＝11.3Hz,1H),1.84(s,2H),1.62(s,1H),1.53(s,1H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例179 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A179)
1H NMR(500MHz,Chloroform)δ8.73(s,1H),8.13(s,1H),7.95(s,1H),7.32–7.18(m,7H),7.08(d,J＝49.9Hz,6H),7.03(s,1H),7.03(s,1H),6.74(s,1H),6.16(s,1H),5.20(s,1H),4.86(s,1H),4.33(s,2H),3.66(s,1H),3.54(s,1H),3.16(d,J＝124.8Hz,2H),3.01(d,J＝6.4Hz,1H),2.57(s,1H),2.22(s,1H),2.02(s,1H),1.93(s,1H).
实施例180 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A180)
1H NMR(500MHz,Chloroform)δ8.71(s,1H),8.11(s,1H),7.96(s,1H),7.46–6.88(m,8H),7.04(s,1H),7.04(s,1H),6.57(s,1H),6.10(s,1H),5.19(s,1H),4.83(s,1H),3.65(s,1H),3.54(s,1H),3.29(s,1H),3.04(s,1H),2.58(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.27(s,9H).
实施例181 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A181)
1H NMR(500MHz,Chloroform)δ8.71(s,2H),8.04(s,2H),7.96(s,2H),7.46–6.88(m,16H),7.04(s,2H),7.04(s,2H),6.46(s,2H),6.12(s,2H),5.20(s,2H),4.83(s,1H),3.67(d,J＝17.5Hz,3H),3.54(s,1H),3.29(s,3H),3.04(s,1H),2.58(s,1H),2.22(s,1H),2.02(s,2H),1.93(s,1H),1.74(s,2H),1.46(t,J＝12.5Hz,6H),1.21(s,3H),1.11(s,2H).
实施例182 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A182)
1H NMR(500MHz,Chloroform)δ8.68(s,2H),8.30(s,2H),7.96(s,2H),7.40(s,2H),7.28(t,J＝11.5Hz,12H),7.15(dd,J＝57.0,32.0Hz,15H),7.04(s,2H),7.04(s,2H),5.92(s,2H),5.05(s,1H),4.71(s,1H),4.34(s,4H),3.29(s,1H),3.21(d,J＝15.0Hz,4H),3.04(s,2H),2.86(s,1H),2.39(s,1H),2.18(s,1H),2.01(s,1H),1.90(d,J＝6.3Hz,4H),1.54(s,1H).
实施例183 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A183)
1H NMR(500MHz,Chloroform)δ8.68(s,1H),8.30(s,11H),7.96(s,1H),7.45–6.97(m,8H),7.04(s,1H),7.04(s,1H),6.62(s,1H),5.92(s,1H),5.06(s,1H),4.69(s,1H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.85(s,1H),2.33(s,1H),2.13(s,1H),2.01(s,1H),1.90(d,J＝13.5Hz,1H),1.53(s,1H),1.27(s,9H).
实施例184 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-6-氟-1H-吲哚-2-羧酰胺(A184)
1H NMR(500MHz,Chloroform)δ8.67(s,1H),8.20(s,1H),7.96(s,1H),7.45–6.89(m,8H),7.14(s,4H),7.09(d,J＝50.0Hz,5H),7.04(s,1H),6.53(s,1H),5.93(s,1H),5.07(s,1H),4.95(s,1H),4.67(s,1H),3.29(s,1H),3.25–2.88(m,3H),2.85(s,1H),2.35(s,1H),2.17(d,J＝17.6Hz,3H),2.01(s,1H),1.90(d,J＝11.7Hz,1H),1.84(s,1H),1.62(s,1H),1.53(s,1H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例185 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A185)
1H NMR(500MHz,Chloroform)δ8.92(s,2H),8.83(s,2H),7.84(s,2H),7.49(s,2H),7.33–7.26(m,11H),7.22(s,2H),7.02(d,J＝21.6Hz,6H),6.97(dd,J＝5.6,2.6Hz,1H),6.77(s,2H),6.28(s,2H),5.16(s,2H),4.91(s,1H),4.34(s,4H),3.67(s,1H),3.55(s,1H),3.29(s,3H),3.04(s,1H),2.61(s,1H),2.23(s,2H),2.02(s,2H),1.93(s,1H).
实施例186 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A186)
1H NMR(500MHz,Chloroform)δ8.75(s,1H),7.97(s,1H),7.45(s,1H),7.31–7.15(m,3H),6.97(d,J＝7.1Hz,5H),6.50(s,1H),6.15(s,1H),5.18(s,1H),4.82(s,1H),3.65(s,1H),3.53(s,1H),3.27(s,1H),3.03(s,3H),2.60(s,1H),2.22(s,1H),2.01(s,1H),1.92(s,1H),1.26(s,9H).
实施例187 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A187)
1H NMR(500MHz,Chloroform)δ8.79(s,2H),8.00(s,2H),7.48(s,2H),7.31(d,J＝14.5Hz,4H),7.19(s,2H),7.01(d,J＝5.2Hz,5H),6.40(s,2H),6.18(s,2H),5.20(s,2H),4.85(s,1H),3.68(d,J＝15.6Hz,3H),3.55(s,1H),3.29(s,1H),3.04(s,3H),2.61(s,2H),2.23(s,1H),2.02(s,2H),1.93(s,1H),1.74(s,2H),1.46(t,J＝12.5Hz,6H),1.21(s,3H),1.11(s,2H).
实施例188 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A188)
1H NMR(500MHz,Chloroform)δ9.00(s,4H),8.91(s,4H),7.70(s,4H),7.49(d,J＝3.7Hz,8H),7.29(dd,J＝9.6,5.4Hz,26H),7.21(s,5H),7.00(d,J＝5.1Hz,11H),6.69(s,4H),4.96(d,J＝17.8Hz,6H),4.33(s,8H),3.29(s,3H),3.21(d,J＝15.0Hz,8H),2.96(d,J＝80.6Hz,8H),2.85–2.81(m,1H),2.48(s,4H),2.27(s,4H),2.00(d,J＝2.8Hz,4H),1.91(s,6H),1.53(s,2H).
实施例189 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A189)
1H NMR(500MHz,Chloroform)δ8.57(s,1H),7.45(s,1H),7.32(d,J＝18.3Hz,2H),7.20(d,J＝6.7Hz,2H),7.04(s,1H),7.00(s,1H),6.57(s,1H),5.75(s,1H),5.11(s,1H),4.79(s,1H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.75(s,1H),2.47(s,1H),2.36(s,1H),2.01(s,1H),1.95(s,1H),1.91(s,1H),1.51(s,1H),1.27(s,9H).
实施例190 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-4,6-二氯-1H-吲哚-2-羧酰胺(A190)
1H NMR(500MHz,Chloroform)δ8.77(s,1H),7.93(s,1H),7.48(s,41H),7.34–7.15(m,3H),7.00(s,1H),6.83(s,2H),6.56(s,1H),6.15(s,1H),5.71(s,1H),5.05(s,2H),4.95(s,2H),4.90(s,1H),3.36–3.12(m,4H),3.20(s,1H),3.12(d,J＝78.0Hz,2H),2.32(s,2H),2.31–2.17(m,3H),2.03–1.86(m,3H),1.84(s,2H),1.62(s,1H),1.49(s,2H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例191 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A191)
1H NMR(500MHz,Chloroform)δ8.78(s,1H),8.27(s,1H),7.75–7.37(m,3H),7.38(s,1H),7.38(s,1H),7.28(d,J＝15.0Hz,5H),7.20–6.87(m,6H),6.90(s,1H),6.90(s,1H),6.78(s,1H),5.71(s,1H),5.15(s,1H),5.06(s,1H),4.33(s,2H),3.80(s,3H),3.63(s,1H),3.50(s,1H),3.29(s,2H),3.04(s,1H),2.54(s,1H),2.22(s,1H),2.02(s,2H),1.91(s,1H).
实施例192 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A192)
1H NMR(500MHz,Chloroform)δ8.78(s,1H),8.27(s,1H),7.75–7.37(m,3H),7.38(s,1H),7.38(s,1H),7.28(d,J＝15.0Hz,5H),7.20–6.87(m,6H),6.90(s,1H),6.90(s,1H),6.78(s,1H),5.71(s,1H),5.15(s,1H),5.06(s,1H),4.33(s,2H),3.80(s,3H),3.63(s,1H),3.50(s,1H),3.29(s,2H),3.04(s,1H),2.54(s,1H),2.22(s,1H),2.02(s,2H),1.91(s,1H)，1.27(s,9H).
实施例193 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A193)
1H NMR(500MHz,Chloroform)δ8.68(s,1H),8.12(s,1H),7.59(s,1H),7.45(s,1H),7.16(t,J＝12.5Hz,6H),6.79(s,1H),6.44(s,1H),6.10(s,1H),5.19(s,1H),4.95(s,1H),4.82(s,2H),3.81(s,3H),3.65(s,1H),3.54(s,1H),3.29(s,1H),3.04(s,1H),2.58(s,2H),2.21(d,J＝16.4Hz,2H),2.02(s,1H),1.88(d,J＝41.9Hz,3H),1.80(s,1H),1.62(s,2H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例194 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A194)
1H NMR(500MHz,Chloroform)δ8.66(s,1H),8.34(s,1H),7.59(s,1H),7.45(s,1H),7.29(d,J＝15.0Hz,5H),7.24–6.99(m,7H),6.79(s,1H),5.90(s,1H),5.04(s,1H),4.72(s,1H),4.34(s,2H),3.81(s,3H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.86(s,1H),2.29(s,1H),2.11(s,1H),2.01(s,21H),1.90(d,J＝11.7Hz,1H),1.52(s,1H).
实施例195 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A195)
1H NMR(500MHz,Chloroform)δ8.46(s,1H),7.57(s,1H),7.43(s,1H),7.17(s,1H),7.12(s,4H),7.00(s,1H),6.92(s,1H),6.77(s,1H),6.49(s,1H),5.75(s,1H),5.20(s,1H),4.67(s,1H),3.80(s,3H),3.28(s,1H),3.20(d,J＝15.0Hz,2H),3.03(s,1H),2.77(s,1H),2.40(s,1H),2.30(s,1H),2.00(s,1H),1.94(s,41H),1.90(s,1H),1.51(s,1H),1.27(s,9H).
实施例196 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-5-甲氧基-1H-吲哚-2-羧酰胺(A196)
1H NMR(500MHz,Chloroform)δ8.61(s,1H),8.10(s,1H),7.59(s,1H),7.45(s,1H),7.19(d,J＝2.6Hz,2H),7.14(s,4H),6.72(d,J＝66.4Hz,2H),5.95(s,1H),5.05(s,1H),4.95(s,1H),4.71(s,1H),3.81(s,3H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.86(s,1H),2.37(s,61H),2.21–2.17(m,2H),2.01(s,1H),1.90(d,J＝11.5Hz,1H),1.84(s,2H),1.62(s,1H),1.54(s,1H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例197 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丙基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A197)
1H NMR(500MHz,Chloroform)δ8.60(s,1H),7.97(s,1H),7.59(s,1H),7.38(s,1H),7.29(d,J＝15.0Hz,5H),7.16(s,1H),7.10(d,J＝9.2Hz,2H),6.97(s,1H),6.16(s,1H),4.87(s,1H),4.67(s,1H),4.34(s,2H),3.65(s,1H),3.54(s,1H),2.61(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.76(s,1H),1.11(s,1H),0.60(s,1H),0.35(s,1H).
实施例198 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丙基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A198)
1H NMR(500MHz,Chloroform)δ8.59(s,1H),7.98(s,1H),7.61(d,J＝10.9Hz,2H),7.12(d,J＝16.2Hz,2H),6.98(s,1H),6.56(s,1H),6.12(s,1H),4.81(s,1H),4.67(s,1H),3.65(s,1H),3.54(s,1H),2.59(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.76(s,1H),1.27(s,9H),1.11(s,1H),0.58(s,1H),0.33(s,1H).
实施例199 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丙基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A199)
1H NMR(500MHz,Chloroform)δ8.65(s,1H),8.25(s,1H),7.98(s,1H),7.60(s,1H),7.12(d,J＝24.7Hz,2H),7.10–7.07(m,1H),6.98(s,1H),6.41(s,1H),6.15(s,1H),4.82(s,1H),4.58(s,1H),3.66(d,J＝5.6Hz,2H),3.54(s,1H),2.59(s,1H),2.23(s,1H),2.02(s,1H),1.93(s,1H),1.75(d,J＝10.0Hz,3H),1.46(t,J＝12.5Hz,3H),1.21(s,2H),1.11(d,J＝0.5Hz,2H),0.57(s,21H),0.28(s,1H).
实施例200 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环丙基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A200)
1H NMR(500MHz,Chloroform)δ8.62(s,1H),8.00(d,J＝20.6Hz,2H),7.60(s,1H),7.30(d,J＝15.0Hz,5H),7.18(d,J＝6.9Hz,2H),7.10(s,1H),6.98(s,1H),6.09(s,1H),4.85(s,1H),4.33(d,J＝13.7Hz,3H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.62(s,1H),2.54(s,1H),2.01(s,1H),1.92(d,J＝12.0Hz,1H),1.76(s,2H),1.59(s,1H),1.11(s,1H),0.45(s,1H),0.13(s,1H).
实施例201 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A201)
1H NMR(500MHz,Chloroform)δ7.98(s,1H),7.60(s,1H),7.29(d,J＝15.0Hz,5H),7.10(s,1H),6.98(s,1H),4.34(s,2H),2.75(s,1H),2.67(s,1H),2.09(s,1H),2.03(d,J＝6.8Hz,4H),1.94(s,1H),1.92–1.82(m,3H),1.76(s,1H),1.66(d,J＝10.0Hz,2H),1.61(s,1H),0.45(s,1H),
实施例202 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A202)
1H NMR(500MHz,Chloroform)δ7.98(s,1H),7.60(s,1H),7.29(m,3H),7.10(s,1H),6.98(s,1H),6.29(m,3H),2.75(s,1H),2.67(s,1H),2.09(s,2H),2.03(d,J＝6.8Hz,3H),1.94(s,1H),1.92–1.82(m,3H),1.76(s,1H),1.66(d,J＝10.0Hz,2H),1.61(s,1H),1.27(s,9H),0.45(s,1H)
实施例203 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A203)
1H NMR(500MHz,Chloroform)δ7.98(s,1H),7.60(s,1H),7.10(s,1H),6.98(s,1H),4.95(s,1H),2.74(s,1H),2.66(s,1H),2.19(s,2H),2.09(s,1H),2.03(d,J＝6.9Hz,2H),1.94(s,1H),1.86(dd,J＝18.2,10.2Hz,5H),1.76(s,2H),1.64(dd,J＝22.9,7.1Hz,3H),1.37(s,1H),1.31(s,2H),1.20(s,2H),0.45(s,1H)
实施例204 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A204)
1H NMR(500MHz,Chloroform)δ7.98(s,1H),7.60(s,1H),7.29(d,J＝15.0Hz,4H),7.10(s,1H),6.98(s,1H),6.05(m,2H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.09(s,1H),2.06–1.69(m,9H),1.76(s,2H),1.76(s,2H),1.65(s,1H),1.61(s,1H),0.53(s,1H),0.39(s,1H).
实施例205 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A205)
1H NMR(500MHz,Chloroform)δ8.62(s,1H),8.00(d,J＝20.6Hz,2H),7.60(s,1H),7.30(d,J＝15.0Hz,5H),7.18(d,J＝6.9Hz,2H),7.10(s,1H),6.98(s,1H),6.09(s,1H),4.85(s,1H),4.33(d,J＝13.7Hz,3H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.62(s,1H),2.54(s,1H),2.01(s,1H),1.92(d,J＝12.0Hz,1H),1.76(s,2H),1.59(s,1H),1.27(s,9H),1.11(s,3H),0.45(s,1H),0.13(s,1H).
实施例206 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环丁基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A206)
1H NMR(500MHz,Chloroform)δ8.62(s,1H),8.00(d,J＝20.6Hz,2H),7.60(s,1H),7.30(d,J＝15.0Hz,5H),7.18(d,J＝6.9Hz,2H),7.10(s,1H),6.98(s,1H),6.09(s,1H),4.85(s,1H),4.33(d,J＝13.7Hz,3H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.62(s,1H),2.54(s,1H),2.01(s,1H),1.92(d,J＝12.0Hz,1H),1.76(s,2H),1.59(s,1H),1.11(s,1H),0.45(s,21H),0.13(s,1H).
实施例207 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A207)
1H NMR(500MHz,Chloroform)δ8.57(s,1H),7.98(s,1H),7.60(s,1H),7.38(s,1H),7.30(d,J＝15.0Hz,5H),7.13–7.07(m,2H),6.98(d,J＝4.1Hz,2H),6.13(s,1H),4.81(d,J＝3.3Hz,1H),4.34(s,2H),3.65(s,1H),3.55(s,1H),2.60(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,3H),1.76(s,3H),1.66(d,J＝4.7Hz,3H),1.36(s,1H),1.23(s,1H).
实施例208 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A208)
1H NMR(500MHz,Chloroform)δ8.60(s,1H),7.98(s,1H),7.77(s,1H),7.60(s,1H),7.11(d,J＝5.1Hz,82H),6.98(s,1H),6.57(s,1H),6.14(s,1H),4.83(s,1H),4.61(s,1H),3.66(s,1H),3.54(s,1H),2.59(s,1H),2.22(s,1H),2.02(s,1H),1.93(s,1H),1.76(s,3H),1.65(d,J＝11.9Hz,5H),1.34(s,4H),1.26(d,J＝8.6Hz,9H).
实施例209 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A209)
1H NMR(500MHz,Chloroform)δ8.54(s,1H),7.98(s,1H),7.60(s,1H),7.28(s,1H),7.08(d,J＝16.5Hz,2H),6.98(s,1H),6.46(s,1H),6.14(s,1H),4.80(s,1H),4.75(s,1H),3.64(d,J＝19.8Hz,2H),3.54(s,1H),2.59(s,1H),2.22(s,1H),2.02(s,1H),1.93(s,1H),1.75(d,J＝10.0Hz,6H),1.65(d,J＝6.5Hz,63H),1.46(t,J＝12.5Hz,4H),1.35(s,3H),1.27(s,1H),1.21(s,2H),1.11(s,1H).
实施例210 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A210)
1H NMR(500MHz,Chloroform)δ8.51(s,1H),7.98(s,1H),7.60(s,1H),7.30(d,J＝15.0Hz,5H),7.24(s,1H),7.09(d,J＝13.7Hz,2H),6.98(s,1H),6.89(s,1H),6.11(s,1H),4.79(s,1H),4.65(s,11H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.50(d,J＝13.8Hz,2H),2.01(s,1H),1.92(d,J＝5.3Hz,1H),1.76(s,3H),1.65(d,J＝5.8Hz,3H),1.58(s,1H),1.36(s,1H),1.23(s,1H).
实施例211 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A211)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),7.98(s,1H),7.60(s,1H),7.10(s,1H),7.00(d,J＝18.5Hz,2H),6.89(s,1H),6.53(s,1H),6.10(s,1H),4.78(s,1H),4.65(s,1H),3.21(d,J＝15.0Hz,2H),2.90(s,1H),2.49(d,J＝13.5Hz,2H),2.01(s,1H),1.91(d,J＝1.6Hz,1H),1.76(s,3H),1.63(t,J＝21.9Hz,4H),1.55–1.52(m,1H),1.37(s,1H),1.27(s,9H),1.22(s,1H).
实施例212 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环戊基-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A212)
1H NMR(500MHz,Chloroform)δ8.45(s,1H),7.98(s,1H),7.60(s,1H),7.10(s,1H),7.00(d,J＝19.1Hz,42H),6.88(s,1H),6.44(s,1H),6.10(s,1H),4.95(s,1H),4.77(s,1H),4.64(s,1H),3.21(d,J＝15.0Hz,2H),2.90(s,1H),2.49(d,J＝19.3Hz,2H),2.19(s,2H),2.01(s,1H),1.93–1.89(m,1H),1.84(s,2H),1.76(s,3H),1.73–1.60(m,6H),1.57(s,1H),1.37(d,J＝2.4Hz,3H),1.31(s,1H),1.21(d,J＝13.0Hz,2H).
实施例213 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A213)
1H NMR(500MHz,Chloroform)δ7.97(s,1H),7.61(s,1H),7.49(s,1H),7.55–7.23(m,6H),7.55–6.98(m,8H),6.13(s,1H),4.86(s,1H),4.49(s,1H),4.34(s,2H),3.66(s,1H),3.54(s,1H),2.59(s,1H),2.23(s,1H),2.02(s,1H),1.93(s,1H),1.80(s,3H),1.69(d,J＝10.0Hz,3H),1.31(s,1H),1.26(s,1H),1.11(s,1H),1.03(s,1H).
实施例214 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A214)
1H NMR(500MHz,Chloroform)δ7.73(s,1H),7.61(s,1H),7.49(s,1H),7.16(s,1H),6.52(s,1H),6.13(s,1H),4.83(s,1H),4.55(s,1H),3.66(s,1H),3.54(s,1H),2.58(s,1H),2.22(s,1H),2.02(s,1H),1.93(s,1H),1.80(s,2H),1.58(s,1H),1.51(d,J＝15.0Hz,3H),1.48–1.41(m,4H),1.28(d,J＝5.4Hz,9H).
实施例215 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A215)
1H NMR(500MHz,Chloroform)δ7.55(d,J＝60.0Hz,2H),7.16(d,J＝2.8Hz,2H),6.45(s,1H),6.14(s,1H),4.95(s,1H),4.77(s,1H),4.66(s,1H),3.66(s,1H),3.54(s,1H),2.58(s,1H),2.21(d,J＝17.0Hz,2H),2.02(s,1H),1.92(s,1H),1.84(s,2H),1.80(s,1H),1.64(d,J＝16.1Hz,3H),1.51(d,J＝15.0Hz,2H),1.44(dd,J＝12.8,7.8Hz,6H),1.37(s,3H),1.31(s,1H),1.20(s,2H).
实施例216 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A216)
1H NMR(500MHz,Chloroform)δ7.55(d,J＝60.0Hz,2H),7.46–7.26(m,6H),7.16(s,1H),7.09(s,1H),6.08(s,1H),4.79(s,1H),4.41(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.85(s,1H),2.53(d,J＝12.1Hz,2H),2.01(s,1H),1.91(d,J＝3.6Hz,1H),1.80(s,1H),1.72(s,1H),1.58(s,1H),1.52(d,J＝15.0Hz,2H),1.48–1.41(m,4H),1.34(s,1H).
实施例217 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A217)
1H NMR(500MHz,Chloroform)δ7.61(s,2H),7.49(s,2H),7.16(s,2H),6.89(s,2H),6.53(s,2H),6.09(s,2H),4.76(s,1H),4.44(s,1H),3.21(d,J＝15.0Hz,4H),2.88(s,2H),2.49(d,J＝3.0Hz,4H),2.01(s,1H),1.93–1.89(m,2H),1.80(s,3H),1.69(d,J＝10.0Hz,2H),1.57(s,1H),1.31(d,J＝4.8Hz,2H),1.27(s,9H),1.11(s,1H),1.03(s,3H).
实施例218 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A218)
1H NMR(500MHz,Chloroform)δ7.58(s,1H),7.46(s,1H),7.13(s,1H),6.47(d,J＝5.5Hz,2H),5.81(s,1H),4.93(d,J＝6.0Hz,2H),4.37(s,1H),3.34(s,1H),3.20(d,J＝15.0Hz,2H),2.37(d,J＝18.2Hz,2H),2.18(s,2H),2.00(s,1H),1.90(d,J＝0.5Hz,1H),1.81(d,J＝19.9Hz,6H),1.69(s,2H),1.64(d,J＝29.9Hz,3H),1.51(s,1H),1.37(s,3H),1.31(s,2H),1.18(d,J＝16.6Hz,3H),1.11(s,1H),1.03(s,2H).
实施例219 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-羧酰胺(A219)
1H NMR(500MHz,Chloroform)δ7.58(s,1H),7.46(s,1H),7.13(s,1H),6.47(d,J＝5.5Hz,2H),5.81(s,1H),4.93(d,J＝6.0Hz,2H),4.37(s,1H),3.34(s,1H),3.20(d,J＝15.0Hz,2H),2.37(d,J＝18.2Hz,2H),2.18(s,2H),2.00(s,1H),1.90(d,J＝0.5Hz,1H),1.81(d,J＝19.9Hz,6H),1.69(s,2H),1.64(d,J＝29.9Hz,3H),1.51(s,1H),1.37(s,3H),1.31(s,2H),1.18(d,J＝16.6Hz,3H),1.11(s,1H),1.03(s,2H).
实施例220 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A220)
1H NMR(500MHz,Chloroform)δ9.90(s,1H),8.66(s,1H),8.26(s,1H),7.77(s,1H),7.30(d,J＝15.0Hz,5H),7.23–7.03(m,6H),6.71(s,1H),6.26(s,1H),5.98(s,1H),5.15(s,1H),4.87(s,1H),4.34(s,2H),3.79(s,6H),3.64(s,1H),3.52(s,1H),3.29(s,1H),3.04(s,1H),2.52(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,2H).
实施例221 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A221)
1H NMR(500MHz,Chloroform)δ8.60(s,1H),8.35(s,1H),7.76(s,1H),7.17(d,J＝25.0Hz,5H),6.69(s,1H),6.58(s,1H),6.23(s,1H),6.00(s,1H),5.18(s,1H),4.81(s,1H),3.79(s,6H),3.64(s,1H),3.53(s,1H),3.29(s,1H),3.04(s,1H),2.55(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.27(s,9H).
实施例222 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A222)
1H NMR(500MHz,Chloroform)δ8.59(s,1H),8.10(s,1H),7.68(s,1H),7.15(d,J＝25.0Hz,5H),6.67(s,1H),6.45(s,1H),6.21(s,1H),6.07(s,1H),5.18(s,1H),4.94(s,1H),4.80(s,1H),3.78(s,6H),3.64(s,1H),3.53(s,1H),3.28(s,1H),3.03(s,1H),2.56(s,1H),2.20(d,J＝16.3Hz,3H),2.02(s,1H),1.88(d,J＝41.4Hz,3H),1.80(s,1H),1.62(s,1H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例223 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A223)
1H NMR(500MHz,Chloroform)δ8.65(s,1H),8.29(s,1H),8.02(s,1H),7.27(d,J＝15.0Hz,5H),7.14(d,J＝24.9Hz,5H),6.92(s,1H),6.59(s,1H),6.20(s,1H),6.08(s,1H),5.01(s,1H),4.76(s,1H),4.33(s,2H),3.78(s,6H),3.28(s,1H),3.20(d,J＝15.0Hz,2H),3.03(s,1H),2.85(d,J＝1.0Hz,2H),2.32(s,1H),2.00(s,1H),1.90(d,J＝1.3Hz,1H),1.61(s,1H).
实施例224 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A224)
1H NMR(500MHz,Chloroform)δ8.80(d,J＝11.2Hz,2H),7.09(t,J＝61.7Hz,6H),6.94(s,1H),6.94(s,1H),6.77(s,1H),6.63(s,1H),6.56(s,1H),5.04(d,J＝1.0Hz,2H),4.99(s,1H),3.79(s,6H),3.29(s,1H),3.21(d,J＝15.0Hz,3H),2.93(d,J＝106.3Hz,2H),2.79–2.70(m,1H),2.40(s,1H),2.27(s,1H),2.01(s,1H),1.92(d,J＝8.4Hz,1H),1.46(s,1H),1.27(s,9H).
实施例225 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-苯基丙-2-基)-4,6-二甲氧基-1H-吲哚-2-羧酰胺(A225)
1H NMR(500MHz,Chloroform)δ8.67(s,1H),7.80(s,1H),7.65(s,1H),7.08(t,J＝67.3Hz,6H),6.91(s,1H),6.91(s,1H),6.55(s,1H),6.49(s,1H),6.07(s,1H),5.09(s,1H),4.95(s,1H),4.69(s,1H),3.79(s,6H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.93(s,1H),2.42(d,J＝15.8Hz,2H),2.19(s,2H),2.03–1.73(m,5H),1.84(s,3H),1.84(s,2H),1.60(d,J＝16.9Hz,2H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例226 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A226)
1H NMR(500MHz,Chloroform)δ8.76(s,1H),8.12(s,1H),7.98(s,1H),7.89(s,1H),7.60(s,1H),7.29(d,J＝15.0Hz,5H),7.19(d,J＝17.1Hz,2H),7.10(d,J＝2.2Hz,2H),6.99(d,J＝15.0Hz,2H),6.31(s,1H),5.05(s,1H),4.91(s,1H),4.34(s,2H),3.67(s,1H),3.56(s,1H),3.29(s,1H),3.04(s,1H),2.70(s,1H),2.23(s,1H),2.02(s,2H),1.93(s,1H).
实施例227 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A227)
1H NMR(500MHz,Chloroform)δ8.72(s,1H),8.44(s,1H),7.96(s,1H),7.59(s,1H),7.25(s,1H),7.16(s,1H),7.09(d,J＝2.1Hz,2H),6.98(d,J＝15.0Hz,2H),6.60(s,1H),5.97(s,1H),5.12(s,1H),4.82(s,1H),3.64(s,1H),3.52(s,1H),3.28(s,1H),3.03(s,1H),2.54(s,1H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.27(s,9H).
实施例228 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A228)
1H NMR(500MHz,Chloroform)δ8.69(s,1H),8.41(s,1H),7.94(s,1H),7.56(s,1H),7.23(s,1H),7.13(s,1H),7.06(d,J＝0.9Hz,2H),6.96(d,J＝14.9Hz,2H),6.65(s,1H),5.95(s,1H),5.11(s,1H),4.92(s,1H),4.81(s,1H),3.63(s,1H),3.51(s,1H),3.27(s,1H),3.02(s,1H),2.53(s,1H),2.19(d,J＝14.6Hz,2H),2.01(s,1H),1.87(d,J＝40.1Hz,3H),1.79(s,1H),1.61(s,1H),1.36(s,2H),1.30(s,1H),1.19(s,2H).
实施例229 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A229)
1H NMR(500MHz,Chloroform)δ8.69(s,1H),8.11(s,1H),7.95(s,1H),7.57(s,1H),7.43(s,1H),7.27(d,J＝15.0Hz,5H),7.14(s,1H),7.07(s,1H),6.97(d,J＝15.0Hz,2H),6.82(s,1H),6.58(s,1H),6.04(s,1H),5.01(s,21H),4.83(s,1H),4.32(s,2H),3.28(s,1H),3.20(d,J＝15.0Hz,2H),3.03(s,1H),2.89(s,1H),2.70(s,1H),2.25(s,1H),2.00(s,1H),1.90(d,J＝2.9Hz,1H),1.60(s,1H).
实施例230 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A230)
1H NMR(500MHz,Chloroform)δ8.74(s,1H),8.06(s,1H),7.98(s,1H),7.60(s,1H),7.17(s,1H),7.11(d,J＝8.4Hz,2H),7.03–6.90(m,3H),6.53(s,1H),5.75(s,1H),5.12(s,1H),4.72(s,1H),3.29(s,1H),3.21(d,J＝15.0Hz,2H),3.04(s,1H),2.75(s,1H),2.43(s,1H),2.33(s,1H),2.01(s,1H),1.96(s,1H),1.91(s,1H),1.52(s,1H),1.27(s,9H).
实施例231 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A231)
1H NMR(500MHz,Chloroform)δ8.72(s,1H),7.99(d,J＝25.5Hz,2H),7.59(s,1H),7.16(s,1H),7.09(d,J＝4.0Hz,2H),6.97(t,J＝11.7Hz,3H),6.45(s,1H),6.07(s,1H),5.09(s,1H),4.94(s,1H),4.68(s,1H),3.28(s,1H),3.21(d,J＝15.0Hz,2H),3.03(s,1H),2.95(s,1H),2.44(d,J＝17.0Hz,2H),2.19(s,2H),2.03–1.73(m,5H),1.84(s,2H),1.84(s,2H),1.60(d,J＝13.6Hz,2H),1.37(s,2H),1.31(s,1H),1.20(s,2H).
实施例232 N-((S)-1-(((S)-4-(苄基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(环己基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A232)
1H NMR(500MHz,Chloroform)δ8.57(s,1H),7.94(s,1H),7.57(s,1H),7.40(s,1H),7.26(d,J＝14.9Hz,4H),7.16–7.03(m,3H),6.95(s,1H),6.45(s,1H),5.67(s,1H),4.95(s,1H),4.48(s,1H),4.32(s,2H),3.79(s,1H),2.20(s,1H),2.15(s,1H),2.04(s,2H),1.77(d,J＝19.9Hz,3H),1.68(d,J＝10.0Hz,4H),1.37(s,1H),1.30(s,1H),1.11(s,1H),1.01(d,J＝14.9Hz,6H).
实施例233 N-((S)-1-(((S)-4-(苄基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A233)
1H NMR(500MHz,Chloroform)δ8.85(s,1H),8.41(s,1H),7.98(s,1H),7.60(s,1H),7.29(d,J＝15.0Hz,5H),7.20(d,J＝16.0Hz,2H),7.12(d,J＝20.0Hz,5H),6.98(s,1H),6.69(s,1H),5.05(s,1H),5.01(s,1H),4.74(s,1H),4.34(s,2H),3.81(s,1H),3.29(s,2H),3.04(s,1H),2.21(d,J＝5.4Hz,2H),2.05(s,2H),1.00(s,6H).
实施例234 N-((S)-1-(((S)-4-(环己基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A234)
1H NMR(500MHz,Chloroform)δ8.73(s,1H),8.16(s,1H),7.98(s,1H),7.60(s,1H),7.27(s,1H),7.19(s,1H),7.12(d,J＝20.0Hz,5H),7.07(s,1H),6.98(s,1H),6.53(s,1H),5.87(s,1H),5.64(s,1H),4.92(s,1H),4.86(s,1H),3.81(s,1H),3.29(s,3H),3.02(d,J＝18.8Hz,3H),2.19(d,J＝11.4Hz,2H),2.05(s,2H),1.80(s,1H),1.69(d,J＝10.0Hz,3H),1.58(s,1H),1.31(s,1H),1.11(s,1H),1.01(d,J＝15.0Hz,8H).
实施例235 N-((S)-1-(((S)-4-(环己基)-3,4-二酮-1-(环己基氨基)并-2-基)氨基)-3-(苯基)-1-氧代丙-2-基)-1H-吲哚-2-羧酰胺(A235)
1H NMR(500MHz,Chloroform)δ8.73(s,1H),8.14(s,1H),7.98(s,1H),7.60(s,1H),7.26(s,1H),7.19(s,1H),7.12(d,J＝20.0Hz,5H),6.98(s,1H),6.56(s,1H),5.90(s,1H),5.63(s,1H),4.93(d,J＝16.9Hz,2H),4.86(s,1H),3.29(s,1H),3.02(d,J＝18.8Hz,3H),2.23–2.14(m,4H),2.05(s,2H),1.82(d,J＝20.0Hz,4H),1.69(d,J＝10.0Hz,3H),1.62(s,1H),1.37(d,J＝0.9Hz,3H),1.31(s,3H),1.20(s,2H),1.11(s,1H),1.03(s,2H).
实施例236 N-((S)-1-(((S)-4-(苄基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(环己基)-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A236)
1H NMR(500MHz,Chloroform)δ9.45(s,1H),7.80(s,2H),7.67(s,2H),7.35–7.26(m,6H),7.11(s,1H),6.67(s,1H),5.75(s,1H),5.11(s,1H),4.33(d,J＝6.4Hz,3H),3.81(s,1H),2.16(d,J＝10.5Hz,2H),2.05(s,1H),1.76(s,1H),1.60(s,1H),1.51(d,J＝15.0Hz,2H),1.48–1.41(m,4H),1.32(s,1H),1.00(s,6H).
实施例237 N-((S)-1-(((S)-4-(环己基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(环己基)-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A237)
1H NMR(500MHz,Chloroform)δ9.32(s,1H),8.17(s,1H),8.12(s,1H),7.76(s,1H),7.66(d,J＝4.6Hz,2H),7.33–7.27(m,4H),7.19(s,1H),5.70(s,1H),4.93(s,1H),4.80(s,1H),4.75(s,1H),4.03(s,1H),3.98(s,1H),3.24(s,1H),3.02–2.98(m,3H),2.30–2.26(m,2H),2.18(s,1H),2.10(s,1H),1.82–1.75(m,2H),1.75–1.71(m,2H),1.67(s,1H),1.45–1.41(m,2H),1.33(s,1H),1.30–1.20(m,6H),1.14–1.07(m,3H).
实施例238 N-((S)-1-(((S)-4-(苄基)-3,4-二酮-1-(异丙基氨基)并-2-基)氨基)-3-(苯基)-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A238)
1H NMR(500MHz,Chloroform)δ9.34(s,1H),8.08(d,J＝10.7Hz,2H),7.62(d,J＝0.9Hz,2H),7.30–7.21(m,8H),7.19(s,1H),7.14(s,1H),6.23(s,1H),6.03(s,1H),5.22(s,1H),5.08(s,1H),4.95(s,1H),4.88(s,1H),4.33(s,1H),4.28(s,1H),3.96(s,1H),3.22(s,1H),2.99(s,1H),2.38–2.34(m,2H),2.21(s,1H),2.16(s,1H),1.33–1.20(m,6H).
实施例239 N-((S)-1-(((S)-4-(苄基)-3,4-二酮-1-(环己基氨基)并-2-基)氨基)-3-(苯基)-1-氧代丙-2-基)-喹喔啉-2-羧酰胺(A239)
1H NMR(500MHz,Chloroform)δ9.31(s,1H),8.12(d,J＝31.2Hz,2H),7.73(s,1H),7.63(d,J＝6.0Hz,2H),7.36–7.24(m,8H),7.17(d,J＝11.8Hz,2H),6.32(s,1H),5.10(s,1H),4.76(s,1H),4.67(s,1H),4.36(s,1H),4.30(d,J＝18.6Hz,2H),4.12(s,1H),3.24(s,1H),2.97(s,1H),2.31–2.27(m,2H),2.12(d,J＝3.2Hz,2H),1.94–1.87(m,2H),1.73–1.63(m,4H),1.61–1.55(m,4H).
实施例240 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-吲哚-6-氟-2-羧酰胺(A240)
1H NMR(500MHz,Chloroform)δ8.12(s,1H),7.57(s,1H),7.52(s,1H),7.36–7.25(m,4H),7.20(d,J＝7.7Hz,2H),6.84(s,1H),6.18(s,1H),5.49(d,J＝11.0Hz,2H),4.70(s,1H),4.39(d,J＝17.7Hz,2H),4.08(s,1H),3.24(d,J＝17.5Hz,2H),2.54(s,1H),2.08–2.04(m,2H),1.82(s,1H),1.78–1.67(m,6H),1.66–1.62(m,2H),1.58(dd,J＝9.5,3.3Hz,5H),1.44(s,1H),1.37–1.27(m,3H).
实施例241 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲基噁唑-2-羧酰胺(A241)
1H NMR(500MHz,Chloroform)δ7.33–7.27(m,4H),7.23(s,1H),6.79(d,J＝13.7Hz,2H),6.29(s,1H),6.09(s,1H),5.05(s,1H),4.99(d,J＝9.8Hz,2H),4.41(s,1H),4.34(s,1H),3.24(d,J＝14.9Hz,2H),2.92(s,1H),2.36–2.32(m,3H),2.08–2.04(m,2H),1.85(s,1H),1.79(s,1H),1.74–1.55(m,11H),1.48(s,1H),1.46–1.23(m,3H).
实施例242 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲基噁唑-2-羧酰胺(A242)
1H NMR(500MHz,Chloroform)δ7.33–7.30(m,22H),7.28(t,J＝15.0Hz,33H),6.83(s,9H),6.14(s,9H),6.09(s,9H),5.94(s,9H),5.19(s,9H),5.01(s,9H),4.36(d,J＝0.5Hz,18H),3.45(s,9H),3.35(s,7H),2.59(s,9H),2.38–2.34(m,27H),2.18(s,8H),2.09–2.05(m,18H),1.96–1.88(m,24H),1.88(s,3H),1.73–1.60(m,46H),1.40–1.36(m,16H),1.32(s,9H),1.15(s,7H),1.12–1.08(m,17H).
实施例243 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并[d]1,3-二氧杂环戊烯-5-羧酰胺(A243)
1H NMR(500MHz,Chloroform)δ7.54(s,6H),7.45(s,6H),7.29–7.18(m,30H),6.96(s,6H),6.49(s,6H),6.01(s,6H),5.92–5.88(m,12H),5.58(s,6H),5.11(s,6H),4.93(s,6H),4.63(s,6H),4.29(s,6H),4.24(s,6H),3.24(d,J＝17.5Hz,11H),2.86(s,6H),2.05(t,J＝4.2Hz,18H),1.95–1.87(m,12H),1.84(s,6H),1.76(t,J＝4.8Hz,17H),1.63(dd,J＝40.8,34.9Hz,22H),1.51(dd,J＝4.6,1.3Hz,1H),1.40–1.36(m,10H),1.32(s,6H),1.17–1.09(m,17H).
实施例244 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-1H-苯并[d]咪唑-2-羧酰胺(A244)
1H NMR(500MHz,Chloroform)δ7.84(s,1H),7.73(s,1H),7.62(s,1H),7.38(s,1H),7.31–7.23(m,6H),7.16(s,1H),6.17(s,1H),5.59(s,1H),5.10(s,1H),4.75(s,1H),4.53(s,1H),4.36(d,J＝17.3Hz,2H),3.24(d,J＝17.5Hz,2H),2.88(s,1H),2.06(t,J＝2.7Hz,3H),1.96–1.81(m,3H),1.77(s,1H),1.73–1.60(m,5H),1.53(s,1H),1.40–1.36(m,2H),1.32(s,1H),1.22–1.15(m,3H).
实施例245 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-7-甲氧基-苯并呋喃-2-羧酰胺(A245)
1H NMR(500MHz,Chloroform)δ7.60(s,8H),7.34–7.22(m,33H),7.15(d,J＝10.0Hz,16H),7.06(s,8H),6.81(s,8H),6.54(s,8H),6.22(s,8H),5.59(s,8H),5.08(s,8H),4.92(s,8H),4.63(s,8H),4.32(d,J＝1.1Hz,16H),3.89–3.85(m,24H),3.24(d,J＝17.4Hz,15H),2.94(s,8H),2.07(t,J＝5.1Hz,23H),1.93–1.85(m,18H),1.84(s,6H),1.78(s,6H),1.73–1.51(m,49H),1.51(d,J＝5.5Hz,1H),1.40–1.36(m,14H),1.32(s,8H),1.16–1.07(m,23H).
实施例246 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-3-甲基-苯并呋喃-2-羧酰胺(A246)
1H NMR(500MHz,Chloroform)δ7.60–7.40(m,3H),7.32–7.18(m,7H),6.67(s,1H),5.57(s,1H),5.15(s,1H),4.67(s,1H),4.55(s,1H),4.30(d,J＝14.7Hz,2H),3.24(d,J＝17.3Hz,2H),2.73(s,1H),2.15–2.10(m,4H),2.08–2.04(m,2H),1.88–1.81(m,3H),1.77(s,1H),1.73–1.59(m,5H),1.55(s,1H),1.40–1.36(m,2H),1.32(s,1H),1.14–1.05(m,3H).
实施例247 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-3，5-二甲基-苯并呋喃-2-羧酰胺(A247)
1H NMR(500MHz,Chloroform)δ7.50–7.34(m,3H),7.32–7.26(m,4H),7.23(s,1H),7.11(s,1H),6.68(s,1H),5.57(s,1H),5.15(s,1H),4.69(s,1H),4.55(s,1H),4.30(d,J＝14.8Hz,2H),3.24(d,J＝17.3Hz,2H),2.73(s,1H),2.45–2.41(m,3H),2.15–2.10(m,4H),2.08–2.04(m,2H),1.88–1.81(m,3H),1.77(s,1H),1.73–1.59(m,5H),1.55(s,1H),1.40–1.36(m,2H),1.32(s,1H),1.14–1.05(m,3H).
实施例248 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4，7-二甲氧基-苯并呋喃-2-羧酰胺(A248)
1H NMR(500MHz,Chloroform)δ7.59(s,1H),7.34–7.27(m,2H),7.27–7.22(m,2H),7.10(s,1H),6.86(s,1H),6.82(s,1H),6.38(s,1H),6.32(s,1H),5.56(s,1H),5.35(s,1H),4.66(d,J＝18.6Hz,2H),4.28(s,1H),4.17(s,1H),3.91–3.87(m,3H),3.85–3.81(m,3H),3.24(d,J＝17.8Hz,2H),3.06(s,1H),2.05(t,J＝6.8Hz,3H),1.96–1.88(m,2H),1.84(s,1H),1.77(s,1H),1.73–1.54(m,5H),1.52(s,1H),1.40–1.36(m,2H),1.32(s,1H),1.17–1.08(m,3H).
实施例249 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-3-羧酰胺(A249)
1H NMR(500MHz,Chloroform)δ8.07(s,91H),7.62(s,92H),7.58(s,94H),7.47(s,94H),7.27(dd,J＝9.9,8.1Hz,379H),7.20(t,J＝5.8Hz,274H),6.24(s,91H),5.61(s,91H),5.16(s,90H),4.93(s,91H),4.52(s,89H),4.32(d,J＝0.6Hz,182H),3.24(d,J＝17.5Hz,174H),2.89(s,93H),2.06(t,J＝2.7Hz,257H),1.92–1.80(m,277H),1.81(s,7H),1.77(s,70H),1.73–1.51(m,541H),1.51(d,J＝1.8Hz,6H),1.40–1.36(m,160H),1.32(s,86H),1.22–1.16(m,264H).
实施例250 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-6-氯-2H-色烯-3-羧酰胺(A250)
1H NMR(500MHz,Chloroform)δ8.16(s,1H),7.32(s,1H),7.32–7.24(m,4H),7.23–7.09(m,3H),6.84(s,1H),6.05(s,1H),5.64(s,1H),5.33(s,1H),5.06–5.02(m,2H),4.50(d,J＝9.3Hz,2H),4.39(s,1H),4.32(s,1H),3.24(d,J＝17.4Hz,2H),2.99(s,1H),2.15(s,1H),2.08–2.04(m,2H),1.85(s,1H),1.79(s,1H),1.73–1.69(m,2H),1.69–1.62(m,5H),1.55(s,1H),1.39–1.35(m,2H),1.31(s,1H),1.23–1.19(m,2H),1.17(s,1H).
实施例251 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-6-氯2,3-二氢苯并[b]1,4-二噁英-6-羧酰胺(A251)
1H NMR(500MHz,Chloroform)δ8.51(s,1H),7.66(s,1H),7.55(s,1H),7.11(s,1H),5.40(s,1H),5.16(s,1H),4.65(s,1H),4.52(s,1H),4.38–4.34(m,4H),3.45(s,1H),3.36(d,J＝13.4Hz,2H),2.68(s,1H),2.18(s,1H),2.11–2.02(m,2H),1.99–1.84(m,3H),1.78–1.72(m,2H),1.71–1.62(m,5H),1.58(dd,J＝9.0,3.3Hz,5H),1.55–1.50(m,2H),1.48(s,1H),1.43–1.39(m,4H),1.37–1.29(m,3H).
实施例252 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-苯基-1-氧代丙-2-基)-6-氯2,3-二氢苯并[b]1,4-二噁英-6-羧酰胺(A252)
1H NMR(500MHz,Chloroform)δ9.01(s,1H),7.52(s,1H),7.29–7.23(m,2H),7.23–7.17(m,2H),7.15(s,1H),7.04(s,1H),6.92(s,1H),6.21(s,1H),5.12(s,1H),5.05(s,1H),4.87(s,1H),4.52(s,1H),4.38–4.34(m,4H),3.44(d,J＝12.5Hz,2H),3.37–3.20(m,3H),2.98(s,1H),2.19(s,1H),2.12–2.04(m,2H),1.92(s,1H),1.85–1.78(m,2H),1.66(s,1H),1.56–1.52(m,2H),1.48–1.39(m,3H),1.23–1.11(m,2H).
实施例253 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲氧基吲哚-6-羧酰胺(A253)
1H NMR(500MHz,Chloroform)δ8.73(s,5H),8.50(s,5H),7.45(s,5H),7.37(s,5H),7.18(s,5H),6.75(s,5H),6.03(s,5H),5.67(s,5H),5.61(s,5H),4.89(s,5H),4.57(s,5H),3.84–3.80(m,15H),3.43(d,J＝16.9Hz,10H),3.35(s,4H),2.70(s,5H),2.19(s,5H),2.09–2.06(m,9H),2.06–2.04(m,1H),2.06–1.91(m,16H),1.73–1.61(m,35H),1.60–1.46(m,47H),1.46–1.39(m,11H),1.35–1.26(m,9H),1.22(s,4H).
实施例254 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-4氟苯基-1-氧代丙-2-基)-5-甲基-苯并呋喃-2-羧酰胺(A254)
1H NMR(500MHz,Chloroform-d)δ8.35(d,J＝9.7Hz,1H),8.11(t,J＝5.8Hz,1H),7.83(d,J＝9.3Hz,1H),7.68(d,J＝2.1Hz,1H),7.60(dd,J＝2.7,1.8Hz,1H),7.41(d,J＝8.2Hz,1H),7.35–7.22(m,7H),7.22–7.17(m,1H),7.07–7.00(m,2H),6.26(t,J＝4.0Hz,1H),4.75(dt,J＝9.7,6.2Hz,1H),4.54–4.46(m,1H),4.50–4.45(m,1H),4.47(t,J＝0.9Hz,1H),3.27–3.14(m,2H),3.08(ddt,J＝6.2,2.9,1.1Hz,2H),2.61(tdd,J＝8.9,6.9,4.3Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.81–1.61(m,4H).
实施例255 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-3-氯-苯并呋喃-2-羧酰胺(A255)
1H NMR(500MHz,Chloroform)δ7.75(s,1H),7.58(s,1H),7.49(s,1H),7.29(d,J＝15.0Hz,6H),7.21(s,1H),6.10(s,1H),4.78(s,1H),4.52(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.53(d,J＝13.0Hz,2H),2.01(s,1H),1.91(d,J＝6.4Hz,1H),1.76(s,1H),1.64(s,1H),1.58(s,1H),1.55–1.37(m,9H).
实施例256 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-氯-苯并呋喃-2-羧酰胺(A256)
1H NMR(500MHz,Chloroform)δ7.66(s,1H),7.44(s,1H),7.23(s,1H),7.15(s,1H),6.88(s,1H),6.44(s,1H),6.11(s,1H),4.95(s,1H),4.76(s,1H),4.54(s,1H),3.21(d,J＝15.0Hz,2H),2.88(s,1H),2.50(d,J＝13.5Hz,2H),2.19(s,2H),2.01(s,1H),1.91(d,J＝0.5Hz,1H),1.84(s,2H),1.76(s,1H),1.59(dd,J＝42.7,19.7Hz,5H),1.53(s,1H),1.51(d,J＝15.0Hz,3H),1.44(dd,J＝9.2,5.8Hz,5H),1.37(s,3H),1.31(s,1H),1.20(s,2H).
实施例257 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-6-溴-苯并呋喃-2-羧酰胺(A257)
1H NMR(500MHz,Chloroform)δ7.54(t,J＝2.6Hz,1H),7.46(d,J＝71.6Hz,5H),7.18(s,3H),7.11(d,J＝2.3Hz,4H),6.42(s,3H),5.73(s,3H),5.65(s,3H),5.03(s,2H),4.95(s,1H),4.47(s,1H),3.21(d,J＝15.0Hz,6H),2.99(s,2H),2.72(s,3H),2.34(s,2H),2.19(s,5H),2.01(s,1H),1.93(d,J＝16.1Hz,5H),1.89–1.74(m,10H),1.69(d,J＝10.0Hz,8H),1.62(s,2H),1.51(s,1H),1.39(d,J＝6.9Hz,1H),1.38–1.28(m,4H),1.20(s,3H),1.11(s,2H),1.03(s,3H).
实施例258 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-1-氧代-3-环己基丙-2-基)-5-氟烟酰胺(A258)
1H NMR(500MHz,Chloroform)δ8.58(s,1H),8.40(s,1H),7.77(s,1H),7.29(d,J＝15.0Hz,4H),7.22(s,1H),7.05(s,1H),6.30(s,1H),5.77(s,1H),4.90(s,1H),4.45(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.97(s,1H),2.67(s,1H),2.13(s,1H),2.01(s,1H),1.93(d,J＝16.5Hz,2H),1.78(m,2H),1.75(d,J＝7.8Hz,1H),1.57(s,1H),1.46(m,9H).
实施例259 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-乙氧基-苯并呋喃-2-羧酰胺(A259)
1H NMR(500MHz,Chloroform)δ7.78–7.52(m,1H),7.29(d,J＝15.0Hz,1H),7.23(d,J＝10.0Hz,1H),7.11(s,1H),6.36(s,1H),5.85(s,1H),4.82(s,1H),4.45(s,1H),4.34(s,1H),4.06(s,1H),3.21(d,J＝15.0Hz,1H),2.82(s,2H),2.45(d,J＝1.0Hz,1H),2.01(s,1H),1.91(s,2H),1.79–1.57(m,2H),1.62–1.57(m,2H),1.55–1.41(m,2H),1.33(d,J＝7.5Hz,1H).
实施例260 N-((S)-1-(((S)-4-(3甲基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A260)
1H NMR(500MHz,Chloroform)δ7.59(s,1H),7.50(d,J＝5.0Hz,2H),7.28(s,1H),7.21(d,J＝5.0Hz,1H),7.11(d,J＝1.5Hz,2H),7.03(s,1H),6.94(s,1H),6.88(s,1H),5.72(s,1H),4.68(s,1H),4.63(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.78(s,1H),2.38–2.29(m,5H),2.08–2.03(m,1H),2.08–1.89(m,2H),1.76(s,1H),1.67(s,1H),1.55–1.41(m,8H).
实施例261 N-((S)-1-(((S)-4-(4氟苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A261)
1H NMR(500MHz,Chloroform)δ7.59(s,1H),7.50(s,1H),7.38(d,J＝2.0Hz,2H),7.28(s,1H),7.22(s,1H),7.16(s,1H),7.07(s,1H),6.86(s,1H),6.12(s,1H),4.80(s,1H),4.53(s,1H),4.34(s,1H),3.21(d,J＝15.0Hz,2H),2.91(s,1H),2.51(d,J＝9.5Hz,2H),2.01(s,1H),1.91(d,J＝4.1Hz,1H),1.76(s,1H),1.65(s,1H),1.58(s,1H),1.51(d,J＝15.0Hz,2H),1.44(dd,J＝8.0,7.0Hz,6H).
实施例262 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-氯-7氮杂吲哚-2-羧酰胺(A262)
1H NMR(500MHz,Chloroform)δ8.71(s,1H),8.52(s,1H),8.09(s,1H),7.29(d,J＝15.0Hz,5H),7.19(s,1H),7.14(s,1H),6.93(s,1H),6.09(s,1H),4.80(s,1H),4.45(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.90(s,1H),2.44(d,J＝5.0Hz,2H),2.01(s,1H),1.91(d,J＝1.4Hz,1H),1.76(s,1H),1.72(s,1H),1.59–1.48(m,3H),1.48–1.41(m,4H),1.36(s,1H).
实施例263 N-((S)-1-(((S)-4-(4氯苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A263)
1H NMR(500MHz,Chloroform)δ7.59(s,1H),7.50(s,1H),7.38(d,J＝9.2Hz,5H),7.28(s,1H),7.22(s,1H),7.16(s,1H),6.86(s,1H),6.12(s,1H),4.80(s,1H),4.53(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.92(s,1H),2.51(d,J＝13.5Hz,2H),2.01(s,1H),1.91(d,J＝3.7Hz,1H),1.76(s,1H),1.65(s,1H),1.58(s,1H),1.51(d,J＝15.0Hz,2H),1.44(dd,J＝8.3,6.7Hz,6H).
实施例264 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-6-溴-苯并呋喃-2-羧酰胺(A264)
1H NMR(500MHz,Chloroform)δ7.50(d,J＝32.8Hz,1H),7.34–7.26(m,3H),7.18(s,1H),7.11(s,1H),6.87(s,1H),6.12(s,1H),4.78(s,1H),4.54(s,1H),4.34(s,1H),3.21(d,J＝15.0Hz,1H),2.90(s,2H),2.54(d,J＝18.2Hz,1H),2.01(s,1H),1.92(d,J＝6.0Hz,1H),1.76(s,2H),1.65(s,2H),1.58(s,2H),1.51(d,J＝15.0Hz,1H),1.44(dd,J＝8.2,6.8Hz,3H).
实施例265 N-((S)-1-(((S)-4-(3，4-二氟苄基氨基)-3,4-二酮-1-(2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A265)
1H NMR(500MHz,Chloroform)δ7.53(d,J＝44.9Hz,1H),7.34(s,1H),7.28–7.12(m,2H),7.05(s,1H),6.84(s,1H),6.11(s,1H),4.79(s,1H),4.53(s,1H),4.33(s,1H),3.21(d,J＝15.0Hz,1H),2.92(s,1H),2.50(d,J＝17.5Hz,1H),2.01(s,1H),1.91(d,J＝3.9Hz,2H),1.76(s,1H),1.65(s,1H),1.58(s,1H),1.55–1.41(m,4H).
实施例266 N-((S)-1-(((S)-4-(2氯苄基氨基)-3,4-二酮-1-(2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A266)
1H NMR(500MHz,Chloroform)δ7.66(s,1H),7.44(s,1H),7.23(s,1H),7.15(s,1H),6.88(s,1H),6.44(s,1H),6.11(s,1H),4.95(s,1H),4.76(s,1H),4.54(s,1H),3.21(d,J＝15.0Hz,2H),2.88(s,1H),2.50(d,J＝13.5Hz,1H),2.19(s,2H),2.01(s,1H),1.91(d,J＝0.5Hz,1H),1.84(s,1H),1.76(s,1H),1.59(dd,J＝42.7,19.7Hz,5H),1.53(s,1H),1.51(d,J＝15.0Hz,3H),1.44(dd,J＝9.2,5.8Hz,5H),1.37(s,3H),1.31(s,1H),1.20(s,2H).
实施例267 N-((S)-1-(((S)-4-(2甲氧基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A267)
1H NMR(500MHz,Chloroform)δ7.54(s,1H),7.30–7.20(m,2H),7.15(s,1H),6.95–6.82(m,2H),6.11(s,1H),4.78(s,1H),4.53(s,1H),4.23(s,1H),3.72(s,1H),3.21(d,J＝15.0Hz,1H),2.89(s,1H),2.55(d,J＝18.5Hz,1H),2.01(s,1H),1.91(d,J＝5.9Hz,1H),1.76(s,1H),1.65(s,1H),1.58(s,1H),1.55–1.35(m,4H).
实施例268 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-哒嗪-2-羧酰胺(A268)
1H NMR(500MHz,Chloroform)δ9.81(s,1H),8.52(s,1H),7.99(s,1H),7.33–7.26(m,6H),6.71(s,1H),6.06(s,1H),4.75(s,1H),4.45(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.83(s,1H),2.65(s,1H),2.52(s,1H),2.01(s,1H),1.90(d,J＝8.1Hz,1H),1.76(s,1H),1.65–1.28(m,9H),1.39–1.28(m,1H).
实施例269 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-4,5吲哚-2-羧酰胺(A269)
1H NMR(500MHz,Chloroform)δ8.49(s,1H),7.33–7.26(m,7H),7.20(s,2H),7.10(s,1H),6.87(s,1H),6.11(s,1H),4.78(s,1H),4.52(s,1H),4.34(s,2H),3.21(d,J＝15.0Hz,2H),2.92(s,1H),2.54(d,J＝17.0Hz,3H),2.01(s,1H),1.92(d,J＝8.4Hz,2H),1.76(s,1H),1.64(s,1H),1.58(s,1H),1.51(d,J＝15.0Hz,4H),1.44(dd,J＝9.9,5.2Hz,6H).
实施例270 N-((S)-1-(((S)-4-(3，5二氟苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A270)
1H NMR(500MHz,Chloroform)δ7.54(d,J＝45.0Hz,1H),7.35(s,1H),7.27(s,1H),7.21(s,1H),7.15(s,2H),6.85(d,J＝1.8Hz,5H),6.79(s,1H),6.11(s,2H),4.79(s,1H),4.53(s,1H),4.33(s,3H),3.21(d,J＝15.0Hz,4H),2.91(s,1H),2.52(s,2H),2.48(s,2H),2.01(s,1H),1.91(d,J＝3.5Hz,2H),1.76(s,2H),1.65(s,2H),1.58(s,2H),1.55–1.41(m,7H).
实施例271 N-((S)-1-(((S)-4-(4甲氧基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A271)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),8.13(t,J＝5.7Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝2.0Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.19(dt,J＝8.4,1.0Hz,2H),6.87–6.82(m,2H),6.26(t,J＝4.0Hz,1H),4.50(ddt,J＝5.8,3.7,1.1Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.78(s,2H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 631.31[M+H]+.
实施例272 N-((S)-1-(((S)-4-(4甲基苄基甲氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A272)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),7.85(d,J＝9.7Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.14(dt,J＝8.0,1.1Hz,2H),7.10(dq,J＝7.3,0.7Hz,2H),6.26(t,J＝4.0Hz,1H),4.55–4.48(m,2H),4.50–4.43(m,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.99(s,2H),2.61(tdd,J＝8.7,6.8,4.1Hz,1H),2.16(ddd,J＝15.0,8.8,7.6Hz,1H),1.94(ddd,J＝15.0,8.8,7.6Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 629.33[M+H]+.
实施例273 N-((S)-1-(((S)-4-(4硝基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A273)
1H NMR(500MHz,Chloroform-d)δ8.21–8.13(m,3H),8.10(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60(q,J＝1.1Hz,1H),7.60–7.52(m,2H),7.43–7.34(m,2H),6.26(t,J＝4.0Hz,1H),4.50(ddt,J＝5.6,4.6,0.9Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.71(m,4H),1.74–1.59(m,3H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 646.28[M+H]+.
实施例274 N-((S)-1-(((S)-4-(2，4，6-三甲基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A274)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),7.89(d,J＝9.3Hz,1H),7.80–7.75(m,2H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),6.78(s,2H),6.26(t,J＝4.0Hz,1H),4.50(dd,J＝6.0,2.9Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.23(s,2H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 643.34[M+H]+.
实施例275 N-((S)-1-(((S)-4-(4苯基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A275)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),8.13(t,J＝5.7Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.62–7.49(m,5H),7.48–7.41(m,2H),7.43–7.34(m,3H),7.30(dt,J＝8.4,1.0Hz,2H),6.26(t,J＝4.0Hz,1H),4.49(ddt,J＝5.7,2.1,1.0Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z677.33[M+H]+.
实施例276 N-((S)-1-(((S)-4-(2，4，6-三甲基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A276)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),7.89(d,J＝9.3Hz,1H),7.79–7.72(m,2H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.08(dd,J＝8.1,7.1Hz,1H),7.00–6.95(m,2H),6.26(t,J＝4.0Hz,1H),4.53–4.44(m,2H),4.46–4.39(m,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 629.33[M+H]+.
实施例277 N-((S)-1-(((S)-4-(4氰基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A277)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),8.13(t,J＝5.7Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.62–7.56(m,2H),7.59–7.52(m,1H),7.44–7.34(m,4H),6.26(t,J＝4.0Hz,1H),4.49(ddt,J＝5.7,2.1,0.9Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 626.29[M+H]+.
实施例278 N-((S)-1-(((S)-4-(4三氟甲氧基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A278)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),8.13(t,J＝5.7Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.23(dt,J＝8.3,1.1Hz,2H),7.17–7.11(m,2H),6.26(t,J＝4.0Hz,1H),4.50(ddt,J＝5.8,3.6,1.0Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z685.27[M+H]+.
实施例279 N-((S)-1-(((S)-4-(2氰基苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A279)
1H NMR(500MHz,Chloroform-d)δ8.23–8.16(m,2H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.64–7.58(m,1H),7.61–7.52(m,1H),7.43–7.32(m,5H),6.26(t,J＝4.0Hz,1H),4.56(dd,J＝5.7,1.0Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 626.30[M+H]+.
实施例280 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-7氮杂吲哚-2-羧酰胺(A280)
1H NMR(500MHz,Chloroform-d)δ8.69(dd,J＝3.8,1.8Hz,1H),8.48(d,J＝8.2Hz,1H),8.28(dt,J＝7.3,1.9Hz,1H),8.11(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.54(d,J＝2.2Hz,1H),7.40–7.32(m,1H),7.34–7.30(m,1H),7.32–7.27(m,2H),7.30–7.22(m,2H),6.26(t,J＝4.0Hz,1H),4.48(t,J＝1.0Hz,1H),4.49–4.39(m,3H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z601.31[M+H]+.
实施例281 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-氯-苯并呋喃-2-羧酰胺(A281)
1H NMR(500MHz,Chloroform-d)δ8.19–8.08(m,2H),7.89(d,J＝9.3Hz,1H),7.83(t,J＝2.1Hz,1H),7.75(d,J＝2.1Hz,1H),7.69(d,J＝8.4Hz,1H),7.48(dd,J＝8.4,2.0Hz,1H),7.35–7.22(m,5H),6.26(t,J＝4.0Hz,1H),4.50–4.39(m,3H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.74(m,3H),1.77–1.59(m,4H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 635.26[M+H]+.
实施例282 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲氧基-苯并呋喃-2-羧酰胺(A282)
1H NMR(500MHz,Chloroform-d)δ8.16(d,J＝9.9Hz,1H),8.11(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.67(d,J＝2.1Hz,1H),7.51(d,J＝8.4Hz,1H),7.35–7.22(m,5H),7.16(t,J＝2.0Hz,1H),7.08(dd,J＝8.4,1.8Hz,1H),6.26(t,J＝4.0Hz,1H),4.47(dt,J＝5.7,1.0Hz,2H),4.44(dt,J＝9.2,7.4Hz,1H),4.26(dt,J＝9.9,6.7Hz,1H),3.82(s,2H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.71(m,4H),1.75–1.59(m,3H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 631.31[M+H]+.
实施例283 N-((R)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A283)
1H NMR(500MHz,Chloroform-d)δ8.19(d,J＝9.9Hz,1H),8.11(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.35(m,2H),7.35–7.22(m,5H),6.26(t,J＝4.0Hz,1H),4.50–4.39(m,3H),4.26(dt,J＝9.9,6.7Hz,1H),3.27–3.14(m,2H),2.61(tdd,J＝8.9,6.9,4.2Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.86–1.59(m,7H),1.57–1.34(m,8H),1.32–1.20(m,2H).ESI-MS m/z 601.29[M+H]+.
实施例284 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A284)
1H NMR(500MHz,Chloroform-d)δ8.37(d,J＝9.7Hz,1H),8.11(t,J＝5.8Hz,1H),7.83(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.35(m,2H),7.35–7.22(m,6H),7.01(td,J＝7.8,1.9Hz,2H),6.96(dtt,J＝7.9,1.9,1.0Hz,1H),6.26(t,J＝4.0Hz,1H),4.78(dt,J＝9.7,6.2Hz,1H),4.54–4.46(m,1H),4.48(s,1H),4.47(t,J＝0.9Hz,1H),3.27–3.14(m,2H),3.05–2.93(m,2H),2.61(tdd,J＝8.9,6.9,4.3Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.81–1.61(m,4H).ESI-MS m/z613.24[M+H]+.
实施例285 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-苯基-1-氧代丙-2-基)-5-氟-吲哚-2-羧酰胺(A285)
1H NMR(500MHz,Chloroform-d)δ9.91(s,1H),8.35(d,J＝8.1Hz,1H),7.83(d,J＝9.3Hz,1H),7.63(dt,J＝8.0,2.5Hz,1H),7.50(dd,J＝7.2,5.0Hz,1H),7.30–7.14(m,7H),7.08(ddd,J＝8.1,7.1,2.7Hz,1H),6.13(t,J＝3.1Hz,1H),4.78(dt,J＝8.1,6.2Hz,1H),4.44(dt,J＝9.3,7.3Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.08–3.01(m,1H),3.04–2.97(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.3Hz,1H).ESI-MS m/z564.25[M+H]+.
实施例286 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲氧基-吲哚-2-羧酰胺(A286)
1H NMR(500MHz,Chloroform-d)δ9.91(s,1H),8.32(d,J＝8.2Hz,1H),7.89(d,J＝9.3Hz,1H),7.48(d,J＝8.2Hz,1H),7.37–7.31(m,2H),6.82(dd,J＝7.3,2.4Hz,1H),6.13(t,J＝3.1Hz,1H),4.49–4.36(m,2H),3.83(s,2H),3.67(dp,J＝8.2,4.9Hz,1H),3.33–3.22(m,2H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.33(m,21H),1.31–1.20(m,2H).ESI-MS m/z 608.34[M+H]+.
实施例287 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-苯基-1-氧代丙-2-基)-1-甲基-吲哚-2-羧酰胺(A287)
1H NMR(500MHz,Chloroform-d)δ8.18(d,J＝7.7Hz,1H),7.85–7.75(m,2H),7.48(d,J＝8.2Hz,1H),7.43(dd,J＝8.3,1.2Hz,1H),7.31–7.15(m,8H),6.13(t,J＝3.1Hz,1H),4.75(dt,J＝7.5,6.2Hz,1H),4.41(dt,J＝9.2,7.4Hz,1H),3.93(s,2H),3.67(dp,J＝8.2,4.9Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.02(ddt,J＝6.2,3.2,1.0Hz,2H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.13(dt,J＝15.3,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.3Hz,1H),1.75–1.40(m,8H),1.43–1.36(m,2H),1.40–1.33(m,1H).ESI-MS m/z 586.29[M+H]+.
实施例288 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-苯基-1-氧代丙-2-基)-5-氟-吲哚-2-羧酰胺(A288)
1H NMR(500MHz,Chloroform-d)δ9.91(s,1H),8.35(d,J＝8.0Hz,1H),7.83(d,J＝9.3Hz,1H),7.63(dt,J＝7.9,2.5Hz,1H),7.53–7.46(m,2H),7.30–7.14(m,5H),7.08(ddd,J＝8.1,7.1,2.7Hz,1H),6.13(t,J＝3.1Hz,1H),4.78(dt,J＝8.1,6.2Hz,1H),4.41(dt,J＝9.2,7.4Hz,1H),3.67(dp,J＝8.2,4.9Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.02(ddt,J＝6.2,3.2,1.0Hz,2H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.3Hz,1H),1.75–1.33(m,11H).ESI-MS m/z 590.27[M+H]+.
实施例289 N-((R)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(4-氟苯基)-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A289)
1H NMR(500MHz,Chloroform-d)δ8.37(d,J＝9.7Hz,1H),8.11(t,J＝5.8Hz,1H),7.83(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.35(m,2H),7.38–7.22(m,8H),7.07–7.00(m,2H),6.26(t,J＝4.0Hz,1H),4.75(dt,J＝9.7,6.2Hz,1H),4.54–4.46(m,1H),4.50–4.45(m,1H),4.47(t,J＝0.9Hz,1H),3.27–3.14(m,2H),3.08(ddt,J＝6.2,2.9,1.1Hz,2H),2.61(tdd,J＝8.9,6.9,4.3Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.81–1.61(m,4H).ESI-MS m/z 613.24[M+H]+.
实施例290 N-((R)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A290)
1H NMR(500MHz,Chloroform-d)δ8.37(d,J＝9.7Hz,1H),8.11(t,J＝5.8Hz,1H),7.83(d,J＝9.3Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.35(m,2H),7.35–7.22(m,5H),7.10–7.03(m,1H),7.03–6.96(m,2H),6.26(t,J＝4.0Hz,1H),4.78(dt,J＝9.7,6.2Hz,1H),4.54–4.46(m,1H),4.50–4.45(m,1H),4.47(t,J＝0.9Hz,1H),3.27–3.14(m,2H),3.07–2.95(m,2H),2.61(tdd,J＝8.9,6.9,4.3Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.81–1.61(m,4H).ESI-MS m/z 631.23[M+H]+.
实施例291 N-((S)-1-(((S)-4-(叔丁基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-苯基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A291)
1H NMR(500MHz,Chloroform-d)δ8.37(d,J＝9.7Hz,1H),7.83(d,J＝9.2Hz,1H),7.76(d,J＝2.2Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.30–7.16(m,6H),6.13(t,J＝3.1Hz,1H),4.70(dt,J＝9.7,6.2Hz,1H),4.44(dt,J＝9.3,7.3Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.08–2.97(m,2H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.3Hz,1H).ESI-MS m/z547.25[M+H]+.
实施例292 N-((S)-1-(((S)-4-(环己基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,3-二氢苯并[b]1,4-二噁英-6-羧酰胺(A292)
1H NMR(500MHz,Chloroform-d)δ7.95–7.87(m,2H),7.54–7.46(m,2H),7.40(d,J＝2.1Hz,1H),6.89(d,J＝8.5Hz,1H),6.13(t,J＝3.1Hz,1H),4.40(dt,J＝9.3,7.3Hz,1H),4.36–4.29(m,1H),4.29(dd,J＝4.8,2.4Hz,2H),4.27(ddd,J＝4.7,3.0,2.2Hz,2H),3.67(dp,J＝8.2,4.9Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.77(m,2H),1.80–1.66(m,4H),1.68–1.61(m,1H),1.64–1.58(m,1H),1.61–1.49(m,2H),1.53–1.38(m,10H),1.41–1.33(m,2H),1.31–1.20(m,2H).ESI-MS m/z597.33[M+H]+.
实施例293 N-((S)-1-(((S)-4-((R)-1苯基-乙基)-氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)–喹啉-2-羧酰胺(A293)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.3Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.89(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.8,1.2Hz,1H),7.36–7.29(m,2H),7.32–7.22(m,4H),6.13(t,J＝3.1Hz,1H),5.01(dtdd,J＝8.4,6.1,5.1,1.1Hz,1H),4.48–4.37(m,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.68(m,4H),1.57–1.34(m,12H),1.31–1.20(m,2H).ESI-MS m/z612.31[M+H]+.
实施例294 N-((S)-1-(((S)-4-吗啉基-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)–喹啉-2-羧酰胺(A294)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.3Hz,1H),8.07–8.01(m,1H),7.94(dt,J＝8.0,0.8Hz,1H),7.84(d,J＝9.7Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.9,1.2Hz,1H),6.13(t,J＝3.1Hz,1H),4.52(dt,J＝9.7,7.7Hz,1H),4.41(dt,J＝9.3,6.6Hz,1H),3.71(ddd,J＝9.7,6.3,3.6Hz,4H),3.63(dd,J＝6.4,3.6Hz,2H),3.55(dd,J＝6.4,3.6Hz,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.64(tdd,J＝7.8,5.7,3.9Hz,1H),2.16(dt,J＝15.3,7.6Hz,1H),2.01(dt,J＝15.1,7.7Hz,1H),1.94–1.86(m,1H),1.86–1.80(m,1H),1.82–1.77(m,1H),1.80–1.75(m,1H),1.77–1.68(m,1H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 578.29[M+H]+.
实施例295 N-((S)-1-(((S)-4-((S)-1苯基-乙基)-氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)–喹啉-2-羧酰胺(A295)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.3Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.89(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.8,1.2Hz,1H),7.36–7.29(m,2H),7.32–7.22(m,4H),6.13(t,J＝3.1Hz,1H),5.03(dqt,J＝8.1,6.1,1.1Hz,1H),4.48–4.37(m,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.68(m,4H),1.57–1.34(m,12H),1.31–1.20(m,2H).ESI-MS m/z 612.31[M+H]+.
实施例296 N-((S)-1-(((S)-4-二乙胺基-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)–喹啉-2-羧酰胺(A296)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.3Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.85(d,J＝9.7Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.8,1.2Hz,1H),6.13(t,J＝3.1Hz,1H),4.52(dt,J＝9.7,7.7Hz,1H),4.41(dt,J＝9.3,6.6Hz,1H),3.45(q,J＝7.3Hz,4H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.67(tdd,J＝7.9,5.7,3.9Hz,1H),2.17(dt,J＝15.3,7.7Hz,1H),2.01(dt,J＝15.1,7.6Hz,1H),1.94–1.86(m,1H),1.86–1.70(m,4H),1.57–1.34(m,8H),1.31–1.20(m,2H),1.20(t,J＝7.3Hz,6H).ESI-MS m/z564.31[M+H]+.
实施例297 N-((S)-1-(((S)-4-(4氟苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)–喹啉-2-羧酰胺(A297)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.2Hz,1H),8.13(t,J＝5.7Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.89(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.7,1.1Hz,1H),7.32(ddt,J＝7.5,5.0,1.0Hz,2H),7.11–7.03(m,2H),6.13(t,J＝3.1Hz,1H),4.55–4.45(m,3H),4.41(dt,J＝9.3,6.6Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.77(m,2H),1.80–1.75(m,1H),1.77–1.68(m,1H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 616.28[M+H]+.
实施例298 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A298)
1H NMR(500MHz,Chloroform-d)δ8.39–8.32(m,2H),8.20(d,J＝8.2Hz,1H),8.13(t,J＝5.7Hz,1H),8.07–8.01(m,1H),7.94(dt,J＝8.0,0.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.9,1.2Hz,1H),7.19(dt,J＝8.4,1.0Hz,2H),6.87–6.82(m,2H),6.13(t,J＝3.1Hz,1H),4.55–4.49(m,1H),4.52–4.44(m,2H),4.41(dt,J＝9.3,6.6Hz,1H),3.78(s,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.07–1.99(m,1H),1.94–1.86(m,1H),1.86–1.68(m,4H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 628.31[M+H]+.
实施例299 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A299)
1H NMR(500MHz,Chloroform-d)δ9.03(d,J＝6.6Hz,1H),8.11(t,J＝5.8Hz,1H),8.01(t,J＝1.6Hz,1H),7.92(dd,J＝23.3,8.9Hz,2H),7.79(dd,J＝7.4,1.6Hz,1H),7.44(s,0H),7.35–7.17(m,6H),6.69(dd,J＝3.3,2.0Hz,1H),6.13(t,J＝3.1Hz,1H),4.54–4.46(m,1H),4.47(dd,J＝5.8,0.9Hz,2H),4.33(dt,J＝8.4,6.7Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.69(m,4H),1.57–1.34(m,9H),1.31–1.20(m,2H).ESI-MS m/z586.30[M+H]+.
实施例300 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-溴咪唑并[1,2-a]吡啶-2-羧酰胺(A300)
1H NMR(500MHz,Chloroform-d)δ8.74–8.70(m,1H),8.58(d,J＝9.3Hz,1H),8.47(s,1H),8.11(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.52(dd,J＝8.8,1.3Hz,1H),7.42(d,J＝8.8Hz,1H),7.35–7.22(m,5H),6.13(t,J＝3.1Hz,1H),4.54–4.46(m,1H),4.48(d,J＝0.9Hz,1H),4.47(t,J＝0.9Hz,1H),4.41(dt,J＝9.3,6.6Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.68(m,4H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z665.20[M+H]+.
实施例301 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-7-溴-喹啉-2-羧酰胺(A301)
1H NMR(500MHz,Chloroform-d)δ8.36–8.30(m,2H),8.19(d,J＝2.1Hz,1H),8.15(d,J＝8.2Hz,1H),8.11(t,J＝5.8Hz,1H),7.94–7.86(m,2H),7.62(dd,J＝8.5,2.3Hz,1H),7.35–7.22(m,5H),6.13(t,J＝3.1Hz,1H),4.54–4.45(m,3H),4.41(dt,J＝9.3,6.6Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.80(m,1H),1.82–1.77(m,1H),1.80–1.75(m,1H),1.77–1.68(m,1H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z676.20[M+H]+.
实施例302 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-2,3-二氢苯并[b]1,4-二噁英-6-羧酰胺(A302)
1H NMR(500MHz,Chloroform-d)δ8.11(t,J＝5.8Hz,1H),7.95–7.87(m,2H),7.52(dd,J＝8.4,2.2Hz,1H),7.40(d,J＝2.1Hz,1H),7.35–7.22(m,5H),6.89(d,J＝8.5Hz,1H),6.13(t,J＝3.1Hz,1H),4.54–4.46(m,1H),4.48(d,J＝0.9Hz,1H),4.47(t,J＝0.9Hz,1H),4.36–4.29(m,1H),4.29(dd,J＝4.8,2.4Hz,2H),4.27(ddd,J＝4.7,3.0,2.2Hz,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.69(m,4H),1.57–1.34(m,9H),1.31–1.20(m,2H).ESI-MS m/z 605.29[M+H]+.
实施例303 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-5-甲基-异噁唑-2-羧酰胺(A303)
1H NMR(500MHz,Chloroform-d)δ8.36(d,J＝9.3Hz,1H),8.11(t,J＝5.8Hz,1H),7.89(d,J＝9.3Hz,1H),7.35–7.22(m,5H),6.50(s,1H),6.13(t,J＝3.1Hz,1H),4.47(dt,J＝5.4,0.9Hz,2H),4.48–4.37(m,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.52(s,2H),2.13(dt,J＝15.2,7.5Hz,1H),2.02(dt,J＝15.0,7.5Hz,1H),1.94–1.86(m,1H),1.86–1.80(m,1H),1.82–1.77(m,1H),1.80–1.75(m,1H),1.77–1.68(m,1H),1.57–1.34(m,8H),1.31–1.20(m,2H).ESI-MS m/z 552.27[M+H]+.
实施例304 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(2氟苯基)-1-氧代丙-2-基)-喹啉-2-羧酰胺(A304)
1H NMR(500MHz,Chloroform-d)δ8.43–8.32(m,2H),8.20(d,J＝8.2Hz,1H),8.11(t,J＝5.8Hz,1H),8.04(dd,J＝8.1,1.2Hz,1H),7.97–7.91(m,1H),7.83(d,J＝9.1Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.7,1.2Hz,1H),7.36–7.15(m,7H),7.10(td,J＝7.9,1.2Hz,1H),6.13(t,J＝3.1Hz,1H),4.80(dt,J＝9.2,7.3Hz,1H),4.54–4.46(m,1H),4.47(dd,J＝5.8,0.9Hz,2H),3.33–3.22(m,2H),3.21(ddd,J＝15.8,7.4,0.9Hz,1H),3.09(ddd,J＝15.9,7.3,0.7Hz,1H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.07–1.99(m,1H),1.90(dddd,J＝12.1,6.1,3.8,2.5Hz,1H),1.82(dtd,J＝12.2,3.7,2.3Hz,1H).ESI-MS m/z 610.24[M+H]+.
实施例305 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3-氟苯基)-1-氧代丙-2-基)-喹啉-2-羧酰胺(A305)
1H NMR(500MHz,Chloroform-d)δ8.43(d,J＝9.1Hz,1H),8.35(d,J＝8.3Hz,1H),8.20(d,J＝8.2Hz,1H),8.11(t,J＝5.8Hz,1H),8.04(dd,J＝8.1,1.2Hz,1H),7.97–7.91(m,1H),7.83(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.7,1.2Hz,1H),7.35–7.22(m,6H),7.01(td,J＝7.8,1.9Hz,2H),6.96(dtt,J＝7.9,1.9,1.0Hz,1H),6.13(t,J＝3.1Hz,1H),4.80(dt,J＝9.3,6.3Hz,1H),4.54–4.46(m,1H),4.47(dd,J＝5.8,0.9Hz,2H),3.33–3.22(m,2H),3.05–2.93(m,2H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.07–1.99(m,1H),1.90(dddd,J＝12.1,6.1,3.8,2.4Hz,1H),1.82(dtd,J＝12.3,3.7,2.3Hz,1H).ESI-MS m/z 610.23[M+H]+.
实施例306 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(4-氟苯基)-1-氧代丙-2-基)-喹啉-2-羧酰胺(A306)
1H NMR(500MHz,Chloroform-d)δ8.43(d,J＝9.1Hz,1H),8.35(d,J＝8.2Hz,1H),8.20(d,J＝8.3Hz,1H),8.11(t,J＝5.8Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.83(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.8,1.2Hz,1H),7.35–7.22(m,7H),7.07–7.00(m,2H),6.13(t,J＝3.1Hz,1H),4.77(dt,J＝9.2,6.2Hz,1H),4.54–4.46(m,1H),4.48(d,J＝0.9Hz,1H),4.47(t,J＝0.9Hz,1H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.13–3.01(m,2H),2.67(tdd,J＝7.8,5.7,3.9Hz,1H),2.13(dt,J＝15.2,7.5Hz,1H),2.07–1.99(m,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.2Hz,1H).ESI-MS m/z610.24[M+H]+.
实施例307 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代吡咯烷-3-基)丁-2-基)氨基)-3-(3,4-二氟苯基)-1-氧代丙-2-基)-喹啉-2-羧酰胺(A307)
1H NMR(500MHz,Chloroform-d)δ8.43(d,J＝9.1Hz,1H),8.35(d,J＝8.2Hz,1H),8.20(d,J＝8.3Hz,1H),8.11(t,J＝5.8Hz,1H),8.07–8.01(m,1H),7.97–7.91(m,1H),7.83(d,J＝9.3Hz,1H),7.73(td,J＝7.9,1.1Hz,1H),7.53(td,J＝7.8,1.2Hz,1H),7.35–7.22(m,5H),7.10–7.03(m,1H),7.03–6.96(m,2H),6.13(t,J＝3.1Hz,1H),4.80(dt,J＝9.3,6.3Hz,1H),4.54–4.46(m,1H),4.47(dd,J＝5.7,0.9Hz,2H),3.33–3.26(m,1H),3.29–3.22(m,1H),3.00(ddt,J＝6.2,2.8,1.0Hz,2H),2.68(tdd,J＝7.7,5.7,3.9Hz,1H),2.17–2.08(m,1H),2.07–1.99(m,1H),1.94–1.86(m,1H),1.82(dtd,J＝12.2,3.7,2.2Hz,1H).ESI-MSm/z 628.23[M+H]+.
实施例308 N-((S)-1-(((S)-4-(苄基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(2-氟苯基)-1-氧代丙-2-基)–苯并呋喃-2-羧酰胺(A308)
1H NMR(500MHz,Chloroform-d)δ8.33(d,J＝9.7Hz,1H),8.11(t,J＝5.8Hz,1H),7.83(d,J＝9.1Hz,1H),7.76(d,J＝1.9Hz,1H),7.75–7.68(m,1H),7.60–7.52(m,1H),7.43–7.34(m,2H),7.37–7.26(m,5H),7.29–7.23(m,1H),7.26–7.18(m,1H),7.21–7.17(m,1H),7.10(td,J＝7.9,1.2Hz,1H),6.26(t,J＝4.0Hz,1H),4.77(dt,J＝9.7,7.3Hz,1H),4.54–4.46(m,1H),4.48(s,1H),4.47(t,J＝0.9Hz,1H),3.27–3.14(m,3H),3.09(ddd,J＝15.9,7.3,0.8Hz,1H),2.61(tdd,J＝8.9,6.9,4.3Hz,1H),2.13(ddd,J＝15.0,8.8,7.3Hz,1H),1.99(ddd,J＝15.2,8.8,7.3Hz,1H),1.81–1.61(m,4H).ESI-MS m/z 613.23[M+H]+.
实施例309 N-((S)-1-(((S)-4-(环丙基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-环己基-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A309)
1H NMR(500MHz,DMSO-d6)δ8.71(d,J＝5.1Hz,1H),8.57(t,J＝8.4Hz,2H),7.81–7.75(m,1H),7.68(dd,J＝8.4,1.0Hz,1H),7.63(d,J＝1.0Hz,1H),7.47(m,2H),7.37–7.30(m,1H),5.08(m,1H),4.59(m,1H),3.10(m,2H),2.72(m,1H),2.28(m,1H),2.11(m,1H),1.90(m,1H),1.77–1.49(m,6H),1.45–1.34(m,2H),1.29–1.06(m,3H),0.97–0.87(m,2H),0.74–0.59(m,2H),0.59–0.26(m,2H).ESI-MS m/z 551.27[M+H]+.
实施例310 N-((S)-1-(((S)-4-(环丙基氨基)-3,4-二酮-1-((S)-2-氧代哌啶-3-基)丁-2-基)氨基)-3-(4-氟苯基)-1-氧代丙-2-基)-苯并呋喃-2-羧酰胺(A310)
1H NMR(500MHz,DMSO-d6)δ8.78–8.63(m,3H),7.76(d,J＝7.8Hz,1H),7.65(d,J＝8.4Hz,1H),7.55(s,1H),7.49–7.43(m,2H),7.41–7.35(m,2H),7.32(t,J＝7.8Hz,1H),7.07(t,J＝8.4Hz,2H),5.13(m,1H),4.78(m,1H),3.16–3.06(m,3H),3.06–2.97(m,1H),2.73(m,1H),2.27(m,1H),2.14(m,1H),2.08–1.89(m,1H),1.73(m,2H),1.56(m,1H),1.42(m,1H),0.71–0.60(m,2H),0.60–0.42(m,2H).ESI-MS m/z 563.22[M+H]+.
活性测试例1：2019新型冠状病毒3CL蛋白酶抑制活性评价
测定化合物对2019新型冠状病毒3CL蛋白酶(2019-nCoV 3CLpro)的抑制活性：利用荧光共振能量转移(fluorescence resonance energy transfer FRET)技术测定针对3C蛋白酶的抑制剂的酶水平抑制活性。在96孔板上，每孔中加入27.5μL缓冲液(20mM Tris，100mM NaCl，1mM EDTA，pH 7.4)，同时加入2.5μL化合物(最终浓度分别为2μM、4μM、6μM、8μM、10μM、12μM、14μM、16μM、18μM、20μM)和5μL EV713Cpro(最终浓度3μM)。在37℃下共孵育15min。之后加入15μL缓冲液稀释的荧光底物(最终浓度20μM)。利用Ge n5荧光分度计测定荧光参数，激发波长和发射波长分别为340nm和490nm，保持37℃，10min后读取数据。采用阴性对照，其中对照不加入化合物，其余相同。所得数据利用软件GraphPad Prism 5处理，实验结果如表1所示。
表1:2019新型冠状病毒3CL蛋白酶抑制活性
注：化合物A42、或DC404001、或4001(省略了“DC40XXXX”中的“DC40”)指同一个化合物；其他化合物依此类推。
实验结果显示：多数化合物对2019-nCoV 3CL蛋白酶具有较好的抑制活性，其中化合物A13(DC403113)和A42(DC404001)对2019-nCoV 3CL蛋白酶的抑制活性IC50达到2.4μM和3.0μM。
活性测试例2：人组织蛋白酶L抑制活性评价
测定化合物对人组织蛋白酶L(cathepsin L,CatL)的抑制活性：利用荧光共振能量转移(fluorescence resonance energy transfer,FRET)技术测定针对组织蛋白酶L的酶水平抑制活性。在96孔板上，每孔中加入10μL缓冲液(50mM CH3COONa,pH 5.5,1mM DTT,2mM EDTA)，同时加入0.2μL化合物(最终浓度分别为100nM,10nM,1nM,0.1nM和0.01nM)和10μL组织蛋白酶L。在25℃下共孵育15min。之后加入10μL缓冲液稀释的荧光底物(Z-Phe-Arg-AMC，最终浓度20μM)。利用Tecan Infinite 200pro荧光分度计测定荧光参数，激发波长和发射波长分别为360nm和465nm，保持25℃，30min后读取数据。采用阴性对照，其中对照不加入化合物，其余相同。所得数据利用软件GraphPad Prism 8.0处理，实验结果如表2所示。
表2:人组织蛋白酶L抑制活性
| 化合物编号 | IC50(nM) | 化合物编号 | IC50(nM) |
| A5(DC406104) | 0.45±0.02 | A13(DC403113) | 1.36±0.04 |
| A284(DC406016) | 0.45±0.01 | A289(DC406009) | 0.66±0.008 |
| A290(DC406020) | 0.47±0.06 | A309(DC406068) | 0.63±0.08 |
| A310(DC406067) | 0.57±0.01 |
实验结果显示：测试化合物对人组织蛋白酶L具有优异的抑制活性，IC50均达纳摩尔级，甚至小于1nM(如化合物A5、A284、A289、A290、A309、A310)。
活性测试例3：化合物2019新型冠状病毒复制抑制活性评价
测定化合物对各2019新型冠状病毒(2019-nCov)复制抑制活性：在96孔中加入100μl/孔梯度浓度的化合物，随后加入50μl/孔病毒缓冲液，随后立即加入50μl/孔培养好后的RD细胞(rhabdomyosarcoma cells)，37℃培养3-4天，直到观察到最大细胞病变效果。吸去培养基，加入75μl 5％MTS的酚红培养基，37℃，5％CO2培养1.5小时，测定各孔在498nM波长的荧光值，画出化合物浓度与细胞反应的曲线图，用在Accelrys公司定制的软件计算化合物抑制病毒的EC50。
试验结果如图1和2所示。
结果表明，本发明的酮酰胺类化合物可有效地抑制2019新型冠状病毒的复制(图1)，对不同分离的病毒株有一定的抑制。
目前抗2019-nCoV的阳性化合物为CQ，其抑制2019-nCoV病毒复制的抑制率EC50＝1.13μM。结果显示：以CQ为阳性对照，在不同的浓度梯度下对专利中的化合物进行测试，化合物A13(3113，DC403113)，A42(4001，DC404001)，A289(6009，DC406009)均具有优良的抑制病毒活性。其中3113的EC50为9237nM，6009和4001的EC50分别为296.5nM和580.5nM，6009和4001在病毒水平上对2019-nCoV的抑制率优于阳性对照CQ，展现出优异的抗2019-nCoV潜力(图2)。
活性测试例4：DC406009：SD大鼠重复静脉输注给药14天毒性试验
本试验的目的是观察SD大鼠连续7天静脉注射DC406009后对机体潜在的毒性，确定可能的毒性靶器官。提供无毒性反应剂量和/或毒性反应剂量，为后续的毒性试验设计以及临床试验的方案设计提供参考。为了评估药物在体内的暴露水平，伴随进行毒代动力学评价。
SD大鼠36只，分为8组(毒性试验组3只/性别/组，共5组；毒代卫星组1只/性别/组，3组)，静脉注射给予溶媒(5％DMSO/5％EtOH/40％PEG300/50％NaCl)、0.9％氯化钠注射液和DC406009(5、15、30mg/kg/day)，每天1次，连续给药7天，所有动物于Day 8进行安乐死解剖。试验期间，对下列指标进行了评价：毒代(仅采集样品)、临床观察、体重、耗食量、临床病理(血液学、血凝、血浆生化)和解剖肉眼形态学观察检查。
结果显示：在本试验条件下，SD大鼠静脉注射给予DC406009(5、15、30mg/kg/day)，每天1次，连续7天，动物均可耐受，最大耐受剂量(MTD)为大于30mg/kg/day，表明化合物DC406009具有良好的安全性。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (12)
1.一种通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体的用途，其特征在于，用于制备(a)2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂；和(b)抑制2019新型冠状病毒复制的药物：
其中，
*表示碳原子的立体化学异构分别独立地为R和/或S；
R1选自下组：氢、氘、氚、取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C6芳基、取代或未取代的C6芳基C1-C5亚烷基；
R2选自下组：氢、氘、氚、取代或未取代的C1-C6烷基；
R3选自下组：取代或未取代的C1-C6烷基、取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C6芳基C1-C5亚烷基；
R4选自下组：含1、2或3个选自N、O、S的杂原子的9-10元杂芳环、含1、2或3个选自N、O、S的杂原子的5-6元杂芳环；所述9-10元杂芳环或5-6元杂芳环为取代或未取代的；其中，所述取代指基团上的氢原子被1、2、3或4个选自下组的取代基取代：卤素、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6烷硫基、卤代C1-C6烷硫基；
R6选自下组：氢、氘、氚、取代或未取代的C1-C6烷基；
当-NR5与其相邻的-(C＝O)-CH2-成环时，R5为-(CH2)n-，n为2或3；
当-NR5不与其相邻的-(C＝O)-CH2-成环时，R5选自下组：氢、氘、氚、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基；
其中，在R1、R2、R3、R5和R6中，所述取代各自独立地指被选自下组的1、2、3或4个取代基取代：卤素、羟基、巯基、硝基、氰基、胺基、C1-C8烷基、卤代C1-C8烷基、C1-C8烷氧基、卤代C1-C8烷氧基、C1-C6烷基羰基、C1-C6烷硫基、C1-C8烷氧基羰基、三氟甲基。
2.如权利要求1所述的用途，其特征在于，所述药物还用于治疗和/或预防、缓解由2019新型冠状病毒感染引起选自下组的疾病：呼吸道感染、肺炎、或其组合。
3.如权利要求1或2所述的用途，其特征在于，R1选自下组：取代或未取代的C3-C8环烷基、取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C6芳基C1-C5亚烷基；
R2选自下组：氢、取代或未取代的C1-C6烷基；
R3选自下组：取代或未取代的C3-C8环烷基C1-C5亚烷基、取代或未取代的C6芳基C1-C5亚烷基；
其中，在R1、R2和R3中，所述取代各自独立地指被选自下组的1、2或3个取代基取代：卤素、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C4烷基羰基、C1-C4烷硫基、C1-C6烷氧基羰基、三氟甲基。
4.如权利要求1或2所述的用途，其特征在于，所述化合物为式AA所示的化合物，
其中，R1、R2、R3、R4、R5和n如权利要求1中所限定；
*表示碳原子的立体化学异构分别独立地为R和/或S。
5.如权利要求1或2所述的用途，其特征在于，R4选自：含1、2或3个选自N、O、S的杂原子的9-10元杂芳环；所述9-10元杂芳环为取代或未取代的；其中，所述取代指基团上的氢原子被1、2、3或4个选自下组的取代基取代：卤素、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6烷硫基、卤代C1-C6烷硫基。
6.如权利要求1或2所述的用途，其特征在于，-NR5与其相邻的-(C＝O)-CH2-成环，R5为-(CH2)n-，n为2或3。
7.如权利要求1或2所述的用途，其特征在于，R4选自下组：
取代或未取代的喹喔啉基、取代或未取代的喹唑啉基、取代或未取代的噌啉基、
取代或未取代的吲哚基、取代或未取代的异吲哚基、
取代或未取代的苯并咪唑基、取代或未取代的吲唑基、
取代或未取代的咪唑[1,2-A]吡啶基、取代或未取代的咪唑[1,5-A]吡啶基、
取代或未取代的吡唑基、取代或未取代的咪唑基、取代或未取代的噻唑基、取代或未取代的噁唑基、取代或未取代的异噁唑基、取代或未取代的1，2，3-三唑基、取代或未取代的1，2-噻二唑基、取代或未取代的1，2，4-三嗪基、
取代或未取代的吡啶基、取代或未取代的吡咯基、取代或未取代的吡嗪基、取代或未取代的嘧啶基、
取代或未取代的喹啉基、取代或未取代的异喹啉基、
取代或未取代的苯并噁唑基、取代或未取代的苯并噻唑基、
取代或未取代的苯并噻吩基、
取代或未取代的苯并呋喃基；
其中，所述取代指基团上的氢原子被1、2或3个选自下组的取代基取代：F、Cl、Br、I、羟基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、卤代C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6烷硫基、卤代C1-C6烷硫基。
8.一种酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体的用途，其特征在于，用于制备(a)2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂；和(b)抑制2019新型冠状病毒复制的药物，其中，所述化合物选自下组：
9.一种体外抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶的活性的方法，包括步骤：将通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体与2019-nCov的3CL蛋白酶接触，从而抑制2019-nCov的3CL蛋白酶的活性,其中所述的通式(A)所示的酮酰胺类化合物如权利要求1中所述。
10.一种体外抑制人组织蛋白酶L的活性的方法，包括步骤：将通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体与人组织蛋白酶L接触，从而抑制人组织蛋白酶L的活性,其中所述的通式(A)所示的酮酰胺类化合物如权利要求1中所述。
11.一种用于抑制2019新型冠状病毒(2019-nCov)3CL蛋白酶和/或人组织蛋白酶L的式(A)化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体，
其中，所述化合物为
12.一种用作2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂和/或人组织蛋白酶L抑制剂和/或用于抑制2019新型冠状病毒复制的药物组合物，其特征在于，所述的药物组合物的活性成分为如权利要求11所述的通式(A)所示的酮酰胺类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体；并且所述的药物组合物含有药学上可接受的载体。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020100777237 | 2020-01-31 | ||
| CN202010077723 | 2020-01-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113197895A CN113197895A (zh) | 2021-08-03 |
| CN113197895B true CN113197895B (zh) | 2023-06-20 |
Family
ID=77025272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110119020.0A Active CN113197895B (zh) | 2020-01-31 | 2021-01-28 | 一种酮酰胺类化合物的药物用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230133600A1 (zh) |
| EP (1) | EP4098258A4 (zh) |
| JP (1) | JP2023513048A (zh) |
| KR (1) | KR20220134772A (zh) |
| CN (1) | CN113197895B (zh) |
| AU (1) | AU2021213137A1 (zh) |
| CA (1) | CA3166596A1 (zh) |
| TW (1) | TW202130628A (zh) |
| WO (1) | WO2021151387A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4165037A4 (en) | 2020-06-10 | 2024-07-03 | Aligos Therapeutics Inc | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS, PICORNAVIRUS AND NOROVIRUS INFECTIONS |
| IL309732A (en) | 2021-07-09 | 2024-02-01 | Aligos Therapeutics Inc | Antiviral compounds |
| WO2023198067A1 (zh) * | 2022-04-11 | 2023-10-19 | 上海科技大学 | 一种化合物及其在制备治疗肠道病毒相关疾病的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850003C (en) * | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| CN103145608B (zh) * | 2011-12-07 | 2015-09-02 | 南开大学 | 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途 |
| CN104592349A (zh) * | 2015-02-15 | 2015-05-06 | 天津国际生物医药联合研究院 | 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用 |
| CN105837487A (zh) * | 2016-03-17 | 2016-08-10 | 天津国际生物医药联合研究院 | MERS-CoV主蛋白酶小分子抑制剂及其制备方法和用途 |
| TW201817714A (zh) * | 2016-08-30 | 2018-05-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抑制3c及3cl蛋白酶之化合物及其使用方法 |
| CN110818691A (zh) * | 2018-08-09 | 2020-02-21 | 中国科学院上海药物研究所 | 酮酰胺类化合物及其制备方法、药物组合物和用途 |
-
2021
- 2021-01-28 CN CN202110119020.0A patent/CN113197895B/zh active Active
- 2021-01-28 KR KR1020227030165A patent/KR20220134772A/ko active Search and Examination
- 2021-01-28 WO PCT/CN2021/074228 patent/WO2021151387A1/zh unknown
- 2021-01-28 AU AU2021213137A patent/AU2021213137A1/en active Pending
- 2021-01-28 TW TW110103317A patent/TW202130628A/zh unknown
- 2021-01-28 CA CA3166596A patent/CA3166596A1/en active Pending
- 2021-01-28 JP JP2022546507A patent/JP2023513048A/ja active Pending
- 2021-01-28 EP EP21748369.2A patent/EP4098258A4/en active Pending
- 2021-01-28 US US17/796,076 patent/US20230133600A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4098258A4 (en) | 2024-02-28 |
| JP2023513048A (ja) | 2023-03-30 |
| KR20220134772A (ko) | 2022-10-05 |
| CN113197895A (zh) | 2021-08-03 |
| CA3166596A1 (en) | 2021-08-05 |
| TW202130628A (zh) | 2021-08-16 |
| AU2021213137A1 (en) | 2022-09-22 |
| WO2021151387A1 (zh) | 2021-08-05 |
| EP4098258A1 (en) | 2022-12-07 |
| US20230133600A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113197895B (zh) | 一种酮酰胺类化合物的药物用途 | |
| CN113015726B (zh) | 酮酰胺类化合物及其制备方法、药物组合物和用途 | |
| CN113181339B (zh) | 一种醛基类化合物的药物用途 | |
| CN104245675B (zh) | 作为MetAP‑2抑制剂的环酰胺 | |
| CN106928206A (zh) | 醛基类化合物及其制法和用途 | |
| EP4178955A1 (en) | Antiviral heteroaryl ketone derivatives | |
| CN116236580B (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
| CN113620929B (zh) | 醛基类化合物及其制备方法、药物组合物和用途 | |
| JP2019502759A (ja) | キノリン−２−オン誘導体 | |
| WO2024037520A1 (zh) | 一种酰胺类化合物及其制备方法、药物组合物和用途 | |
| CN113350330B (zh) | 杨梅素类化合物在制备防治新冠肺炎药物中的应用 | |
| CN113332363A (zh) | 茶叶提取物及其组合物在抗冠状病毒中的应用 | |
| JPWO2009119167A1 (ja) | 抗ｒｎａウイルス作用を有するアニリン誘導体 | |
| RU2819346C1 (ru) | Фармацевтическое применение соединения на основе кетоамида | |
| TW202321196A (zh) | 冠狀病毒抑制劑 | |
| CN103908447B (zh) | 苦参提取物和降苦参酮在抗ev71病毒感染中的应用 | |
| EP2565194A1 (en) | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | |
| CN115385984A (zh) | 一种拟肽类衍生物、制备方法和应用 | |
| TW202304888A (zh) | 醚連接之抗病毒化合物 | |
| US9206412B2 (en) | Thioxothiazolidine inhibitors | |
| EP4301407A1 (en) | Suppression of covid-19 replication by covid-19 entry inhibitors | |
| CN115141206A (zh) | 一种ɑ-硫辛酸石蒜碱偶联物及其制备方法和应用 | |
| CN107823629A (zh) | 以单宁酸为代表的一系列化合物在抗基孔肯雅等甲病毒感染中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |